oligonucleotides containing phosphoramidate nucleotide internucleotide bonds

Modified phosphoramidite bonds in oligonucleotides address the issue of in vivo degradation by enhancing stability and cellular uptake, resulting in improved therapeutic efficacy.

JP2026538937APending Publication Date: 2026-11-19KORRO BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025572765
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-31
Filing Date
2024-10-31
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Oligonucleotide therapeutics are susceptible to in vivo degradation due to the action of endogenous nucleases, necessitating the use of non-natural nucleotides to improve robustness and stability.

Method used

Development of oligonucleotides containing modified internucleotide bonds, specifically phosphoramidite bonds, which enhance nuclease stability, protein binding, and cellular uptake, thereby improving the pharmacokinetic profile and editing efficiency.

Benefits of technology

The modified phosphoramidite bonds in oligonucleotides provide enhanced nuclease stability, protein binding, and cellular uptake, leading to improved therapeutic efficacy and durability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026538937000001_ABST
    Figure 2026538937000001_ABST
Patent Text Reader

Abstract

Provided herein are oligonucleotides comprising a phosphoramidite internucleotide linkage of Formula (I) below, wherein R 1 is isopropyl, isobutyl, sec-butyl, C 1-6 haloalkyl, C 2-6 hydroxyalkyl, C 2-8 alkylene-N(R N )2, C 0-2 alkylene-C 3-8 cycloalkyl, 4- to 10-membered heterocycloalkyl having 1 to 3 ring heteroatoms selected from O, N, and S, or 5- to 10-membered heteroaryl having 1 to 3 ring heteroatoms selected from O, N, and S, with the proviso that the heterocycloalkyl or heteroaryl is bonded to sulfur via a carbon ring atom, and the cycloalkyl, heterocycloalkyl, or heteroaryl is substituted with 0, 1, 2, or 3 R 2 groups, each R 2 is independently halo, CN, N(R N )2, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, oxo, CO2R N , or C(O)C 1-3 alkyl, and each R N is independently H or C 1-3 alkyl. Also provided are formulations comprising the oligonucleotides disclosed herein, as well as methods of treating diseases and disorders using the oligonucleotides disclosed herein and formulations thereof. Chemical Formula 1 JPEG2026538937000029.jpg57170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure relates, in general, to oligonucleotides containing phosphoramidite nucleotide internucleotide bonds, formulations thereof, and methods for preparing and using oligonucleotides and formulations thereof.

[0002] Several nucleic acid-derived drugs, including homivirsen, patisirane, and gibosilane, have been approved for commercialization in recent years, and many more are in clinical trials. However, the sensitivity of oligonucleotide drugs to nuclease digestion in vivo necessitates the use of non-natural nucleotides to improve the robustness of oligonucleotide-based drugs.

[0003] While various structural aspects of oligonucleotides can be modified, the phosphodiester nucleotide bonds found in natural oligonucleotides are an attractive target for modification, and altering them can modulate drug properties such as plasma stability, binding characteristics, solubility, cell permeability, and bioactivity of oligonucleotide drugs.

[0004] Therefore, there is a need for oligonucleotide therapeutic agents having modified nucleotide bonds with improved properties. [Overview of the Initiative]

[0005] In this specification, oligonucleotides comprising 10 to 300 nucleotides are provided, each nucleotide comprising a sugar moiety, a nucleic acid base, and an internucleotide bond, wherein at least one internucleotide bond is of formula (I): [ka] This is a PAX nucleotide internucleotide bond having the structure, where R 1 isopropyl, isobutyl, sec-butyl, C 1-6 Haloalkyl, C 2-6 Hydroxyalkyl, C 2-8 Alkylene-N(R) N)2, C 0-2 alkylene-C 3-8 cycloalkyl, 4- to 10-membered heterocycloalkyl having 1 to 3 ring heteroatoms selected from O, N, and S, or 5- to 10-membered heteroaryl having 1 to 3 ring heteroatoms selected from O, N, and S, with the proviso that the heterocycloalkyl or heteroaryl is bonded to sulfur via a ring carbon atom, and the cycloalkyl, heterocycloalkyl, or heteroaryl is 0, 1, 2, or 3 R 2 groups, and each R 2 is independently halo, CN, N(R N )2, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, oxo, CO2R N , or C(O)C 1-3 alkyl, and each R N is independently H or C 1-3 alkyl.

[0006] Also provided is a formulation comprising the oligonucleotide disclosed herein and a pharmaceutically acceptable excipient. Further provided herein is a method of treating a disease or disorder in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the oligonucleotide disclosed herein, or a formulation comprising the oligonucleotide disclosed herein. Further provided is a kit comprising the oligonucleotide disclosed herein, or a formulation thereof, and optionally one or more containers, one or more additional therapeutic agents, a package insert having instructions for performing any of the methods disclosed herein, one or more syringes for parenteral injection, one or more filter needles, and / or one or more needles.

[0007] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this disclosure belongs. Methods and materials are described herein for use in this disclosure, and other preferred methods and materials known in the art may also be used. Materials, methods, and examples are illustrative and not intended to limit the scope. All publications, patent applications, patents, sequences, database entries, and other references referenced herein are incorporated in their entirety by reference. In case of any conflict, this specification, including definitions, shall prevail. [Brief explanation of the drawing]

[0008] [Figure 1A-1B] The results of editing efficiency tests comparing the editing percentage of target sites in a PiZ mouse hepatocyte model are shown. The data represent the editing efficiency of the oligonucleotides disclosed herein when measured by free uptake (Figure 1A) and transfection (Figure 1B). [Figure 2] The percentage of E342K mutation editing by the oligonucleotides of this disclosure in PiZ mouse models, measured on days 4, 7, and 14 after administration, is shown. [Figure 3A-3B] The effect of PA1 versus modified nucleotide binding of the 42-mer (Figure 3A) and 30-mer (Figure 3B) oligonucleotides disclosed herein, as measured by serum A1AT expression in a PiZ mouse model, is shown. [Figure 4A-4B] The results of the stability assay for oligos A1-A4 (Figure 4A) and A5-A7 (Figure 4B) are shown. [Figure 5] The results of editing efficiency tests comparing the editing percentage of target sites in a PiZ mouse hepatocyte model are shown. The data represent the editing efficiency of the L4-linked oligonucleotides disclosed herein when transfected at concentrations ranging from 0.1 nM to 100 nM against two controls, oligo A1(A) and oligo A1a(B). [Figure 6]The results of editing efficiency tests comparing the editing percentage of target sites in a PiZ mouse hepatocyte model are shown. The data represent the editing efficiency of the L15-linked oligonucleotides disclosed herein when measured by transfection at concentrations ranging from 0.1 nM to 100 nM against two controls, oligo A1(A) and oligo A1a(B). [Figure 7] The results of editing efficiency tests comparing the editing percentage of target sites in a PiZ mouse hepatocyte model are shown. The data represent the editing efficiency of the oligonucleotides disclosed herein when measured by transfection (A) and free uptake (B). [Figure 8] The results of an in vivo editing efficiency test in the liver of a mouse model are shown. [Modes for carrying out the invention]

[0009] This specification provides oligonucleotides containing modified nucleotide bonds such as phosphoramidite bonds. It also provides formulations containing oligonucleotides containing modified nucleotide bonds such as phosphoramidite bonds. Furthermore, it provides therapeutic methods using modified nucleotide bonds such as phosphoramidite bonds, and formulations thereof, as well as methods for producing oligonucleotides containing modified nucleotide bonds such as phosphoramidite bonds, and formulations thereof.

[0010] Oligonucleotides are attractive as therapeutic platforms; however, oligonucleotide therapeutics containing natural phosphate links are susceptible to in vivo degradation, for example, via the action of endogenous nucleases. Several skeletal modification strategies have been devised to address this problem, including the introduction of phosphorothioate (PS) or methylsulfonamide (PA1) skeletal links into the oligonucleotide structure. In particular, PA1 links have been shown to improve nuclease degradation stability and durability compared to PS links. While we do not wish to be bound by any particular theory, PA1-containing oligonucleotides are thought to exhibit improved interactions with serum proteins, resulting in a longer pharmacokinetic (PK) profile, as well as enhanced translocation across biological membranes to improve potency, compared to natural phosphate links. L1 (isopropylsulfonamide) and L2 (cyclopropylsulfonamide) links are phosphoamidite links and are more hydrophobic than PA1. The enhanced hydrophobicity of L1- and L2-containing oligonucleotides can improve nuclease stability, protein binding, and cellular uptake properties. In addition, L1- and L2-modified oligonucleotides can improve the activity and durability of in vivo editing.

[0011] phosphoramidite-containing oligonucleotides This specification provides oligonucleotides containing modified internucleotide bonds such as phosphoramidite bonds.

[0012] The oligonucleotides disclosed herein comprise 10 to 300 nucleotides, each comprising a sugar moiety, a nucleic acid base, and an internucleotide bond, with at least one internucleotide bond comprising formula (I): [ka] This is a PAX nucleotide internucleotide bond having the structure, in the formula, R 1 isopropyl, isobutyl, sec-butyl, C 1-6 Haloalkyl, C2-6 Hydroxyalkyl, C 2-8 Alkylene-N(R) N )2, C 0-2 Alkylene-C 3-8 A 4-10 membered heterocycloalkyl having 1-3 ring heteroatoms selected from cycloalkyl, O, N, and S, or a 5-10 membered heteroaryl having 1-3 ring heteroatoms selected from O, N, and S, wherein the heterocycloalkyl or heteroaryl is bonded to sulfur via a carbon ring atom, and the cycloalkyl, heterocycloalkyl, or heteroaryl has 0, 1, 2, or 3 R 2 Provided that it is substituted with the base, Each R 2 These are independently: Haro, CN, N(R) N )2C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, Oxo, CO2R N , or C(O)C 1-3 It is alkyl, Each R N H or C 1-3 It is alkyl.

[0013] In some cases, R 1 It is isopropyl. In some cases, R 1 It is isobutyl. In some cases, R 1 It is sec-butyl. In some cases, R 1 C 3-8 It is cycloalkyl, and in some cases, spiroC 7-8 It is a cycloalkyl. In some cases, R 1 These are cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some cases, R 1 These are cyclobutyl, cyclopentyl, or cyclohexyl. In some cases, R 1 It is cyclopropyl. In some cases, R 1 It is cyclobutyl. In some cases, R 1It is cyclopentyl. In some cases, R 1 It is cyclohexyl. In some cases, R 1 is spiro[3.3]heptyl. In some cases, R 1 C 1-6 Haloalkyl or C 1-6 It is a hydroxyalkyl group. In some cases, R 1 C 1-6 It is a haloalkyl. In some cases, R 1 is, C 1-6 It is a fluoroalkyl. In some cases, R 1 It is CH2F or CHF2. In some cases, R 1 It is CH2F. In some cases, R 1 It is CHF2. In some cases, R 1 C 1-6 Hydroxyalkyl. In some cases, R 1 C 2-8 Alkylene-N(R) N )2. In some cases, R 1 It is a 4- to 8-membered heterosylcoalkyl group. In some cases, R 1 These are azetidine, pyrrolidine, piperidine, oxetane, tetrahydrofuran, or tetrahydropyran. In some cases, R 1 It is 5-10 heteroaryl. In some cases, R 1 These are furan, thiophene, thiazole, isoxazole, imidazole, pyridine, or pyrazine. In some cases, R 1 It is a non-substitution. In some cases, R 1 is 1, 2, or 3 R 2 It is replaced with R 1 is one R 2 It is replaced with R 1 This is two R's 2 It is replaced with R 1 It is the three R's 2 It has been replaced with.

[0014] In some cases, at least one R 2 is oxo, CO2R N , or halo. In some cases, at least one R 2 is oxo, CO2H, or halo. In some cases, at least one R 2 is oxo. In some cases, at least one R 2 is CO2H. In some cases, at least one R 2 is halo. In some cases, at least one R 2 is CN, N(R N )2C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, or C(O)C 1-3 alkyl. In some cases, at least one R N is H. In some cases, at least one R N is C 1-3 alkyl. In some cases, each R N is H. In some cases, each R N is C 1-3 alkyl.

[0015] As used herein, the term "alkyl" or "alkylene" means a saturated straight or branched chain hydrocarbon. C n The term means that the alkyl group has "n" carbon atoms. For example, C4 alkyl refers to an alkyl group having 4 carbon atoms. C 1-6 alkyl refers to an alkyl group having a number of carbon atoms encompassing the entire range (i.e., 1 to 6 carbon atoms), as well as all subgroups (e.g., 1 to 6, 2 to 6, 1 to 5, 2 to 6, 1 to 4, 2 to 5, 1, 2, 3, 4, 5, and 6 carbon atoms). Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, and t-butyl.

[0016] As used herein, the term "alkoxy" means an O-alkyl group.

[0017] As used herein, the terms "halogen" and "halo" mean F, Cl, Br, or I.

[0018] As used herein, the term "haloalkyl" refers to an alkyl group as defined herein that is substituted with one or more halogen atoms.

[0019] As used herein, the term "hydroxyalkyl" refers to an alkyl group as defined herein that is substituted with one or more OH groups.

[0020] The term "oxo" refers to the =O group.

[0021] The term "cycloalkyl" refers to a non-aromatic monocyclic, condensed, bridged, or spirocyclic system in which the ring atom is carbon and can be saturated or has one or more unsaturated units. A carbocyclic ring may have 3 to 8 ring carbon atoms. In some embodiments, the number of carbon atoms is 4 to 6. A "condensed" bicyclic ring system contains two rings sharing two adjacent ring atoms. A bridged bicyclic group contains two rings sharing three or four adjacent ring atoms. A spiro-dicyclic ring system shares one ring atom. Cycloalkyl groups may contain cycloalkenyl groups. Specific examples include, but are not limited to, cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. When described herein, carbocyclic rings are either unsubstituted or substituted.

[0022] As used herein, the term "heterocycloalkyl" refers to a non-aromatic monocyclic, fused, spiro, or bridging ring system that can be saturated or contain one or more unsaturated units, having 4 to 10 ring atoms in which one or more (e.g., 1 to 3, or 1, 2, or 3) ring atoms are heteroatoms selected from O, N, and S. Examples of heterocycloalkyls include quinuclidinyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, azepanil, diazepanil, triazepanil, azocanil, diazocanil, triazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxazocanil, oxazepanil, thiazepanil, thiazocanil, benzimidazolonyl, tetrahydrofuranil, tetrahydrothiophenyl, morpholino (e.g., including 3-morpholino and 4-morpholino), 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 5-mune5din-2-one, 1-teto Examples include, but are not limited to, lahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothioluanyl, benzodithianyl, 3-(1-alkyl)-benzimidazole-2-onyl, and 1,3-dihydroimidazole-2-onyl. When described herein, heterocycloalkyl rings are either unsubstituted or substituted.

[0023] The term "heteroaryl" refers to heterocyclic aromatic rings having 5 to 10 members (e.g., 5 to 6 members), including monocyclic heteroaromatic rings and polycyclic aromatic rings in which a monocyclic aromatic ring is fused to one or more other aromatic rings. A heteroaryl group has one or more rings (e.g., 1 to 3, 1, 2, or 3) heteroatoms selected from O, N, and S. The term "heteroaryl" also includes, as used herein, groups in which an aromatic ring is "fused" to one or more nonaromatic rings (carbocyclic or heterocyclic rings) whose radical or bond site lies on the aromatic ring. Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, pyridadinyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, or thiadiazolyl, for example, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-pyrazolyl, 4-pyrazolyl, 1- Examples include pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-triazolyl, 5-triazolyl, tetrazolyl, 2-thienyl, 3-thienyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyrazinyl, and 1,3,5-triazinyl. When described herein, heteroaryl rings are either unsubstituted or substituted.

[0024] In some cases, the oligonucleotide contains one PAX internucleotide bond. In some cases, the oligonucleotide contains two to ten PAX internucleotide bonds. The nucleotides herein may also contain other modified internucleotide bonds. In some cases, at least one internucleotide bond is a phosphorothioate (PS). In some cases, at least one internucleotide bond is a mesylphosphoamidate (PA1).

[0025] The oligonucleotides disclosed herein contain 10 to 300 nucleotides. In some cases, the oligonucleotides contain 25 to 100 nucleotides. In some cases, the oligonucleotides contain 30 to 50 nucleotides.

[0026] The oligonucleotides disclosed herein can be used for any number of end uses. Exemplary oligonucleotides include, but are not limited to, structural genes, genes containing regulatory and termination regions, self-replicating systems such as viruses or plasmid DNA, single-stranded and double-stranded RNAi agents, and other RNA interference reagents (RNAi agents or iRNA agents), shRNA, antisense oligonucleotides, ribozymes, microRNAs, microRNA mimes, supermirs, aptamers, antimirs, antagonistmirs, adapters, triple-stranded oligonucleotides, tRNA (transfer RNA), G-quadrivalent oligonucleotides, RNA activators, immunostimulatory oligonucleotides, and decoy oligonucleotides. The selection of oligonucleotide characteristics (other than the presence of one or more PAX bonds disclosed herein) is within the scope of the art of the art in terms of the intended activity and use of the oligonucleotides.

[0027] In some examples, the PAX nucleotide bond of formula (I) has the structure shown in Table 1: [Table 1-1] [Table 1-2]

[0028] As used herein, the term “ADAR mobilization domain” refers to a sequence that acts as a mobilization and binding region for ADAR enzymes. Oligonucleotides containing such ADAR mobilization domains may be referred to as “axiomer AONs” or “self-loop AONs.” In some embodiments, a stem-loop structure can act as a mobilization domain for ADAR enzymes (e.g., an ADAR mobilization domain), but oligonucleotides disclosed herein can influence ADAR mobilization and activity to target adenosine in target RNA without such a stem-loop structure. Therefore, in some embodiments, the oligonucleotides disclosed herein do not contain a stem-loop structure. Alternatively, in some embodiments, the oligonucleotides disclosed herein include a stem-loop structure. The ADAR mobilization domain portion may act to mobilize endogenous ADAR enzymes present in cells. Such ADAR mobilization domains do not require the presence of a conjugated entity or a modified recombinant ADAR enzyme. Alternatively, the ADAR mobilization domain may act to mobilize a recombinant ADAR fusion protein delivered to a cell or target via an expression vector construct containing a polynucleotide encoding the ADAR fusion protein. Such an ADAR fusion protein may include the deaminase domain of the ADAR1 or ADAR2 enzyme fused to another protein, e.g., the MS2 bacteriophage coat protein. The ADAR mobilization domain may be a native substrate (e.g., GluR2 receptor premRNA, GluR2 ADAR mobilization domain), a Z-DNA structure, or a nucleotide sequence based on a domain known to mobilize another protein that is part of the ADAR fusion protein, e.g., the MS2 ADAR mobilization domain known to be recognized by the dsRNA binding region of ADAR. The stem-loop structure of the ADAR mobilization domain may be an intermolecular stem-loop structure formed by two separate nucleic acid strands, or an intramolecular stem-loop structure formed within a single nucleic acid strand.

[0029] In various cases, the oligonucleotides described herein include an ADAR mobilization moiety and a targeting moiety complementary to the target RNA having the target adenosine, where “position 0” of the oligonucleotide in this disclosure is the nucleotide opposite the target adenosine, and the “central triplet” of the oligonucleotide is the oligonucleotide at positions -1, 0, and +1. In some cases, the nucleotide bonds between position -1 and position 0, and between position 0 and position +1 are not phosphoramidites (e.g., parts of formula (I), such as any of L1 to L17). In some cases, the nucleotide bonds between positions +1 and +2 are phosphoramidites (e.g., parts of formula (I), such as any of L1 to L17). In some cases, the nucleotide bonds between positions +4 and +5 are phosphoramidites (e.g., parts of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions +5 and +6 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions +9 and +10 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions -31 and -30 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions -27 and -26 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions -25 and -24 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the internucleotide bond between positions -23 and -22 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the internucleotide bond between positions -19 and -18 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17).In some cases, the nucleotide bond between positions -13 and -12 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions -11 and -10 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions -10 and -9 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions -9 and -8 is a phosphoramidite (e.g., a part of formula (I), such as any of L1 to L17). In some cases, the nucleotide bonds between positions -x and -(x-1), and between positions -(x-1) and -(x-2), are phosphoramidites (e.g., parts of formula (I), such as any of L1 to L17), where x is the terminal position at the 5' end of the oligonucleotide. In some cases, the nucleotide bond between position +(y-1) and position +y is a phosphoramidite (e.g., parts of formula (I), such as any of L1 to L17), where +y is the terminal position at the 3' end of the oligonucleotide. In some cases, the nucleotide bond between positions +(y-2) and +(y-1) is a phosphoramidite (e.g., parts of formula (I), such as any of L1 to L17). In some cases, the nucleotide bond between positions +(y-3) and +(y-2) is a phosphoramidite (e.g., parts of formula (I), such as any of L1 to L17).

[0030] In some embodiments, the oligonucleotides described herein may further include a 5' cap structure. In some embodiments, the 5' cap structure is a 2,2,7-trimethylguanosine cap.

[0031] Modified oligonucleotides This disclosure provides oligonucleotides comprising unmodified or modified nucleotides and combinations thereof. Whereas used herein, “nucleoside” is defined as a compound comprising a sugar moiety (e.g., a pentose or ribose or other sugar moiety as used herein) or a derivative thereof, in combination with a nucleic acid base as used herein. “Nucleotide” is defined as a nucleoside comprising an internucleotide bond, such as a phosphate group or a modified phosphate group, such as a PAX bond of formula (I) as used herein. Modified nucleotides may be synthesized by any useful method as used herein (e.g., chemically, enzymatically, or recombinantly, to include one or more modified or unnatural nucleosides).

[0032] The oligonucleotides described herein may include various modifications from naturally occurring oligonucleotides. Where used herein, when referring to oligonucleotides, the terms “chemically modified” or, as they may be, “chemically modified” refer to modifications relating to nucleic acid bases (e.g., adenosine (A), guanosine (G), uridine (U), thymidine (T), or cytidine (C)), or sugar moieties (e.g., ribo- or deoxyribose), or to internucleotide bonds at one or more of these positions. Generally, these terms are not intended herein to refer to modifications found in naturally occurring oligonucleotides. In some embodiments, one or more nucleotides of the oligonucleotides described herein are chemically modified to enhance stability or other beneficial characteristics. Without being bound by theory, it is believed that certain modifications may increase nuclease resistance and / or serum stability, or reduce immunogenicity. For example, the oligonucleotides described herein may include nucleotides found to be naturally present in DNA or RNA (e.g., adenine, thymidine, guanosine, cytidine, uridine, or inosine), or may include nucleotides having one or more chemical modifications to one or more components of the nucleotide (e.g., nucleic acid bases, sugars, or internucleotide bonds) as described herein.

[0033] The modifications can be various distinct modifications. In some embodiments, the region may contain one, two, or more (optionally different) nucleotide modifications. In some embodiments, modified oligonucleotides introduced into cells may exhibit reduced intracellular degradation compared to unmodified oligonucleotides.

[0034] Modifications of oligonucleotides in this disclosure include, but are not limited to, those listed in detail below. Oligonucleotides may include naturally occurring or unnaturally occurring modifications, or oligonucleotides may include both naturally occurring and unnaturally occurring modifications.

[0035] The oligonucleotides of this disclosure may include any modifications to sugars, nucleic acid bases, or internucleotide bonds (e.g., to linked phosphates, phosphodiester bonds, or phosphodiester skeletons) as described in detail below. For example, one or more atoms of a pyrimidine or purine nucleic acid base may be replaced or substituted with optionally substituted aminos, optionally substituted thiols, optionally substituted alkyls (e.g., methyl or ethyl), or halos (e.g., chloro or fluoro). In certain embodiments, the modifications (e.g., one or more modifications) are present in both the sugar and the internucleotide bond. The modifications according to this disclosure may be modifications of ribonucleic acid (RNA) to deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), or hybrids thereof. Additional modifications are described herein.

[0036] Unnatural and / or modified nucleotides can be introduced into oligonucleotides during or after chain synthesis to achieve desired functions or properties. The modifications may be in internucleotide bonds, nucleic acid bases, or sugars. The modifications may be introduced at the ends of the chain or at any other location within the chain, using chemosynthesis or polymerase enzymes. Any region of the oligonucleotide may be chemically modified.

[0037] Nucleotide inter-nucleotide bonding The oligonucleotides disclosed herein include one or more nucleotide bonds. In all cases, at least one nucleotide bond of the oligonucleotides disclosed herein is a PAX nucleotide bond having the structure of formula (I) as described herein. The remaining nucleotide bonds of the oligonucleotides disclosed herein may be unmodified or natural nucleotide bonds and / or alternative nucleotide bonds. Unmodified or natural nucleotide bonds may be phosphate bonds. Alternative nucleotide bonds include unnatural nucleotide bonds and / or modified natural nucleotide bonds. Examples of alternative nucleotide bonds known in the art include, but are not limited to, phosphorothioates, boronophosphates, phosphotryesters, phosphorothionates, or phosphoramidate bonds, and other variations of the phosphate skeleton. In some embodiments, the oligonucleotides disclosed herein include at least one alternative nucleotide bond.

[0038] In some examples, the phosphate group (PO) of the natural internucleotide bond can be replaced with a phosphorothioate (PS) group or a boranophosphonate (PB) group, or the 3',5' phosphodiester bond of the natural internucleotide bond can be replaced with a 2',5' bond, or the ester bond can be replaced with an amide bond. Some embodiments include oligonucleotides having heteroatom skeletons, particularly the -CH2-NH-CH2-, -CH2-N(CH3)-O-CH2- [known as the methylene (methylimino) or MMI skeleton], -CH2-ON(CH3)-CH2-, -CH2-N(CH3)-N(CH3)-CH2-, and -N(CH3)-CH2-CH2- [the natural phosphodiester skeleton is represented as -OPO-CH2-] of U.S. Patent No. 5,489,677 referenced above, and the amide skeleton of U.S. Patent No. 5,602,240 referenced above. In some embodiments, the oligonucleotides featured herein have the morpholino backbone structure of U.S. Patent No. 5,034,506, referenced above. In some embodiments, the internucleotide bonds within a sequence of consecutive nucleotides are alternative internucleotide bonds. In some embodiments, the internucleotide bonds within a sequence of consecutive nucleotides are phosphoramidate bonds, for example, PAX internucleotide bonds having the structure of formula (I) disclosed herein. In some embodiments, the alternative internucleotide bonds are stereochemically pure alternative phosphoramidate bonds. In some embodiments, the alternative internucleotide bonds are Sp phosphoramidate bonds. In other embodiments, the alternative internucleotide bonds are Rp phosphoramidate bonds. In all cases, the oligonucleotides disclosed herein include at least one PAX internucleotide bond having the structure of formula (I) disclosed herein.

[0039] Other alternative chemistry for oligonucleotides described herein includes 5'-phosphate or 5'-phosphate mimics, e.g., 5'-terminal phosphate or oligonucleotide phosphate mimics. Suitable phosphate mimics are disclosed, for example, in U.S. Patent Publication 2012 / 0157511, the entirety of which is incorporated herein by reference.

[0040] Nucleic acid bases Oligonucleotides described herein may also include one or more nucleic acid bases (often simply referred to in the art as “bases”), including one or more standard nucleic acid bases and / or alternative nucleic acid bases (e.g., non-natural nucleic acid bases, or natural nucleic acid bases including modifications or substitutions). In some cases, at least one nucleotide in the oligonucleotides disclosed herein is debasal, i.e., a debasal oligonucleotide.

[0041] Standard nucleic acid bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Alternative nucleic acid bases include other non-natural / synthetic and natural nucleic acid bases described herein, including modified or substituted nucleic acid bases.

[0042] In some examples, oligonucleotides contain at least one non-natural nucleic acid base. In some examples, oligonucleotides contain at least one modified natural nucleic acid base. The terms “modified” or, as may be used, “modified” refer to structural and / or chemical modifications with respect to A, G, U, T, or C nucleic acid bases, nucleosides, and / or nucleotides. The nucleotides in the oligonucleotides of this disclosure may include non-standard nucleotides such as non-naturally occurring nucleotides ("non-natural nucleotides") or chemically synthesized nucleotides. One or more atoms of the nucleic acid bases may be replaced or substituted with optionally substituted aminos, optionally substituted thiols, optionally substituted alkyls (e.g., methyl or ethyl), or halos (e.g., chloro or fluoro).

[0043] Non-limiting examples of synthetic and natural nucleic acid bases that can function as alternative nucleic acid bases include 5-methylcytosine, 5-hydroxymethylcytosine, 5-formylcytosine, 5-carboxycytosine, pyrrolocytosine, dideoxycytosine, uracil, 5-methoxyuracil, 5-hydroxydeoxyuracil, dihydrouracil, 4-thiouracil, pseudouracil, 1-methyl-pseudracil, deoxy Uracil, 5-hydroxybutynur-2'-deoxyuracil, xanthine, hypoxanthine, 7-deaza-xanthine, thienoguanine, 8-aza-7-deazaguanine, 7-methylguanine, 7-deazaguanine, 6-aminomethyl-7-deazaguanine, 8-aminoguanine, 2,2,7-trimethylguanine, 8-methyladenine, 8-azidodenine, 7-methyladenine, 7-deazaadenine, 3- Deazaadenine, 2,6-diaminopurine, 2-aminopurine, 7-deaza-8-aza-adenine, 8-amino-adenine, thymine, dideoxythymine, 5-nitroindole, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cyanoacrylate Examples include tosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosine, 8-azaguanine and 8-azaadenine, and 3-deazaguanine.In some embodiments, the nucleic acid base moiety is modified by changing the purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or substituted pyrimidine, which is a "substitute nucleic acid base" selected from isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thiozolocytosine, 5-propynylcytosine, 5-propynyluracil, 5-bromouracil, 5-thiazolouracil, 2-thiouracil, pseudouracil, 1-methylpseudracil, 5-methoxyuracil, 2'-thiothymine, hypoxanthine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine, and 2-chloro-6-aminopurine. Further nucleic acid bases are disclosed in U.S. Patent No. 3,687,808, Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008, The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, JL, ed. John Wiley & Sons, 1990, Englisch et al., (1991) Angewandte Chemie, International Edition, 30:613, Sanghvi, Y S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, STand Lebleu, B., Ed., CRC Press, 1993, Hirao et al (2012) Accounts of Chemical Research vol 45, page 2055 and Examples include those disclosed in Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1. Certain nucleic acid bases are particularly useful for increasing the binding affinity of oligonucleotides described herein.These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and 0-6 substituted purines, such as 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. 5-methylcytosine substitution has been shown to increase nucleic acid double-strand stability by 0.6–1.2°C (Sanghvi, YS, Crooke, ST and Lebleu, B., Eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp.276–278) and is an exemplary base substitution.

[0044] In other embodiments, the nucleic acid bases in the oligonucleotide may be independently selected for each position from adenine, uridine, guanine, or cytidine, or analogs of adenine, uridine, guanine, or cytidine, such as modified adenine, uridine, guanine, or cytidine. Non-limiting examples of adenine, uridine, guanine, and cytidine analogs, as well as modified adenine, uridine, guanine, and cytidine, include N6-methyladenine, N1-methylademine, N6-2'-O-dimethyladenosine, pseudouridine, N1-methylpseudridine, 5-ioduridine, 4-thiouridine, 2-thiouridine, 5-methyluridine, pseudoisocytosine, 5-methoxycytosine, 2-thiocytosine, 5-hydroxycytosine, N4-methylcytosine, 5-hydroxymethylcytosine, hypoxanthine, N1-methylguanine, O6-methylguanine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 2-methylguanosine, N7-methylguanosine, 1-methylguanosine, N2,N7-dimethylguanosine, and isoguanine. For example, uridine (U) can be replaced with pseudouridine (ψ), 2-thiouridine (s2U), dihydrouridine (D), 5-bromo-U, 5-iodine-U, etc. Purines can be replaced with 2,6-diaminopurines.

[0045] Representative U.S. patents teaching the preparation of some of the above nucleic acid bases and other nucleic acid bases include U.S. Patents No. 3,687,808, No. 4,845,205, No. 5,130,30, No. 5,134,066, No. 5,175,273, No. 5,367,066, No. 5,432,272, No. 5,457,187, No. 5,459,255, No. 5,484,908, No. 5,502,177, No. 5,525,711, No. 5,552,540, No. 5,587,469, No. 5,594,121, and No. 5,596. Nos. 091, 5,614,617, 5,681,941, 5,750,692, 6,015,886, 6,147,200, 6,166,197, 6,222,025, 6,235,887, 6,380,368, 6,528,640, 6,639,062, 6,617,438, 7,045,610, 7,427,672, and 7,495,088 are examples of, but are not limited to, the entire contents of each of these publications which are incorporated herein by reference.

[0046] Additional nucleic acid bases found in the oligonucleotides disclosed herein include: 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-methyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6-glycinylcarbamoyladenosine, N6-isopentenyladenosine, N6-methyladenosine, N6-threonylcarbamoyladenosine, 1,2'-O-dimethyladenosine, 1-methyladenosine, 2'-O-methyladenosine, 2'-O-ribosyladenosine (phosphate), 2-methyladenosine, 2-methylthio-N6-isopentenyladenosine, 2-methylthio-N6 -Hydroxynorvalylcarbamoyladenosine, 2'-O-methyladenosine, 21-O-ribosyladenosine (phosphate), isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, N6,2'-O-dimethyladenosine, N6,2'-O-dimethyladenosine, N6,N6,2'-O-trimethyladenosine, N6,N6-dimethyladenosine, N6-acetyladenosine, N6-hydroxynorvalylcarbamoyladenosine, N6-methyl-N6-threonylcarbamoyladenosine, 2-methyladenosine, 2-methylthio-N6-isopentenyladenosine, 7-deaza-adenosine, N1-methyladenosine, N6,N6(dimethyl)adenine, N6-cis-hydroxyisopentenyl-adenosine, α-thio-adenosine, 2(amino)adenine, 2(aminopropyl)adenine, 2(methylthio)N6(isopentenyl)adenine, 2-(alkyl)adenine, 2-(aminoalkyl)adenine, 2-(aminopropyl)adenine, 2-(halo)adenine, 2-(halo)adenine, 2-(propyl)adenine, 2'-amino-2'-deoxy-ATP, 2' -Azido-2'-deoxy-ATP, 2'-deoxy-2'-α-aminoadenosine TP, 2'-deoxy-2'-α-azideadodenosine TP, 6(alkyl)adenine, 6(methyl)adenine, 6-(alkyl)adenine, 6-(methyl)adenine, 7(deaza)adenine, 8(alkenyl)adenine, 8(alkynyl)adenine, 8(amino)adenine, 8(thioalkyl)adenine, 8-(alkenyl)adenine, 8-(alkyl)adenine, 8-(alkynyl)adenine, 8-(amino)adenine, 8-(halo)adenine, 8-(hydroxyl)adenine, 8-(thioalkyl)adenine, 8-(thiol)adenine, 8-azido-adenosine, azaadenine, deazaadenine, N6(methyl)adenine, N6(isopentyl)adenine, 7-deaza-8-aza-adenosine, 7-methyladenine, 1-deazaadenosine TP, 2'-fluoro-N6-Bz-deoxyadenosine TP, 2' -OMe-2-amino-ATP, 2'0-methyl-N6-Bz-deoxyadenosine TP, 2'-α-ethynyladenosine TP, 2-aminoadenine, 2-aminoadenosine TP, 2-amino-ATP, 2'-α-trifluoromethyladenosine TP, 2-azidoadenosine TP, 2'-β-ethynyladenosine TP, 2-bromoadenosine TP, 2'-β-trifluoromethyladenosine TP, 2-chloroadenosine TP, 2'-deoxy-2',2'-Difluoroadenosine TP, 2'-Deoxy-2'-α-Mercaptoadenosine TP, 2'-Deoxy-2'-α-Thiomethoxyadenosine TP, 2'-Deoxy-2'-β-Aminoadenosine TP, 2'-Deoxy-2'-β-Azidoadenosine TP, 2'-Deoxy-2'-β-Bromoadenosine TP, 2'-Deoxy-2'-β-Chloroadenosine TP, 2'-Deoxy-2'-β-Fluoroadenosine TP, 2'-Deoxy-2'-β-Iodoadenosine TP , 2'-deoxy-2'-β-mercaptoadenosine TP, 2'-deoxy-2'-β-thiomethoxyadenosine TP, 2-fluoroadenosine TP, 2-iodoadenosine TP, 2-mercaptoadenosine TP, 2-methoxyadenine, 2-methylthioadenine, 2-trifluoromethyladenosine TP, 3-deaza-3-bromoadenosine TP, 3-deaza-3-chloroadenosine TP, 3-deaza-3-ruoroadenosine TP, 3-deaza-3-iodoadenosine T P, 3-deazaadenosine TP, 4'-azidoadenosine TP, 4'-carbocyclic adenosine TP, 4'-ethinyladenosine TP, 5'-homo-adenosine TP, 8-aza-ATP, 8-bromoadenosine TP, 8-trifluoromethyladenosine TP, 9-deazaadenosine TP, 2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 7-deaza-8-aza-2-aminopurine, 2,6-diaminopurine, 7-de Aza-8-aza-adenine, 7-deaza-2-aminopurine, 2-thiocytidine, 3-methylcytidine, 5-formylcytidine, 5-hydroxymethylcytidine, 5-methylcytidine, N4-acetylcytidine, 2'-O-methylcytidine, 21-O-methylcytidine, 5,2'-O-dimethylcytidine, 5-formi-1-2'-O-methylcytidine, lysidine, N4,2'-O-dimethylcytidine, N4-acetyl-2'-O-methylcytidine, N4-methylcytidine, N4,N4-dimethyl-2'-OMe-cytidine TP, 4-methylcytidine, 5-aza-cytidine, pseudo-isocytidine, pyrrolo-cytidine, α-thiocytidine, 2-(thio)cytosine, 2'-amino-2'-deoxy-CTP, 2'-azido-2'-deoxy-CTP, 2'-deoxy-2'-α-aminocytidine TP, 2'-deoxy-2'-α-azidocytidine TP, 3(deaza)5(aza)cytosine, 3(methyl)cytosine, 3-(alkyl)cytosine, 3-(deaza)5(aza)cytosine, 3-( Methylcytidine, 4,21-O-dimethylcytidine, 5(halo)cytosine, 5(methyl)cytosine, 5(propynyl)cytosine, 5(trifluoromethyl)cytosine, 5-(alkyl)cytosine, 5-(alkynyl)cytosine, 5-(halo)cytosine, 5-(propynyl)cytosine, 5-(trifluoromethyl)cytosine, 5-bromocytidine, 5-iodocytidine, 5-propynylcytosine, 6-(azo)cytosine, 6-azacytidine, azacytosine, deazacytosine, N4(acetyl)cytosine, 1-methyl-l-deaza-pseudoisocytidine, 1-methyl-pseudoisocytidine, 2-methoxy-5-methylcytidine, 2-methoxycytidine, 2-thio-5-methylcytidine, 4-methoxy-l-methyl-pseudoisocytidine, 4-methoxy-pseudoisocytidine, 4-thio-l-methyl-1-deaza-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio-pseudoisocytidine, 5-aza-zebralin, 5-methylzebralin, pyrrolo-pseudoisocytidine N, Zebralin, (E)-5-(2-bromo-vinyl)cytidine TP, 2,2'-anhydrocytidine TP hydrochloride, 2'-fluor-N4-Bz-cytidine TP, 2'fluoro-N4-acetylcytidine TP, 2'-O-methyl-N4-acetylcytidine TP, 2'O-methyl-N4-Bz-cytidine TP, 2'-α-ethynylcytidine TP, 2'α-trifluoromethylcytidine TP, 2'-β-ethynylcytidine TP, 2'β-trifluoromethylcytidine TP, 2'-deoxy-2',2'-Difluorocytidine TP, 2'-Deoxy-2'-α-Mercaptocytidine TP, 2'-Deoxy-2'-α-Thiomethoxycytidine TP, 2'-Deoxy-2'-β-Aminocytidine TP, 2'-Deoxy-2'-β-Azidocytidine TP, 2'-Deoxy-2'-β-Bromocytidine TP, 2'-Deoxy-2'-β-Chlorocytidine TP, 2'-Deoxy-2'-β-Fluorocytidine TP, 2'-Deoxy-2'-β-Iodocytidine TP, 2 '-Deoxy-2'-β-mercaptocytidine TP, 2'-Deoxy-2'-β-thiomethoxycytidine TP, 21-O-methyl-5-(1-propynyl)cytidine TP, 3'-ethynylcytidine TP, 4'-azidocytidine TP, 4'-carbocyclic cytidine TP, 4'-ethynylcytidine TP, 5-(1-propynyl)ala-cytidine TP, 5-(2-chlorophenyl)-2-thiocytidine TP, 5-(4-aminophenyl)-2-thiocytidine TP, 5- Aminoallyl-CTP, 5-cyanocytidine TP, 5-ethinylala-cytidine TP, 5-ethinylcytidine TP, 5'-homocytidine TP, 5-methoxycytidine TP, 5-trifluoromethylcytidine TP, N4-aminocytidine TP, N4-benzoylcytidine TP, pseudoisocytidine, 7-methylguanosine, N2,2'-O-dimethylguanosine, N2-methylguanosine, waiosin, 1,2'-O-dimethylguanosine, 1-methyl Guanosine, 2'-O-methylguanosine, 2'-O-ribosylguanosine (phosphate), 2'-O-methylguanosine, 2'-O-ribosylguanosine (phosphate), 7-aminomethyl-7-deazaguanosine, 7-cyano-7-deazaguanosine, alkaeosin, methylwyosin, N2,7-dimethylguanosine, N2,N2,2'-O-trimethylguanosine, N2,N2,7-trimethylguanosine, N2,N2-dimethylguanosine, N2,7,2'-O-trimethylguanosine, 6-thio-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, N1-methyl-guanosine, α-thio-guanosine, 2-(propyl)guanine, 2-(alkyl)guanine, 2'-amino-2'-deoxy-GTP, 2'-azido-2'-deoxy-GTP, 2'-deoxy-2'-α-aminoguanosine TP, 2'-deoxy-2'-α-azidoguanosine TP, 6-(methyl)guanine, 6-(alkyl)guanine, 6-(methyl ) Guanine, 6-methyl-guanosine, 7(alkyl)guanine, 7(deaza)guanine, 7(methyl)guanine, 7-(alkyl)guanine, 7-(deaza)guanine, 7-(methyl)guanine, 8(alkyl)guanine, 8(alkynyl)guanine, 8(halo)guanine, 8(thioalkyl)guanine, 8-(alkenyl)guanine, 8-(alkyl)guanine, 8-(alkynyl)guanine, 8-(amino)guanine, 8-(halo)guanine, 8-(hydroxyl)guanine, 8-(thioalkyl)guanine, 8-(thiol)guanine, azaguanine, deazaguanine, N(methyl)guanine, N(methyl)guanine, 1-methyl-6-thio-guanosine, 6-methoxy-guanosine, 6-thio-7-deaza-8-azaguanosine, 6-thio-7-deaza-guanosine, 6-thio-7-methyl-guanosine, 7-deaza-8-azaguanosine, 7-ethyl-8-oxo-guanosine, N2, N2-dimethyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, 1-Me-GTP, 2'-fluoro-N2-isobutyl-guanosine TP, 2'O-methyl-N2-isobutyl-guanosine TP, 2'-α-ethynylguanosine TP, 2'-α-trifluoromethylguanosine TP, 2'-β-ethynylguanosine TP, 2'-β-trifluoromethylguanosine TP, 2'-deoxy-2',2'-diflu Ologuanosine TP, 2'-deoxy-2'-α-mercaptoguanosine TP, 2'-deoxy-2'-α-thiomethoxyguanosine TP, 2'-deoxy-2'-β-aminoguanosine TP, 2'-deoxy-2'-β-azidoguanosine TP, 2'-deoxy-2'-β-bromoguanosine TP, 2'-deoxy-2'-β-chloroguanosine TP, 2'-deoxy-2'-β-fluoroguanosine TP, 2'-deoxy C-2'-β-iodoguanosine TP, 2'-deoxy-2'-β-mercaptoguanosine TP, 2'-deoxy-2'-β-thiomethoxyguanosine TP, 4'-azidoguanosine TP, 4'-carbocyclic guanosine TP, 4'-ethynylguanosine TP, 5'-homo-guanosine TP, 8-bromo-guanosine TP, 9-deazaguanosine TP, N2-isobutylguanosine TP, 1-methylinosine, inosine, 1,2'-O-dimethylinosine, 2'-O-methylinosine, 7-methylinosine, 2'-O-methylinosine, epiquiqueosin, galactosylqueosin, mannosylqueosin, queosin, allylaminothymidine, azathymidine, deazathymidine, deoxythymidine, 2'-O-methyluridine, 2-thiouridine, 3-methyluridine, 5-carboxymethyluridine, 5-hydroxyuridine, 5-methyluridine, 5-taurinomethyl-2-thiouridine, 5-ta Urinomethyluridine, dihydrouridine, pseudouridine, (3-(3-amino-3-carboxypropyl)uridine, 1-methyl-3-(3-amino-5-carboxypropyl)pseudridine, 1-methylpseudridine, 1-ethylpseudridine, 2'-O-methyluridine, 2'-O-methylpseudridine, 2'-O-methyluridine, 2-thio-2'-O-methyluridine, 3-(3-amino-3-carboxypropyl)uridine, 3,2'-O-dimethyluridine Zin, 3-methyl-pseud-uridine TP, 4-thiouridine, 5-(carboxyhydroxymethyl)uridine, 5-(carboxyhydroxymethyl)uridine methyl ester, 5,2'-O-dimethyluridine, 5,6-dihydrouridine, 5-aminomethyl-2-thiouridine, 5-carbamoylmethyl-2'-O-methyluridine, 5-carbamoylmethyluridine, 5-carboxyhydroxymethyluridine, 5-carboxyhydroxymethyluridine methyl ester, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, 5-carboxymethylaminomethyluridine, 5-carbamoylmethyluridine TP, 5-methoxycarbonylmethyl-2'-O-methyluridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-methoxycarbonylmethyluridine, 5-methyluridine,)5-Methoxyuridine, 5-Methyl-2-thiouridine, 5-Methylaminomethyl-1-2-selenouridine, 5-Methylaminomethyl-2-thiouridine, 5-Methylaminomethyluridine, 5-Methyldihydrouridine, 5-Oxyacetate-uridine TP, 5-Oxyacetate-methylester-uridine TP, N1-Methyl-pseudouracil, N1-Ethyl-pseudouracil, Uridine 5-oxyacetic acid, Uridine 5-oxyacetate methylester, 3-(3-amino-3-carboxypropyl-1)-uridine T P, 5-(iso-pentenylaminomethyl)-2-thiouridine TP, 5-(iso-pentenylaminomethyl)-2'-O-methyluridine TP, 5-(iso-pentenylaminomethyl-O-uridine TP, 5-propynyluracil, α-thiouridine, 1(aminoalkylamino-carbonylethylenyl)-2(thio)-pseudracil, 1(aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudracil, 1(aminoalkylaminocarbonylethylenyl)-4(thio)pseudracil Cyl, 1(aminoalkylaminocarbonylethylenyl)-pseudracil, 1(aminocarbonylethylenyl)-2(thio)-pseudracil, 1(aminocarbonylethylenyl)-2,4-(dithio)pseudracil, 1(aminocarbonylethylenyl)-4(thio)pseudracil, 1(aminocarbonylethylenyl)-pseudracil, 1-substituted 2(thio)-pseudracil, 1-substituted 2,4-(dithio)pseudracil, 1-substituted 4(thio)pseudracil, 1-substituted pseudouracil, 1-(aminoalkylamino-carbonylethylenel)-2-(thio)-pseudracil, 1-methi-1-3-(3-amino-3-carboxypropyl)pseudraidine TP, 1-methi-1-3-(3-amino-3-carboxypropyl)pseudra-UTP, 1-methyl-pseudra-UTP, 1-ethyl-pseudra-UTP, 2(thio)pseudracil, 2'deoxyuridine, 2'fluorouridine, 2-(thio)uracil, 2,4-(dithio)pseudracil, 2'methyl, 2'amino, 2'azide,2'-Fluoro-guanosine, 2'-amino-2'-deoxy-UTP, 2'-azido-2'-deoxy-UTP, 2'-azido-deoxyuridine TP, 2'-O-methylpseudouridine, 2'deoxyuridine, 2'fluorouridine, 2'-deoxy-2'-α-aminouridine TP, 2'-deoxy-2'-α-azidouridine TP, 2-methylpseudouridine, 3(3-amino-3-carboxypropyl)uracil, 4(thio)pseudracil, 4-(thio)pseudracil, 4-(thio)uracil, 4-thio Ouracil, 5(1,3-diazole-l-alkyl)uracil, 5(2-aminopropyl)uracil, 5(aminoalkyl)uracil, 5(dimethylaminoalkyl)uracil, 5(guanidiniumalkyl)uracil, 5(methoxycarbonylmethyl)-2-(thio)uracil, 5(methoxycarbonyl-methyl)uracil, 5(methyl)2(thio)uracil, 5(methyl)2,4(dithio)uracil, 5(methyl)4(thio)uracil, 5(methylaminomethyl)-2(thio)uracil, 5(methylaminomethyl)-2,4 (Dithio)uracil, 5(methylaminomethyl)-4(thio)uracil, 5(propynyl)uracil, 5(trifluoromethyl)uracil, 5-(2-aminopropyl)uracil, 5-(alkyl)-2-(thio)pseudracil, 5-(alkyl)-2,4(dithio)pseudracil, 5-(alkyl)-4(thio)pseudracil, 5-(alkyl)pseudracil, 5-(alkyl)uracil, 5-(alkynyl)uracil, 5-(allylamino)uracil, 5-(cyanoalkyl)uracil, 5-(dialkyl Minoalkyl)uracil, 5-(dimethylaminoalkyl)uracil, 5-(guanidiniumalkyl)uracil, 5-(halo)uracil, 5-(1,3-diazole-l-alkyl)uracil, 5-(methoxy)uracil, 5-(methoxycarbonylmethyl)-2-(thio)uracil, 5-(methoxycarbonyl-methyl)uracil, 5-(methyl)2(thio)uracil, 5-(methyl)2,4(dithio)uracil, 5-(methyl)4(thio)uracil, 5-(methyl)-2-(thio)pseudracil, 5-(methyl)-2,4(dithio)pseudracil, 5-(methyl)-4(thio)pseudracil, 5-(methyl)pseudracil, 5-(methylaminomethyl)-2(thio)uracil, 5-(methylaminomethyl)-2,4(dithio)uracil, 5-(methylaminomethyl)-4-(thio)uracil, 5-(propynyl)uracil, 5-(trifluoromethyl)uracil, 5-aminoallyl-uridine, 5-bromo-uridine, 5-iodo-uridine, 5-uracil, 6(azo)uracil, 6(azo)uracil, 6-aza-uridine, allylaminouracil, azau Racil, Deazauracil, N3(methyl)uracil, Pseudo-UTP-1-2-ethaneic acid, Pseudouracil, 4-thio-pseudo-UTP, 1-carboxymethyl-pseuduridine, 1-methi-1-1-deaza-pseuduridine, 1-propynyl-uridine, 1-taurinomethyl-1-methyl-uridine, 1-taurinomethyl-4-thio-uridine, 1-taurinomethyl-pseuduridine, 2-methoxy-4-thio-pseuduridine, 2-thio-l-methyl-1-deaza-pseuduridine, 2-thio-l-methyl-pseuduridine, 2-thio -5-Aza-uridine, 2-thio-dihydropsuduridine, 2-thio-dihydropsuduridine, 2-thio-psuduridine, 4-methoxy-2-thio-psuduridine, 4-methoxy-psuduridine, 4-thio-l-methylpsuduridine, 4-thio-psuduridine, 5-Aza-uridine, dihydropsuduridine, (±)1-(2-hydroxypropyl)psuduridine TP, (2R)-1-(2-hydroxypropyl)psuduridine TP, (2S)-1-(2-hydroxypropyl)psuduridine TP, (E)-5-(2 -bromo-vinyl)alara-uridine TP, (E)-5-(2-bromo-vinyl)uridine TP, (Z)-5-(2-bromo-vinyl)alara-uridine TP, (Z)-5-(2-bromo-vinyl)uridine TP, 1-(2,2,2-trifluoroethyl)pseudo-UTP, 1-(2,2,3,3,3-pentafluoropropyl)pseudouridine TP, 1-(2,2-diethoxyethyl)pseudouridine TP, 1-(2,4,6-trimethylbenzyl)pseudouridine TP, 1-(2,4,6-trimethylphenyl)pseudo-UTP, 1-(2-amino-2-carboxyethyl)pseudo-UTP, 1-(2-amino-ethyl)pseudo-UTP, 1-(2-hydroxyethyl)pseuduridine TP, 1-(2-methoxyethyl)pseuduridine TP, 1-(3,4-bis-trifluoromethoxybenzyl)pseuduridine TP, 1-(3,4-dimethoxybenzyl)pseuduridine TP, 1-(3-amino-3-carboxypropyl)pseudo-UTP, 1-(3-amino-propyl)pseudo-UTP, 1-(3-cyclopropyl-prop-2-inyl)pseuduridine TP, 1-(4-amino-4-carboxybutyl)pseudo-UTP, 1-(4-aminobenzyl)pseudo-UTP, 1-(4-amino-butyl)pseudo-UTP, 1-(4-aminophenyl)pseudo-UTP, 1-(4-azidobenzyl)pseudridine TP, 1-(4-bromobenzyl)pseudridine TP, 1-(4-chlorobenzyl)pseudridine TP, 1-(4-fluorobenzyl)pseudridine TP, 1-(4-iodobenzyl)pseudridine TP, 1-(4-methanesulfonylbenzyl)pseudridine TP, 1-(4-methoxybenzyl)pseudridine TP, 1-(4-methoxy-benzyl)pseudo-UTP, 1-(4-methoxy-phenyl)pseudo-UTP, 1-(4-methylbenzyl)pseudridine TP, 1-(4-methyl-benzyl)pseudo-UTP, 1-(4-nitrobenzyl)pseuduridine TP, 1-(4-nitro-benzyl)pseudo-UTP, 1-(4-nitro-phenyl)pseudo-UTP, 1-(4-thiomethoxybenzyl)pseuduridine TP, 1-(4-trifluoromethoxybenzyl)pseuduridine TP, 1-(4-trifluoromethylbenzyl)pseuduridine TP, 1-(5-amino-pentyl)pseudo-UTP, 1-(6-amino-hexyl)pseudo-UTP, 1,6-dimethyl-pseudo-UTP, 1- [3-(2-{2-[2-(2-aminoethoxy)-ethoxy]-ethoxy-ethoxy)-propionyl]psuduridine TP, 1-13-[2-(2-aminoethoxy)-ethoxy]-propionyl}psuduridine TP, 1-acetylpsuduridine TP, 1-alkyl-6-(1-propini-1)-psud-UTP, 1-alkyl-6-(2-propynyl)-psud-UTP, 1-alkyl-6-allyl-psud-UTP, 1-alkyl-6-ethynyl-psud-UTP, 1- Alkyl-6-vinyl-pseudo-UTP, 1-allyl-pseudouridine TP, 1-aminomethyl-pseudo-UTP, 1-benzoyl-pseudouridine TP, 1-benzyloxymethyl-pseudouridine TP, 1-benzyl-pseudo-UTP, 1-biotinyl-PEG2-pseudouridine TP, 1-biotinyl-pseudouridine TP, 1-butyl-pseudo-UTP, 1-cyanomethyl-pseudouridine TP, 1-cyclobutylmethyl-pseudo-UTP, 1-cyclobutyl-pseudo-UTP, 1-cycloheptylmethyl-pseudo-UTP,1-Cycloheptyl-pseudo-UTP, 1-Cyclohexylmethyl-pseudo-UTP, 1-Cyclohexyl-pseudo-UTP, 1-Cyclooctylmethyl-pseudo-UTP, 1-Cyclooctyl-pseudo-UTP, 1-Cyclopentylmethyl-pseudo-UTP, 1-Cyclopentyl-pseudo-UTP, 1-Cyclopropylmethyl-pseudo-UTP, 1-Cyclopropyl-pseudo-UTP, 1-Ethyl-pseudo-UTP, 1-Hexyl-pseudo-UTP, 1-Homoallylpseudouridine TP, 1-Hydroxymethylpseudouridine 1-Iso-propyl-pseudo-UTP, 1-Me-2-thio-pseudo-UTP, 1-Me-4-thio-pseudo-UTP, 1-Me-alpha-thio-pseudo-UTP, 1-methanesulfonylmethylpseudouridine TP, 1-methoxymethylpseudouridine TP, 1-methyl-6-(2,2,2-trifluoroethyl)pseudo-UTP, 1-methyl-6-(4-morpholino)pseudo-UTP, 1-methyl-6-(4-thiomorpholino)pseudo-UTP, 1-methyl-6-(substituted phenyl)pseudo-UTP, 1-methyl-6 -amino-pseudo-UTP, 1-methyl-6-azido-pseudo-UTP, 1-methyl-6-bromo-pseudo-UTP, 1-methyl-6-butyl-pseudo-UTP, 1-methyl-6-chloro-pseudo-UTP, 1-methyl-6-cyano-pseudo-UTP, 1-methyl-6-dimethylamino-pseudo-UTP, 1-methyl-6-ethoxy-pseudo-UTP, 1-methyl-6-ethylcarboxylate-pseudo-UTP, 1-methyl-6-ethyl-pseudo-UTP, 1-methyl-6-fluoro-pseudo-UTP, 1-methyl-6-horm Lu-pseu-UTP, 1-methyl-6-hydroxyamino-pseu-UTP, 1-methyl-6-hydroxy-pseu-UTP, 1-methyl-6-iodo-pseu-UTP, 1-methyl-6-iso-propyl-pseu-UTP, 1-methyl-6-methoxy-pseu-UTP, 1-methyl-6-methylamino-pseu-UTP, 1-methyl-6-phenyl-pseu-UTP, 1-methyl-6-propyl-pseu-UTP, 1-methyl-6-tert-butyl-pseu-UTP, 1-methyl-6-trifluoromethoxy-pseu-UTP,1-Methyl-6-trifluoromethyl-pseudo-UTP, 1-morpholinomethylpseuduridine TP, 1-pentyl-pseudo-UTP, 1-phenyl-pseudo-UTP, 1-pivaloylpseuduridine TP, 1-propargylpseuduridine TP, 1-propyl-pseudo-UTP, 1-propynyl-pseuduridine, 1-p-tolyl-pseudo-UTP, 1-tert-butyl-pseudo-UTP, 1-thiomethoxymethylpseuduridine TP, 1-thiomorpholinomethylpseuduridine TP, 1-trifluoroacetylsulfate Douridine TP, 1-trifluoromethyl-pseudo-UTP, 1-vinyl pseudouridine TP, 2,2'-anhydrouridine TP, 2'-bromodeoxyuridine TP, 2'-F-5-methyl-2'-deoxy-UTP, 2'-OMe-5-Me-UTP, 2'-OMe-pseudo-UTP, 2'-α-ethynyluridine TP, 2'-α-trifluoromethyluridine TP, 2'-β-ethynyluridine TP, 2'-β-trifluoromethyluridine TP, 2'-deoxy-2',2'-difluorouridine TP, 2'-deoxy-2 '-α-mercaptouridine TP, 2'-deoxy-2'-α-thiomethoxyuridine TP, 2'-deoxy-2'-β-aminouridine TP, 2'-deoxy-2'-β-aziduridine TP, 2'-deoxy-2'-β-bromouridine TP, 2'-deoxy-2'-β-chlorouridine TP, 2'-deoxy-2'-β-fluorouridine TP, 2'-deoxy-2'-β-ioduridine TP, 2'-deoxy-2'-β-mercaptouridine TP, 2'-deoxy-2'-β-thiomethoxyuridine TP, 2-methoxy-4-thio-uridine Zin, 2-methoxyuridine, 2'-O-methyl-5-(1-propynyl)uridine TP, 3-alkyl-pseudo-UTP, 4'-aziduridine TP, 4'-carbocyclic uridine TP, 4'-ethynyluridine TP, 5-(1-propynyl)ala-uridine TP, 5-(2-furanyl)uridine TP, 5-cyanouridine TP, 5-dimethylaminouridine TP, 5'-homo-uridine TP, 5-iodo-2'-fluorodeoxyuridine TP, 5-phenylethynyluridine TP, 5-trijuteromethyl-6-juterouridine TP,5-Trifluoromethyluridine TP, 5-Vinylalauridine TP, 6-(2,2,2-trifluoroethyl)-pseudo-UTP, 6-(4-morpholino)-pseudo-UTP, 6-(4-thiomorpholino)-pseudo-UTP, 6-(substituted-phenyl)-pseudo-UTP, 6-amino-pseudo-UTP, 6-azido-pseudo-UTP, 6-bromo-pseudo-UTP, 6-butyl-pseudo-UTP, 6-chloro-pseudo-UTP, 6-cyano-pseudo-UTP, 6-dimethylamino-pseudo-UTP, 6-ethoxy-pseudo -UTP, 6-ethylcarboxylate-pseudo-UTP, 6-ethyl-pseudo-UTP, 6-fluoro-pseudo-UTP, 6-formyl-pseudo-UTP, 6-hydroxyamino-pseudo-UTP, 6-hydroxy-pseudo-UTP, 6-iodo-pseudo-UTP, 6-iso-propyl-pseudo-UTP, 6-methoxy-pseudo-UTP, 6-methylamino-pseudo-UTP, 6-methyl-pseudo-UTP, 6-phenyl-pseudo-UTP, 6-phenyl-pseudo-UTP, 6-propyl-pseudo-UTP, 6-ter t-butyl-pseudo-UTP, 6-trifluoromethoxy-pseudo-UTP, 6-trifluoromethyl-pseudo-UTP, alpha-thio-pseudo-UTP, pseudouridine 1-(4-methylbenzenesulfonic acid)TP, pseudouridine 1-(4-methylbenzoic acid)TP, pseudouridine TP1-[3-(2-ethoxy)]propionic acid, pseudouridine TP1-[3-12-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy1]propionic acid, pseudouridine TP1-[3-{24242-12(2-ethoxy )-Ethoxy-1-Ethoxy]-Ethoxy)-Ethoxy-1]propionic acid, Pseudouridine TP1-[3-12-(2-[2-Ethoxy]-Ethoxy)-Ethoxylpropionic acid, Pseudouridine TP143-12-(2-Ethoxy)-Ethoxylpropionic acid, Pseudouridine TP1-Methylphosphonic acid, Pseudouridine TP1-Methylphosphonic acid diethyl ester, Pseudo-UTP-N1-3-propionic acid, Pseudo-UTP-N1-4-Butanoic acid, Pseudo-UTP-N1-5-Pentanoic acid, Pseudo-UTP-N1-6-Hexanoic acid,Pseudo-UTP-N1-7-heptanoic acid, Pseudo-UTP-N1-methyl-p-benzoic acid, Pseudo-UTP-N1-p-benzoic acid, Weibutosin, Hydroxyweibutosin, Isoyosin, Peroxyweibutosin, Low-modified hydroxyweibutosin, 4-Demethylweosin, 2,6-(diamino)purine, 1-(aza)-2-(thio)-3-(aza)-phenoxazine-l-yl, 1,3-(diaza)-2-(oxo)-phenoxazine-l-yl, 1 ,3,5-(triaza)-2,6-(dioxa)-naphthalene, 2(amino)purine, 2,4,5-(trimethyl)phenyl-1, 2'methyl,2'amino,2'azide,2'fluorocytidine, 21methyl,2'amino,2'azide,2'fluoroadenine, 2'methyl,2'amino,2'azide,2'fluorouridine, 2'-amino-2'-deoxyribose, 2-amino-6-chloropurine, 2-aza-inosinyl, 2'-azide-2'-deoxyribose, 2'fluoro-2'-deoxyribose, 2'-fluoro- Modified bases, 2'-O-methyl-ribose, 2-oxo-7-aminopyridopyrimidine-3-yl, 2-oxo-pyridopyrimidine-3-yl, 2-pyridinone, 3-nitropyrrole, 3-(methyl)-7-(propynyl)isocarbostyrylyl, 3-(methyl)isocarbostyrylyl, 4-(fluoro)-6-(methyl)benzimidazole, 4-(methyl)benzimidazole, 4-(methyl)indolyl, 4,6-(dimethyl)indolyl, 5-nitroindole, 5-substituted pyrimidine, 5-(methyl)isocarbostyrylyl, 5-nitroindole, 6-(aza)pyrimidine, 6-(azo)thymine, 6-(methyl)-7-(aza)indolyl, 6-chloropurine, 6-phenyl-pyrrolo-pyrimidine-2-one-3-i-1, 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiadin-l-yl, 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazine-1-yl, 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazine-1-yl,7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiadin-1-yl, 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 7-(aza)indolyl, 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazine-yl, 7-(guanidinium alkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiadin-l-i1, 7-(guanidinium alkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazine-l-i1, 7-(guanidinium alkylhydroxy)-1,3-(diaza)-2-(oxo)phenoxazine-1-yl, 7-(guanidinium alkyl-hydroxy)-1,3-(dia Za)-2-(oxo)-phenthiadin-1-yl, 7-(guanidinium alkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 7-(propynyl)isocarbostyrylyl, 7-(propynyl)isocarbostyrylyl,propynyl-7-(aza)indolyl, 7-deaza-inosinyl, 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenoxazine-1-yl, 7-substituted 1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 9-(methyl)-imidizopyridinyl, aminoindolyl, anthracenyl, bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, difluorotolyl, hypoxanthine, imidazopyridinyl, inosinyl, isocarbostyrylyl, isoguanisine, N2-substituted purine, N6-methyl-2-amino-purine, N6-substituted purine, N-alkylated derivative, naphthalenyl, nitrobenzimidazolyl, nitroimidazolyl, nitroindazolyl, nitropyrazolyl, nubularin, O6-substituted purine, O-alkylation derivative Body, ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-on-3-yl, ortho-substituted-6-phenyl-pyrrolo-pyrimidine-2-on-3-yl, oxoformicin TP, para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-on-3-yl1, para-substituted-6-phenyl-pyrrolo-pyrimidine-2-on-3-yl1, pentacenyl, phenanthracenyl, phenyl, propynyl-7-(aza)indolyl, pyrenyl, pyridopyrimidine-3-yl, pyridopyrimidine-3-yl, 2-oxo-7-amino-pyridopyrimidine-3-yl, pyrrolo-pyrimidine-2-on-3-yl, pyrrolopyrimidinyl, pyrrolopyrimidinyl, stilbenzyl, substituted 1,2,Examples include, but are not limited to, 4-triazole, tetrasenyl, tubercidine, xanthine, xanthosine-5'-TP, 2-thio-zebraline, 5-aza-2-thio-zebraline, 7-deaza-2-amino-purine, pyridine-4-onribonucleoside, 2-amino-riboside-TP, hormicin ATP, hormicin BTP, pyrrolosin TP, 2'-OH-ala-adenosine TP, 2'-OH-ala-cytidine TP, 2'-OH-ala-uridine TP, 2'-OH-ala-guanosine TP, 5-(2-carbomethoxyvinyl)uridine TP, and N6-(19-amino-pentaoxanonadecyl)adenosine TP. In some embodiments, alternative nucleic acid bases include pseudouridine (ψ), 2-thiouridine (s2U), 4'-thiouridine, 5-methylcytosine, 2-thio-l-methyl-pseudridine, 2-thio-l-methyl-pseudridine, 2-thio-5-azauridine, 2-thio-dihydropseudridine, 2-thio-dihydropseudridine, 2-thio-pseudridine, 4-methoxy-2-thiopseudridine, 4-methoxypseudridine, 4-thio-l-methylpseudridine, 4-thiopseudridine, 5-azauridine, dihydropseudridine, 5-methyluridine, 5-methoxyuridine, 21-O-methyluridine, 1-methylpseudridine (m1ψ), 1-ethyl-pseudridine Din (e1ψ), 5-methoxyuridine (mo5U), 5-methylcytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyanouridine, 4'-thiouridine, 7-deaza-adenine, 1-methyl-adenosine (mlA), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-diaminopurine, (I), 1-methyl Lu-inosine (m1I), waiosine (imG), methylwaiosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQO), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (mlG), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 2,8-Dimethyladenosine, 2-Geranylthiouridine, 2-Lysidine, 2-Selenouridine, 3-(3-Amino-3-Carboxypropyl)-5,6-Dihydrouridine, 3-(3-Amino-3-Carboxypropyl)Pseudouridine, 3-Methylpseuduridine, 5-(Carboxyhydroxymethyl)-2'-O-Methyluridine Methyl Ester, 5-Aminomethi-1-2-Geranylthiouridine, 5-Aminomethyl-2-Selenouridine, 5-Aminomethyluridine, 5-Carbamoylhydroxymethyluridine, 5-Carbamoylmethyl-2-Thiouridine, 5-Carboxymethi-1-2-Thiouridine, 5-Carboxymethylaminomethi-1-2-Geranylthiouridine, 5-Carboxymethylaminomethi-1-2-Selenouridine, 5-Cyanomethyluridine, 5-H Selected from the group consisting of droxycytidine, 5-methylaminomethyl-1-2-geranylthiouridine, 7-aminocarboxypropyl-demethylwyosin, 7-aminocarboxypropylwyosin, 7-aminocarboxypropylwyosin methyl ester, 8-methyladenosine, N4,N4-dimethylcytidine, N6-formyladenosine, N6-hydroxymethyladenosine, agmatidine, cyclic N6-threonylcarbamoyladenosine, glutamyl-queusin, methylated low-modified hydroxywyobutosin, N4,N4,2'-O-trimethylcytidine, geranylated 5-methylaminomethyl-2-thiouridine, geranylated 5-carboxymethylaminomethyl-1-2-thiouridine, Q base, pre-QO base, pre-Q1 base, and two or more combinations thereof. In some embodiments, the alternative nucleic acid base is selected from the group consisting of pseudouridine, 1-methyl-pseudridine, 1-ethyl-pseudridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.

[0047] In some embodiments, the nucleic acid base is modified uracil. Exemplary nucleic acid bases and nucleosides having modified uracil include pseudouridine (ψ), pyridine-4-onyribonucleoside, 5-azauridine, 6-azauridine, 2-thio-5-azauridine, 2-thiouridine (s2U), 4-thiouridine (s4U), 4-thio-pseudridine, 2-thio-pseudridine, 5-hydroxyuridine (ho5U), 5-aminoallyluridine, 5-halouridine (e.g., 5-iodouridine or 5-bromouridine), 3-methyluridine (m3U), 5-Methoxyuridine (mo5U), Uridine 5-oxyacetic acid (cmo5U), Uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyluridine (cm5U), 1-carboxymethyl-pseudridine, 5-carboxyhydroxymethyluridine (chm5U), 5-carboxyhydroxymethyluridine methyl ester (mchm5U), 5-methoxycarbonylmethyluridine (mcm5U), 5-methoxycarbonylmethyl-1-2-thiouridine (mcm5s2U), 5-aminomethyl-2- Thio-uridine (nm5s2U), 5-methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-methylaminomethi-1-2-seleno-uridine (mnm5se2U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5-carboxymethylaminomethi-1-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1-propynyl-pseuduridine, 5-taurinomethyl-uridine (τm 5U), 1-taurinomethyl-pseuduridine, 5-taurinomethyl-1-2-thio-uridine (τm5s2U), 1-taurinomethyl-4-thio-pseuduridine, 5-methyl-uridine (m5U, i.e., having the nucleic acid base deoxythymine), 1-methyl-pseuduridine (m1ψ), 1-ethyl-pseuduridine (e1ψ), 5-methyl-2-thio-uridine (m5s2U), 1-methyl-4-thio-pseuduridine (m1s4ψ), 4-thio-l-methyl-pseuduridine, 3-methyl-pseuduridine (m3ψ),2-Thio-1-methyl-pseuduridine, 1-methyl-1-deaza-pseuduridine, 2-Thio-l-methyl-1-deaza-pseuduridine, dihydrouridine(D), dihydropseuduridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine(m5D), 2-thio-dihydrouridine, 2-thio-dihydropseuduridine, 2-methoxy-uridine, 2-methoxy-4-thiouridine, 4-methoxy C-pseudridine, 4-methoxy-2-thio-pseudridine, N1-methyl-pseudridine, 3-(3-amino-3-carboxypropyl)uridine (acp3U), 1-methi-1-3-(3-amino-3-carboxypropyl)pseudridine (acp3kv), 5-(isopentenylaminomethyl)uridine (inm5U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm5s2U), a -Thio-uridine, 2'-O-methyluridine (Um), 5,2'-O-dimethyluridine (m5Um), 2'-O-methyl-pseudridine (ψm), 2-thio-2'-O-methyluridine (s2Um), 5-methoxycarbonylmethyluridine (mcm5Um), 5-carbamoylmethyluridine (ncm5Um), 5-carboxymethylaminomethyluridine (ncm5Um), 5-carboxymethylaminomethyluridine (mcm5Um) Examples include thio-uridine (cmnm5Um), 3,2'-O-dimethyl-uridine (m3Um), and 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2'-F-ala-uridine, 2'-F-uridine, 2'-OH-ala-uridine, 5-(2-carbomethoxyvinyl)uridine, and 5-[3-(1-E-propenylamino)]uridine.

[0048] In some embodiments, the nucleic acid base is modified cytosine. Exemplary nucleic acid bases and nucleosides having modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methylcytidine (m3C), N4-acetylcytidine (ac4C), 5-formylcytidine (f5C), N4-methylcytidine (m4C), 5-methylcytidine (m5C), 5-halocytidine (e.g., 5-iodocytidine), and 5-hydr Roxymethylcytidine (hm5C), 1-methyl-pseudoisocytidine, pyrrolocytidine, pyrrolo-pseudoisocytidine, 2-thiocytidine (s2C), 2-thio-5-methylcytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine Zebralin, 5-aza-zebralin, 5-methyl-zebralin, 5-aza-2-thio-zebralin, 2-thio-zebralin, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-l-methyl-pseudoisocytidine, lysidine (k2C), α-thiocytidine, 2'-O-methyl-cytidine (Cm), 5,2'-O-dimethyl Examples include ethylcytidine (m5Cm), N4-acetyl-2'-O-methylcytidine (ac4Cm), N4,2'-O-dimethylcytidine (m4Cm), 5-formi-1-2'-O-methylcytidine (f5Cm), N4,N4,2'-O-trimethylcytidine (m42Cm), 1-thiocytidine, 2'-F-alacytidine, 2'-F-cytidine, and 2'-OH-alacytidine.

[0049] In some embodiments, the nucleic acid base is a modified adenine.Examples of nucleic acid bases and nucleosides having modified adenine include 2-aminopurine, 2,6-diaminopurine, 2-amino-6-halopurine (e.g., 2-amino-6-chloropurine), 6-halopurine (e.g., 6-chloropurine), 2-amino-6-methylpurine, 8-azidoadenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-Methyl-adenosine (m1A), 2-Methyl-adenine (m2A), N6-methyl-adenosine (m6A), 2-methylthio-N6-methyl-adenosine (ms2m6A), N6-isopentenyl-adenosine (i6A), 2-methylthio-N6-isopentenyl-adenosine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenosine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms2io6A), N6-glycinylcarbamoyl-adenosine (g6A), N6-threonylcarbamoyl Il-adenosine (t6A), N6-methyl-N6-threonylcarbamoyl-adenosine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms2g6A), N6,N6-dimethyl-adenosine (m62A), N6-hydroxynorvalylcarbamoyl-adenosine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms2hn6A), N6-acetyl-adenosine (ac6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, α-thio-adenosine Examples include nosine, 2'-O-methyl-adenosine (Am), N6,2'-O-dimethyl-adenosine (m6Am), N6,N6,2'-O-trimethyl-adenosine (m62Am), 1,2'-O-dimethyl-adenosine (miAm), 2'-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2'-F-ala-adenosine, 2'-F-adenosine, 2'-OH-ala-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.

[0050] In some embodiments, the nucleic acid base is a modified guanine. Exemplary nucleic acid bases and nucleosides having modified guanine include inosine (I), 1-methyl-inosine (miI), yosine (imG), methylyosine (mimG), 4-demethylyosine (imG-14), isoyosine (imG2), yibutosine (yW), peroxyyibutosine (o2yW), hydroxyyibutosine (OhyW), low-modified hydroxyyibutosine (OhyW*), 7-deaza-guanosine, quosine (Q), epioxyquosine (oQ), and galactosine. Sil-Quosin (galQ), Mannosyl-Quosin (manQ), 7-Cyano-7-Deaza-Guanosine (preQo), 7-Aminomethyl-7-Deaza-Guanosine (preQi), Alkaeosin (G+), 7-Deaza-8-Aza-Guanosine, 6-Thio-Guanosine, 6-Thio-7-Deaza-Guanosine, 6-Thio-7-Deaza-8-Aza-Guanosine, 7-Methyl-Guanosine (m7G), 6-Thio-7-Methyl-Guanosine, 7-Methyl-Inosine, 6-Methoxy-Guanosine, 1 -Methyl-guanosine, N2-methyl-guanosine (m2G), N2,N2-dimethyl-guanosine (m22G), N2,7-dimethyl-guanosine (m2'7G), N2,N2,7-dimethyl-guanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, α-thio-guanosine, 2'-O-methyl-guanosine (Gm), N2-methyl-2'-O-methyl Examples include -guanosine (m2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m22Gm), 1-methyl-2'-O-methyl-guanosine (miGm), N2,7-dimethyl-2'-O-methyl-guanosine (m2'7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine, 2'-O-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine, O6-methyl-guanosine, 2'-F-ala-guanosine, and 2'-F-guanosine.

[0051] Further, non-limiting examples of alternative nucleic acid bases, nucleosides, and nucleotides suitable for use in oligonucleotides disclosed herein include those disclosed in WO2020 / 154342, WO2020 / 154344, and WO2020 / 154343, each of which is incorporated herein by reference in whole.

[0052] In some embodiments, oligonucleotides are uniformly modified for a specific modification (e.g., completely modified, modified throughout the entire sequence). For example, an oligonucleotide can be uniformly modified with 1-methylpseudridine, meaning that all uridine residues in the oligonucleotide sequence are replaced with 1-methylpseudridine. Similarly, an oligonucleotide can be uniformly modified by replacing any type of nucleic acid base present in the sequence with alternative nucleic acid bases, such as those shown above.

[0053] The oligonucleotides of this disclosure may be partially or completely modified along the entire length of the molecule. For example, one or more or all or a given type of nucleic acid base (e.g., purines or pyrimidines, or one or more or all of A, G, U, T, or C) may be uniformly modified in the oligonucleotides of this disclosure or in a given predetermined sequence region thereof (e.g., in mRNA that includes or excludes a poly-A tail). In some embodiments, all nucleotides X in the oligonucleotides of this disclosure (or a given sequence region thereof) are modified nucleotides, where X may be one of the nucleotides A, G, U, T, or C, or one of the combinations A+G, A+U, A+C, G-HU, G-FC, U+C, A+G-HU, A+G-FC, G-HU+C, or A+G+C.

[0054] In some embodiments, oligonucleotides are 1% to 100% modified nucleic acid bases (relative to the total nucleic acid base content, or relative to one or more types of nucleic acid bases, i.e., one or more of A, G, U, T, and / or C), or any percentage in between (e.g., 1% to 5%, 1% to 10%, 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%). This includes percentages of 10%-80%, 10%-90%, 10%-95%, 10%-100%, 20%-25%, 20%-50%, 20%-60%, 20%-70%, 20%-80%, 20%-90%, 20%-95%, 20%-100%, 50%-60%, 50%-70%, 50%-80%, 50%-90%, 50%-95%, 50%-100%, 70%-80%, 70%-90%, 70%-95%, 70%-100%, 80%-90%, 80%-95%, 80%-100%, 90%-95%, 90%-100%, and 95%-100%). It will be understood that any remaining percentage is occupied by the presence of standard nucleic acid bases A, G, T, U, and / or C.

[0055] Oligonucleotides may contain at least 0% and at most 100% modified nucleic acid bases, or any percentage in between, for example, at least 1% modified nucleic acid bases, at least 5% modified nucleic acid bases, at least 10% modified nucleic acid bases, at least 25% modified nucleic acid bases, at least 50% modified nucleic acid bases, at least 80% modified nucleic acid bases, or at least 90% modified nucleic acid bases. For example, oligonucleotides may contain modified pyrimidines such as modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the uracil in the oligonucleotide is replaced with modified uracil (e.g., 5-substituted uracil). Modified uracil can be replaced by a compound having a single unique structure, or by multiple compounds having different structures (e.g., two, three, four, or more unique structures). In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the cytosine in the oligonucleotide is replaced with modified cytosine (e.g., 5-substituted cytosine). The modified cytosine can be replaced by a compound having a single unique structure, or by multiple compounds having different structures (e.g., two, three, four, or more unique structures).

[0056] In some embodiments, the oligonucleotides described herein include at least one modified nucleoside, such as at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, or at least sixteen modified nucleosides. In other embodiments, the oligonucleotides include 1 to 10 modified nucleic acid bases, such as 2 to 9 modified nucleic acid bases, 3 to 8 modified nucleic acid bases, 4 to 7 modified nucleic acid bases, or 6 or 7 modified nucleic acid bases. In some embodiments, the oligonucleotides include a combination of at least two (e.g., two, three, four, or more) of the above-mentioned modified nucleic acid bases.

[0057] sugar part The oligonucleotides described herein may also include one or more sugar moieties, including one or more standard sugar moieties and / or alternative sugar moieties (e.g., non-natural sugar moieties, sugar analogs, or natural sugar moieties including modifications or substitutions).

[0058] Standard sugar moieties include ribose and deoxyribose. In some embodiments, the oligonucleotides disclosed herein include a ribose or modified ribose moiety. In some embodiments, the sugar moiety in the oligonucleotide may be ribose having optionally 2'-O-methyl, 2'-O-MOE, 2'-F, 2'-amino, 2'-O-propyl, 2'-aminopropyl, or 2'-OH modifications. In some embodiments, the oligonucleotides disclosed herein include a deoxyribose or modified deoxyribose moiety. Alternative sugar moieties include other unnatural and natural sugars described herein, as well as sugar analogs including modified or substituted sugar moieties.

[0059] The surrogate sugar moiety also includes a substituted sugar moiety. The oligonucleotides disclosed herein have at the 2'-position the following: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl (where alkyl, alkenyl, and alkynyl are substituted or unsubstituted C1-C 10 alkyl or C2-C 10 alkenyl and alkynyl) may comprise substituted furanose sugar moieties having one or more of the foregoing. Exemplary suitable modifications include -O[(CH2) n O] m CH3, -O(CH2) n OCH3, -O(CH2) n -NH2, -O(CH2) n CH3, -O(CH2) n -ONH2, and -O(CH2) n -ON[(CH2) n CH3]2, where n and m are from 1 to about 10. In other embodiments, the oligonucleotides disclosed herein have at the 2'-position the following: C1-C 10 alkyl, substituted C1-C 10The modification may include alkyl groups (e.g., substituted with one or more of OH, halo, amino, alkoxy, or thiol groups, or combinations thereof), alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl groups, RNA cleavage groups, reporter groups, intercalators, groups for improving the pharmacokinetic properties of oligonucleotides, or groups for improving the pharmacodynamic properties of oligonucleotides, and substituted furanose sugar moieties having one or more of other substituents having similar properties. In some embodiments, the modification includes 2'-methoxyethoxy (also known as 2'-O-CH2CH2OCH3, 2'-O-(2-methoxyethyl) or 2'-O-MOE), i.e., alkoxy-alkoxy groups. 2'-O-MOE nucleosides confer several beneficial properties to oligonucleotides, including, but are not limited to, increased nuclease resistance, improved pharmacokinetic properties, reduced nonspecific protein binding, reduced toxicity, reduced immunostimulatory properties, and enhanced target affinity compared to unmodified oligonucleotides.

[0060] Another exemplary alternative sugar moiety includes 2'-dimethylaminooxyethoxy, also known as 2'-DMAOE as described in the following examples, comprising an -O(CH2)2ON(CH3)2 group, and 2'-dimethylaminoethoxyethoxy (also known as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-(CH2)2-O-(CH2)2-N(CH3)2. Further exemplary alternative sugar moieties include 5'-Me-2'-F nucleotide, 5'-Me-2'-OMe nucleotide, 5'-Me-2'-deoxynucleotide (both R and S isomers in these three families), 2'-alkoxyalkyl, and 2'-NMA (N-methylacetamide).

[0061] Other alternatives include 2'-methoxy(2'-OCH3), 2'-aminopropoxy(2'-OCH2CH2CH2NH2), and 2'-fluoro(2'-F). Similar modifications can be made at other positions of the sugar moiety of the oligonucleotide, particularly at the 3' position of the sugar in the 3'-terminal nucleotide or 2'-5' linked oligonucleotide, and at the 5' position of the 5'-terminal nucleotide. Oligonucleotides can also have sugar analogs or mimics, such as a cyclobutyl moiety instead of pentofuranosyl sugar. Representative U.S. patents teaching the preparation of such modified sugar structures include U.S. Patents No. 4,981,957, No. 5,118,800, No. 5,319,080, No. 5,359,044, No. 5,393,878, No. 5,446,137, No. 5,466,786, No. 5,514,785, No. 5,519,134, No. 5,567,811, and No. 5, Examples include, but are not limited to, patents 576,427, 5,591,722, 5,597,909, 5,610,300, 5,627,053, 5,639,873, 5,646,265, 5,658,873, 5,670,633, and 5,700,920, some of which are generally recognized in this application. The entire contents of each of the foregoing are incorporated herein by reference.

[0062] The oligonucleotides of this disclosure may contain one or more bicyclic sugar moieties. A “bicyclic sugar” is a furanosyl ring modified by a bridge between two atoms. A “bicyclic nucleoside” (“BNA”) is a nucleoside having a sugar moiety that includes a bridge connecting two carbon atoms of a sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and 2'-carbon of the sugar ring. Thus, in some embodiments, the oligonucleotides of this disclosure may contain one or more locked nucleosides. A locked nucleoside is a nucleoside having a modified ribose moiety that includes an extra bridge connecting the 2' and 4' carbons of the ribose moiety. In other words, a locked nucleoside is a nucleoside having a bicyclic sugar moiety that includes a 4'-CH2-O-2' bridge. This structure effectively “locks” the ribose in its 3'-internal configuration. The addition of locked nucleosides to oligonucleotides has been shown to increase oligonucleotide stability in serum and reduce off-target effects (Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in oligonucleotides of this disclosure include, but are not limited to, nucleosides containing bridges between 4' and 2' ribosyl ring atoms. In certain embodiments, the oligonucleotides of this disclosure comprise one or more bicyclic nucleosides containing 4'-to-2' bridges.Examples of such 4'-to-2' cross-linked bicyclic nucleosides include 4'-(CH2)-O-2'(LNA), 4'-(CH2)-S-2', 4'-(CH2)2-O-2'(ENA), 4'-CH(CH3)-O-2' (also known as "restricted ethyl" or "cEt") and 4'-CH(CH2OCH3)-O-2' (and their analogues, see, for example, U.S. Patent No. 7,399,845), 4' -C(CH3)(CH3)-O-2' (and analogues, see, e.g., U.S. Patent No. 8,278,283), 4'-CH2-N(OCH3)-2' (and analogues, see, e.g., U.S. Patent No. 8,278,425), 4'-CH2-ON(CH3)2-2' (see, e.g., U.S. Patent Publication No. 2004 / 0171570), 4'-CH2-N(R)-O-2' (wherein R is H, C1-C). 12 Examples include, but are not limited to, alkyl or protecting groups (see, for example, U.S. Patent No. 7,427,672), 4'-CH2-C(H)(CH3)-2' (see, for example, Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134), and 4'-CH2-C(=CH2)-2' (and its analogues, see, for example, U.S. Patent No. 8,278,426). The entire contents of each of the foregoing are incorporated herein by reference. In some embodiments, at least one of the alternative sugar moieties is BNA (e.g., LNA), and for example, at least two of the alternative sugar moieties, for example, at least three, at least four, at least five, at least six, at least seven, or at least eight are BNA. In further embodiments, all alternative moieties are BNA.

[0063] Additional representative U.S. patents and U.S. patent publications teaching the preparation of locked nucleic acid nucleotides include: U.S. Patent Nos. 6,268,490, 6,525,191, 6,670,461, 6,770,748, 6,794,499, 6,998,484, 7,053,207, 7,034,133, 7,084,125, 7,399,845, and This includes, but is not limited to, US Nos. 7,427,672, 7,569,686, 7,741,457, 8,022,193, 8,030,467, 8,278,425, 8,278,426, 8,278,283, US2008 / 0039618, and US2009 / 0012281, the entire contents of each of these are incorporated herein by reference.

[0064] Any of the aforementioned bicyclic nucleosides can be prepared to have one or more stereochemical sugar configurations, for example, α-L-ribofuranose and β-D-ribofuranose (see WO99 / 14226).

[0065] The oligonucleotides of this disclosure can also be modified to include one or more restricted ethyl nucleotides. As used herein, “restricted ethyl nucleotide” or “cEt” is a locked nucleic acid comprising a bicyclic sugar moiety including a 4'-CH(CH3)-O-2' bridge. In one embodiment, the restricted ethyl nucleotide is in an S configuration which is referred herein to as “S-cEt”.

[0066] The oligonucleotides of this disclosure may also comprise one or more “configurationally constrained nucleotides” (“CRNs”). A CRN is a nucleotide analog having a linker connecting the C2' and C4' carbons of ribose or the C3 and --C5' carbons of ribose. CRNs lock the ribose ring into a stable configuration and increase hybridization affinity to mRNA. The linker is long enough to position the oxygen optimally for stability and affinity, resulting in less strain on the ribose ring.

[0067] Representative publications teaching some preparations of the above-mentioned CRNs include, but are not limited to, U.S. Patent Publication No. 2013 / 0190383 and PCT Publication No. WO2013 / 036868, the entire contents of each of these publications are incorporated herein by reference.

[0068] In some embodiments, the oligonucleotides of this disclosure comprise one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA are unlocked acyclic nucleic acids in which one of the sugar bonds has been removed to form an unlocked "sugar" residue. In one example, UNA also comprises monomers in which the C1'-C4' bond has been removed (i.e., a covalent carbon-oxygen-carbon bond between the C1' and C4' carbons). In another example, the C2'-C3' bond of the sugar (i.e., a covalent carbon-carbon bond between the C2' and C3' carbons) has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039 (incorporated herein by reference)).

[0069] Representative U.S. publications teaching the preparation of UNA include, but are not limited to, U.S. Patent Publication No. 8,314,227, and U.S. Patent Publications 2013 / 0096289, 2013 / 0011922, and 2011 / 0313020, the entire contents of each of these publications being incorporated herein by reference.

[0070] The sugar moiety can also be modified with a cyclopropane ring to produce tricyclodeoxynucleic acid (tricycloDNA). The sugar moiety may be, for example, 1,5,-anhydrohexitol, threose to produce threose nucleosides (TNAs), or arabinose to produce arabino nucleosides.

[0071] The sugar portion can also be non-sugar, such as cyclohexene to produce cyclohexene nucleic acid (CeNA), or glycol to produce glycol nucleic acid (GNA). Potentially stable modifications to the ends of nucleotide molecules include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyluridine-3''-phosphate, and the reverse base dT (idT). Disclosure of these modifications can be found in PCT Publication WO2011 / 005861.

[0072] The exemplary oligonucleotides of this disclosure include standard and / or alternative sugar moieties in any combination and at various positions, and may also include DNA or RNA oligonucleotides. Incorporation of modified sugar moieties into the oligonucleotides of this disclosure may enhance the affinity of the oligonucleotide to the target nucleic acid.

[0073] In some embodiments, the sugar moiety may be independently selected from ribose and deoxyribose at each position and / or may include modifications such as 2'-O-alkyl, 2'-O-methoxyethyl, 2'-O-allyl, 2'-O-alcalamine, 2'-fluororibs 2'-deoxyreverse, and locked nucleic acid (LNA). In some embodiments, the oligonucleotide comprises one or more modified sugar moieties, e.g., 2'-modified sugar moieties. In some embodiments, the oligonucleotides described herein comprise one or more 2'-modified sugar moieties independently selected from the group consisting of 2'-O-alkyl-RNA (e.g., 2'-O-methyl-RNA), 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, ANA, 2'-fluoro-ANA, and crosslinked nucleic acid ("BNA", e.g., locked nucleic acid "LNA") moieties. In some embodiments, one or more modified sugar moieties are BNA. In some cases, at least one sugar moiety is a ribose sugar or a modified ribose sugar. In some cases, at least one sugar moiety is a ribose sugar. In some cases, at least one sugar moiety is a modified ribose sugar. In some cases, at least one sugar moiety is independently 2'-methoxy-ribose, 2'-MOE-ribose, 5'-methyl-2'deoxyribose, 2'-deoxy-2'-fluororibose, 2'-fluoroarabinose, 2-methoxyarabinose, 2'deoxyribose, locked nucleic acid (LNA), or deoxyhexose. In some cases, each sugar moiety is independently 2'-methoxy-ribose, 2'-MOE-ribose, 5'-methyl-2'deoxyribose, 2'-deoxy-2'-fluororibose, 2'-fluoroarabinose, 2-methoxy-arabinose, 2'deoxyribose, locked nucleic acid (LNA), or deoxyhexose.

[0074] In some embodiments, the oligonucleotides described herein include phosphorodiamidate morpholino oligomers (PMOs) in which the deoxyribose moiety is replaced by a morpholine ring and the inter-bonding between charged phosphodiester subunits is replaced by an uncharged phosphoramidate bond, as described in Summerton, et al., Antisense Nucleic Acid Drug Dev. 1997, 7:63-70. In some cases, the oligonucleotides include a modified sugar moiety containing a bicyclic sugar derivative (e.g., LNA, ENA, CLNA, CENA, AENA), an acyclic sugar analog (e.g., UNA, PNA), or an analog containing a sugar other than ribose or deoxyribose (e.g., a pyranose ring (ANA, HNA)).

[0075] In some embodiments, the oligonucleotide contains at least one modified sugar moiety, such as at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, or at least sixteen modified sugar moieties. In other embodiments, the oligonucleotide contains 1 to 10 modified sugar moieties, such as 2 to 9 modified sugar moieties, 3 to 8 modified sugar moieties, 4 to 7 modified sugar moieties, or 6 or 7 modified sugar moieties. In some embodiments, the oligonucleotide is 1% to 100% modified sugar moiety (relative to the total sugar moiety content, or relative to one or more types of sugar moiety, e.g., ribose, deoxyribose, or derivatives thereof), or any percentage in between (e.g., 1% to 5%, 1% to 10%, 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%). This includes 10%~80%, 10%~90%, 10%~95%, 10%~100%, 20%~25%, 20%~50%, 20%~60%, 20%~70%, 20%~80%, 20%~90%, 20%~95%, 20%~100%, 50%~60%, 50%~70%, 50%~80%, 50%~90%, 50%~95%, 50%~100%, 70%~80%, 70%~90%, 70%~95%, 70%~100%, 80%~90%, 80%~95%, 80%~100%, 90%~95%, 90%~100%, and 95%~100%). It will be understood that any remaining sugar portion in an oligonucleotide is a standard sugar portion, i.e., a ribose or deoxyribose sugar portion.

[0076] In some embodiments, the sugar portion is given by formula IA~VA: [ka] It has one of the following structures, in the formula, N 1 These are hydrogen or nucleic acid bases, R 1A These are hydroxyl, halogen, or C1-C6 alkoxy compounds. R 2A is hydrogen, hydroxyl, halogen, or C1-C6 alkoxy, R 3A is hydrogen, hydroxyl, halogen, or C1-C6 alkoxy, R 4A is hydrogen, hydroxyl, halogen, or C1-C6 alkoxy, R 5A These are hydrogen, hydroxyl, halogen, or C1-C6 alkoxy.

[0077] In some embodiments, the sugar portion is expressed in formula IB~VIB: [ka] It has one of the following structures, in the formula, N 1 These are hydrogen or nucleic acid bases, R 12 These are hydrogen, hydroxyl, fluoro, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, or C1-C6 alkoxy. R 13 This is hydrogen or a C1-C6 alkyl group.

[0078] In some embodiments, the sugar portion is represented by formula IC~IVC: [ka] It has one of the following structures, in the formula, N 1 These are hydrogen or nucleic acid bases, R 6C is hydrogen, hydroxyl, or halogen, R 7C is hydrogen, hydroxyl, halogen, or C1-C6 alkoxy, R 8C is hydrogen or halogen, R 9C is hydrogen, hydroxyl, halogen, or C1-C6 alkoxy, R10C is hydrogen or halogen, R 11C This is hydrogen, hydroxyl, halogen, or C1-C6 alkoxy.

[0079] Non-limiting further examples of sugars suitable for use in oligonucleotides disclosed herein include those disclosed in WO2020 / 154342, WO2020 / 154344, and WO2020 / 154343, each of which is incorporated herein by reference in whole.

[0080] Oligonucleotides conjugated to additional parts In some embodiments, the oligonucleotides disclosed herein include one or more additional chemical moieties (or ligands). Various additional chemical moieties, such as targeting moieties, carbohydrate moieties, lipid moieties, etc., are known in the art and can be used in accordance with this disclosure to modulate the properties and / or activities of the provided oligonucleotides, such as stability, half-life, activity, delivery, pharmacodynamics, and pharmacokinetic properties. In some embodiments, certain additional chemical moieties facilitate the delivery of the oligonucleotide to desired cells, tissues, and / or organs, including but not limited to cells of the central nervous system. In some embodiments, certain additional chemical moieties facilitate the internalization of the oligonucleotide. In some embodiments, certain additional chemical moieties increase the stability of the oligonucleotide. In some embodiments, this disclosure provides techniques for incorporating various additional chemical moieties into oligonucleotides. In some embodiments, the additional chemical moiety is or includes a small molecule moiety. In some embodiments, the small molecule is a ligand for a protein (e.g., a receptor). In some embodiments, the small molecule binds to a polypeptide. In some embodiments, the small molecule is an inhibitor of a polypeptide. In some embodiments, the additional chemical moiety is or includes a peptide moiety (e.g., an antibody). In some embodiments, the additional chemical moiety is or includes a nucleic acid moiety, such as a nucleic acid moiety that forms a double helix or other secondary structure with the original oligonucleotide chain (before conjugation) or a portion thereof. In some embodiments, the nucleic acid is or includes an oligonucleotide that targets the same or different targets and may exert its activity via the same or different mechanisms. In some embodiments, the nucleic acid is or includes an RNAi agent. In some embodiments, the nucleic acid is or includes a miRNA agent. In some embodiments, the nucleic acid is or includes an RNase H-dependent agent. In some embodiments, the nucleic acid is or includes a gRNA. In some embodiments, the nucleic acid is or includes an aptamer. In some embodiments, the additional chemical moiety is or includes a carbohydrate moiety as described herein.Many useful drugs, such as small molecules, peptides, carbohydrates, and nucleic acid drugs, can be conjugated with oligonucleotides as provided herein in accordance with this disclosure. In some embodiments, the oligonucleotides provided may include two or more additional chemical moieties, which may be the same or different.

[0081] The oligonucleotides described herein may be chemically conjugated to one or more ligands, moieties, or conjugates that enhance the activity, cell distribution, or cell uptake of the oligonucleotide. Such moieties may include lipid moieties such as cholesterol moieties (Letsinger et al., (1989) Proc. Natl. Acid. Sci. USA, 86:6553-6556), cholic acid (Manoharan et al., (1994) Biorg. Med. Chem. Let., 4:1053-1060), thioethers, such as beryl-S-tritylthiol (Manoharan et al., (1992) Ann. NYAcad. Sci., 660:306-309, Manoharan et al., (1993) Biorg. Med. Chem. Let., 3:2765-2770), and thiocholesterol (Oberhauser et al., (1992) Nucl. Acids Res.,20:533-538), aliphatic chains, e.g., dodecanediol or undecyl residues (Saison-Behmoaras et al.,(1991)EMBO J,10:1111-1118, Kabanov et al.,(1990)FEBS Lett.,259:327-330, Svinarchuk et al.,(1993)Biochimie,75:49-54), phospholipids, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al.,(1995)Tetrahedron Lett.,36:3651-3654, Shea et al.,(1990)Nucl.Acids Res., 18:3777-3783), polyamine or polyethylene glycol chain (Manoharan et al., (1995) Nucleosides & Nucleotides, 14:969-973), or adamantane acetate (Manoharan et al., (1995) Tetrahedron Lett., 36:3651-3654), palmityl moiety (Mishra et al., (1995) Biochim. Biophys.This includes, but is not limited to, octadecylamine or hexylamino-carbonyloxycholesterol moieties (Acta, 1264:229-237), or octadecylamine or hexylamino-carbonyloxycholesterol moieties (Crooke et al., (1996) J. Pharmacol. Exp. Ther., 277:923-937).

[0082] In some embodiments, ligands alter the distribution, targeting, or lifetime of the oligonucleotide agent into which they are incorporated. In some embodiments, ligands provide enhanced affinity to selected targets, such as molecules, cells or cell types, compartments, such as compartments of cells or organs, tissues, organs, or regions of the body, compared to species in which such ligands are absent.

[0083] Ligands can include naturally occurring substances such as proteins (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin), carbohydrates (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylglucosamine, N-acetylgalactosamine, or hyaluronic acid), or lipids. Ligands can also be recombinant or synthetic molecules (such as synthetic polymers, e.g., synthetic polyamino acids). Examples of polyamino acids include polyamino acid polylysine (PLL), poly-L-aspartic acid, poly-L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic acid anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymer, or polyphosphatidine. Examples of polyamines include polyethyleneimine, polylysine (PLL), spermine, spermidine, polyamines, pseudopeptide-polyamines, peptide mimetic polyamines, dendrimer polyamines, arginine, amidine, protamine, cationic lipids, cationic porphyrins, quaternary salts of polyamines, or alpha-helical peptides.

[0084] The ligand may also include a cell or tissue targeting agent, such as a lectin, glycoprotein, lipid, or protein, such as an antibody, that binds to a specific cell type, such as kidney cells. The targeting moiety may be thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, polyhydric lactose, polyhydric galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, polyhydric mannose, polyhydric fucose, glycosylated polyamino acids, polyhydric galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, lipid, cholesterol, steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or RGD peptide or RGD peptide mimetic.

[0085] Other examples of ligands include dyes, inserts (e.g., acridine), crosslinking agents (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphylline, saffrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g., cholesterol, cholic acid, adamantane acetate, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl) Examples include oils (colenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., Antennapedia peptide, Tat peptide), alkylating agents, phosphoric acid, amino acids, mercaptos, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino acids, alkyls, substituted alkyls, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraaza macrocyclic compounds), dinitrophenyl, HRP, or AP.

[0086] In some embodiments, the additional chemical moiety is a targeting moiety. In some embodiments, the oligonucleotides disclosed herein further comprise one or more targeting moieties. In some embodiments, one or more targeting moieties comprise lipids, sterols, carbohydrates, vitamins, and / or peptides. In some embodiments, one or more targeting moieties comprise thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, polyhydric lactose, polyhydric galactose, ASGPR binding moiety, N-acetyl-galactosamine (GalNAc) moiety, N-acetyl-glucosamine polyhydric mannose, polyhydric fucose, glycosylated polyamino acids, polyhydric galactose, transferrin, polyglutamate, polyaspartate, cholesterol, bile acid, folate, vitamin B12, vitamin A, biotin, RGD peptide, or RGD peptide mimetic. In some embodiments, the ASGPR binding moiety is N-acetyl-galactosamine (GalNAc) or N-acetyl-glucosamine polyhydric mannose. In some embodiments, one or more targeting moieties include an N-acetyl-galactosamine (GalNAc) moiety. In some embodiments, one or more targeting moieties are located at the 5' end, the 3' end, or both of the oligonucleotide. In some embodiments, one or more targeting moieties are located at both the 5' and 3' ends of the oligonucleotide. In some embodiments, one or more targeting moieties are located at the 5' end of the oligonucleotide. In some embodiments, one or more targeting moieties are located at the 3' end of the oligonucleotide. In some embodiments, one or more targeting moieties are linked to the oligonucleotide by a linker moiety. In some embodiments, the linker moiety includes an alkylene, polyalkylene oxide, and / or peptide moiety. In some embodiments, the additional chemical moiety is or includes a carbohydrate moiety. In some embodiments, the additional chemical moiety is or includes a lipid moiety. In some embodiments, the additional chemical moiety is or includes a ligand moiety for a cellular receptor, such as a sigma receptor or an asial glycoprotein receptor.In some embodiments, the ligand moiety is or comprises an anisamide moiety that may be the ligand moiety for a sigma receptor. In some embodiments, the ligand moiety is or comprises a GalNAc moiety that may be the ligand moiety for an asial glycoprotein receptor. In some embodiments, an additional chemical moiety facilitates delivery to the liver. In some cases, the oligonucleotide contains a GalNAc moiety. In some cases, the GalNAc moiety is located at the 5' end of the oligonucleotide. In some cases, the GalNAc moiety is located at the 3' end of the oligonucleotide.

[0087] Ligands can be proteins, such as glycoproteins, or peptides, such as molecules with specific affinity for a co-ligand, or antibodies, such as antibodies that bind to specific cell types, such as hepatocytes. Ligands can also include hormones and hormone receptors. They can also include lipids, lectins, carbohydrates, vitamins, cofactors, and non-peptide species such as polyvalent lactose, polyvalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, polyvalent mannose, or polyvalent fucose.

[0088] A ligand can be a substance, such as a drug, that can increase the uptake of an oligonucleotide agent into a cell, for example, by disrupting the cytoskeleton of the cell, for example, by disrupting the microtubules, microfibrils, and / or intermediate fibrils of the cell. A drug can be, for example, taxone, vincristine, vinblastine, cytochalasin, nocodazole, japlaquinolide, latruncrine A, phalloidin, swinford A, indanosine, or myocerbin.

[0089] In some embodiments, ligands attached to oligonucleotides described herein act as pharmacokinetic modifiers (PK modifiers). PK modifiers include lipophilic substances, bile acids, steroids, phospholipid analogs, peptides, protein binders, PEGs, vitamins, and the like. Exemplary PK modifiers include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglycerides, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, and biotin. Oligonucleotides containing several phosphorothioate bonds are also known to bind to serum proteins; therefore, short oligonucleotides, such as those containing multiple phosphorothioate bonds in the backbone and consisting of approximately 5, 10, 15, or 20 bases, can also be used as ligands (e.g., as PK modulating ligands) according to the oligonucleotides disclosed herein. In addition, aptamers that bind to serum components (e.g., serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

[0090] In some embodiments, additional chemical moieties conjugated to the oligonucleotide can target the oligonucleotide to cells in the central nervous system.

[0091] In some embodiments, the additional chemical moiety includes or is a cell receptor ligand. In some embodiments, the additional chemical moiety includes or is a protein binder, for example, one that binds to a cell surface protein. Such moieties can be useful, among other things, for targeted delivery of oligonucleotides to cells expressing the corresponding receptor or protein. In some embodiments, the additional chemical moiety of the provided oligonucleotide includes anisamide or a derivative or analog thereof, which can target the oligonucleotide to cells expressing a specific receptor, such as a sigma-1 receptor.

[0092] In some embodiments, the provided oligonucleotide is formulated for administration to somatic cells and / or tissues expressing its target. In some embodiments, an additional chemical moiety conjugated to the oligonucleotide can target the oligonucleotide to cells.

[0093] In some embodiments, the additional chemical part is or includes an asial glycoprotein receptor (ASGPR) ligand. While we do not wish to be bound by any particular theory, ASGPR1 has been reported to be expressed in the mouse hippocampal region and / or cerebellar Purkinje cell layer. http: / / mouse.brain-map.org / experiment / show / 2048. Various ASGPR ligands are known in the art and can be utilized in accordance with this disclosure. In some embodiments, the ASGPR ligand is a carbohydrate. In some embodiments, the ASGPR ligand is GalNac or its derivatives or analogs. In some embodiments, the ASGPR ligand is one described in Sanhueza et al. J.Am.Chem.Soc., 2017, 139(9), pp 3528-3536. In some embodiments, the ASGPR ligand is one described in Mamidyala et al. J.Am.Chem.Soc., 2012, 134, pp 1978-1981. In some embodiments, the ASGPR ligand is one described in US2016 / 0207953. In some embodiments, the ASGPR ligand is, for example, a substituted -6,8-dioxabicyclo[3.2.1]octane-2,3-diol derivative disclosed in US2016 / 0207953. In some embodiments, the ASGPR ligand is one described in, for example, US2015 / 0329555. In some embodiments, the ASGPR ligand is, for example, a substituted -6,8-dioxabicyclo[3.2.1]octane-2,3-diol derivative disclosed in US2015 / 0329555. In some embodiments, the ASGPR ligand is one described in US8877917, US2016 / 0376585, US10086081, or US8106022. The ASGPR ligands described in these documents are incorporated herein by reference. Those skilled in the art will understand that various techniques, including those described in these documents, are known in the art and can be used in accordance with this disclosure for evaluating the binding of chemical moieties to ASGPR.In some embodiments, the provided oligonucleotide is conjugated with an ASGPR ligand. In some embodiments, the provided oligonucleotide contains an ASGPR ligand.

[0094] In some embodiments, additional chemical moieties in oligonucleotides disclosed herein are linked via linkers. Various linkers, for example, those used for conjugation with various protein moieties (e.g., antibodies for forming antibody-drug conjugates), nucleic acids, etc., are available in the art and may be used in accordance with this disclosure. Certain useful linkers are listed in US9982257, US2017 / 0037399, US2018 / 0216108, US2018 / 0216107, US9598458, WO2017 / 062862, WO2018 / 067973, WO2017 / 160741, WO2017 / 192679, WO2017 / 210647, WO2018 / 098264, and WO2018 / 223056. These linker portions are described in WO2018 / 237194, WO2019 / 032607, WO2019 / 055951, WO2019 / 075357, WO2019 / 200185, WO2019 / 217784, WO2019 / 032612, WO2020 / 191252, and / or WO2021 / 071858, and each of these linker portions is independently incorporated herein by reference. In some embodiments, the linker can link two or more additional chemical moieties to the oligonucleotide chain described herein. For example, in some embodiments, one, two, three or more additional chemical moieties, such as a GalNAc moiety, are linked to the oligonucleotide chain (e.g., at the 5' end) via a polyvalent linker portion.

[0095] In some embodiments, an additional chemical moiety is cleaved from the oligonucleotide, e.g., the rest of the oligonucleotide chain, after administration to a system, cell, tissue, organ, or subject, for example. In some embodiments, the additional chemical moiety facilitates, increases, and / or accelerates delivery to a particular cell, and after delivery of the oligonucleotide to such cell, the additional chemical moiety is cleaved from the oligonucleotide. In some embodiments, the linker moiety includes one or more cleavable moieties that can be cleaved at a desired location (e.g., within a particular cell type, within a subcellular compartment such as a lysosome, etc.) and / or timing. In some embodiments, the cleavable moieties are selectively cleaved by a polypeptide, e.g., by an enzyme such as a nuclease. Many useful cleavable moieties and cleavable linkers have been reported and can be utilized in accordance with this disclosure. In some embodiments, the cleavable moiety is or includes one or more functional groups selected from amides, esters, ethers, phosphodiesters, disulfides, carbamates, etc. In some embodiments, the linker is as described in WO2012 / 030683, WO2021 / 030778, WO2020 / 154344, WO2020 / 154343, WO2020 / 154342, WO2020 / 165077, WO2020 / 201406, WO2020 / 216637, or WO2020 / 252376.

[0096] Lipid conjugate In some embodiments, the ligand or conjugate is a lipid or lipid-based molecule. Such lipid or lipid-based molecules preferably bind to serum proteins, such as human serum albumin (HSA). HSA-binding ligands enable the distribution of the conjugate to target tissues, such as non-renal target tissues of the body. For example, the target tissue can be the liver and include hepatic parenchymal cells. Other molecules that can bind to HSA can also be used as ligands. For example, neproxine or aspirin can be used. Lipid or lipid-based ligands can (a) increase resistance to the degradation of the conjugate, (b) increase targeting or transport to target cells or cell membranes, and / or (c) modulate binding to serum proteins, such as HSA.

[0097] The binding of conjugates to target tissues can be inhibited, for example, controlled, using lipid-based ligands. For instance, lipids or lipid-based ligands that bind more strongly to HSAs are less likely to target the kidneys and therefore less likely to be eliminated from the body. Conjugates can be targeted to the kidneys using lipids or lipid-based ligands that do not bind as strongly to HSAs.

[0098] In some embodiments, the ligand is a portion of the target cell, such as a proliferating cell, that is taken up by the target cell, such as a vitamin. Exemplary vitamins include vitamins A, E, and K.

[0099] Cell permeabilizing agent In some embodiments, the ligand is a cell permeabilizer, preferably a helical cell permeabilizer. Preferably, the agent is amphiphilic. Exemplary agents are peptides such as tat or antenopedia. If the agent is a peptide, it can be modified, including the use of peptidyl mimes, invertomers, non-peptide or pseudopeptide bonds, and D-amino acids. The helical agent is preferably an alpha-helical agent having an oleophilic phase and an oleophobic phase.

[0100] The ligand can be a peptide or a peptide mimetic. A peptide mimetic (also referred to herein as an oligopeptide mimetic) is a molecule that can fold into a three-dimensional structure similar to that of a natural peptide. The attachment of peptides and peptide mimes to oligonucleotide agents can affect the pharmacokinetic distribution of the oligonucleotide, for example, by enhancing cell recognition and absorption. The peptide or peptide mimetic portion can have an amino acid length of about 5 to 50 amino acids, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids.

[0101] The peptide or peptide mimetic can be, for example, a cell-permeable peptide, a cationic peptide, an amphiphilic peptide, or a hydrophobic peptide (e.g., mainly composed of Tyr, Trp, or Phe). The peptide moiety can be a dendrimer peptide, a restricting peptide, or a crosslinked peptide. Alternatively, the peptide moiety can contain a hydrophobic membrane transport sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 64). RFGF analogues containing a hydrophobic MTS (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 65)) can also be the targeting moiety. The peptide moiety can be a “delivery” peptide capable of transporting large polar molecules, including peptides, oligonucleotides, and proteins, across the cell membrane. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ, SEQ ID NO: 66) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK, SEQ ID NO: 67) have been found to function as delivery peptides. Peptides or peptide mimes can be encoded by random sequences of DNA, such as peptides identified from phage-display libraries or one-bead-one-compound (OBOC) combinatorial libraries (Lam et al., Nature, 354:82-84, 1991). Examples of peptides or peptide mimes linked to oligonucleotide agents via monomer units incorporated for cell targeting purposes include arginine-glycine-aspartate (RGD) peptides or RGD mimes. The peptide portion can range in length from approximately 5 to approximately 40 amino acids. The peptide portion can have structural modifications, such as to increase stability or to indicate configurational properties. Any of the structural modifications described below can be utilized.

[0102] The RGD peptides for use in the compositions and methods described herein may be linear or cyclic and may be modified, for example, glycosylated or methylated, to facilitate targeting to specific tissues. RGD-containing peptides and peptide mimes may include D-amino acids and synthetic RGD mimes. In addition to RGD, other parts that target integrin ligands may be used. Some conjugates of these ligands target PECAM-1 or VEGF.

[0103] Cell-permeable peptides can permeate cells, such as microbial cells like bacterial or fungal cells, or mammalian cells like human cells. Microbial cell-permeable peptides can be, for example, α-helical peptides (e.g., LL-37 or seropin P1), disulfide bond-containing peptides (e.g., α-defensin, β-defensin, or bactenesin), or peptides containing only one or two dominant amino acids (e.g., PR-39 or indolicidine). Cell-permeable peptides can also contain nuclear localization signals (NLS). For example, cell-permeable peptides can be double amphiphilic peptides such as MPG derived from the fusion peptide domain of the NLS of HIV-1 gp41 and SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).

[0104] Carbohydrate conjugate In some embodiments, the oligonucleotides described herein further comprise carbohydrates. Carbohydrate-conjugated oligonucleotides are advantageous for compositions suitable for in vivo delivery of nucleic acids and for in vivo therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound that is either a carbohydrate itself, consisting of one or more monosaccharide units having at least six carbon atoms (which may be linear, branched, or cyclic) each having an oxygen, nitrogen, or sulfur atom bonded to each carbon atom, or a compound having as part a carbohydrate portion consisting of one or more monosaccharide units, each having at least six carbon atoms (which may be linear, branched, or cyclic) each having an oxygen, nitrogen, or sulfur atom bonded to each carbon atom. Typical carbohydrates include sugars (monosaccharides, disaccharides, trisaccharides, and oligosaccharides containing about 4, 5, 6, 7, 8, or 9 monosaccharide units), as well as polysaccharides such as starch, glycogen, cellulose, and polysaccharide gums. Certain monosaccharides contain 5 or more monosaccharide units (e.g., C5, C6, C7, or C8), while disaccharides and trisaccharides contain 2 or 3 monosaccharide units (e.g., C5, C6, C7, or C8).

[0105] In some embodiments, the carbohydrate conjugate is a monosaccharide.

[0106] In some embodiments, the carbohydrate conjugate further comprises one or more of the above-mentioned additional ligands, not limited to PK modifiers and / or cell-permeable peptides.

[0107] Additional carbohydrate conjugates (and linkers) suitable for use in oligonucleotides described herein include those described in PCT Publications WO2014 / 179620 and WO2014 / 179627, the entire contents of each of which are incorporated herein by reference.

[0108] Linker In some embodiments, the conjugates or ligands described herein can be attached to oligonucleotides using a variety of linkers that may be cleavable or non-cleavable.

[0109] Linkers are typically direct bonds or atoms such as oxygen or sulfur, units such as NR8, C(O), C(O)NH, SO, SO2, SO2NH, or substituted or unsubstituted alkyls, substituted or unsubstituted alkenyls, substituted or unsubstituted alkynyls, arylalkyls, arylalkenyls, arylalkynyls, heteroarylalkyls, heteroarylalkenyls, heteroarylalkynyls, heterocyclylalkyls, heterocyclylalkenyls, heterocyclylalkynyls, aryls, heteroaryls, heterocyclyl, cycloalkyls, cycloalkenyls, alkylarylalkyls, alkylarylalkenyls, alkylarylalkynyls, alkenylarylalkyls, alkenylarylalkenyls, alkenylarylalkynyls, alkenylarylalkynyls, alkynylarylalkyls, alkynylarylalkenyls, alkynylarylalkynyls, alkylheteroarylalkyls, alkylheteroarylalkenyls, alkylheteroarylalkynyls, alkenylheteroarylal Alkenyl heteroaryl alkenyl, alkenyl heteroaryl alkynyl, alkynyl heteroaryl alkyl, alkynyl heteroaryl alkenyl, alkynyl heteroaryl alkynyl, alkyl heterocyclyl alkyl, alkyl heterocyclyl alkenyl, alkyl herrerocyclyl alkynyl, alkenyl heterocyclyl alkyl, alkenyl heterocyclyl alkenyl, alkenyl heterocyclyl alkynyl, alkynyl heterocyclyl alkyl, alkynyl heterocyclyl alkynyl This includes, but is not limited to, kenyl, alkynyl heterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, and alkynylheroaryl atomic chains, in which one or more methylene groups may be interrupted or terminated by O, S, S(O), SO2, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic formulas, where R8 is hydrogen, acyl, aliphatic, or substituted aliphatic.In one embodiment, the linker consists of approximately 1 to 24 atoms, 2 to 24, 3 to 24, 4 to 24, 5 to 24, 6 to 24, 6 to 18, 7 to 18, 8 to 18 atoms, 7 to 17, 8 to 17, 6 to 16, 7 to 17, or 8 to 16 atoms.

[0110] The cleavable binding group is sufficiently stable outside the cell but, upon entering the target cell, is cleaved, releasing the two parts held together by the linker. In a preferred embodiment, the cleavable binding group is cleaved at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, or more, or at least about 100 times faster, in the target cell or under a first reference condition (which may be selected to mimic or represent an intracellular state, for example) than in the target blood or under a second reference condition (which may be selected to mimic or represent a state found in blood or serum, for example).

[0111] Cleavable binding groups are sensitive to cleavage factors, such as pH, redox potential, or the presence of degradable molecules. Generally, cleavage factors are found or present more widely and at higher levels or activity within cells than in serum or blood. Examples of such degradation factors include redox substances that are selective for or non-substrate specific to a particular substrate, such as oxidizing or reductases present within cells, or reducing substances such as mercaptans that can degrade oxidatively cleavable binding groups by reduction; esterases; endosomes or factors that can create an acidic environment, such as those that result in a pH of 5 or less; common acids, peptidases (which may be substrate-specific), and enzymes that can hydrolyze or degrade acid-cleavable binding groups by acting as phosphatases.

[0112] Cleavable binding groups, such as disulfide bonds, can be pH-sensitive. Human serum has a pH of 7.4, while the intracellular mean pH is slightly lower, ranging from approximately 7.1 to 7.3. Endosomes have a more acidic pH in the range of 5.5 to 6.0, and lysosomes have an even more acidic pH at approximately 5.0. Some linkers have cleavable binding groups that are cleaved at a favorable pH, thereby releasing cationic lipids from their ligands into the cell or into desired compartments of the cell.

[0113] Linkers can contain cleavable binding groups that can be cleaved by specific enzymes. The type of cleavable binding group incorporated into a linker can depend on the target cell. For example, liver-targeting ligands can bind to cationic lipids via linkers containing ester groups. Hepatocytes are rich in esterases, and therefore, linkers will be cleaved more efficiently in hepatocytes than in cell types that are not rich in esterases. Other cell types rich in esterases include lung, renal cortex, and testicular cells.

[0114] Linkers containing peptide bonds can be used when targeting peptidase-rich cell types such as hepatocytes and synovial cells.

[0115] Generally, the suitability of a candidate cleavable binding group can be evaluated by testing the ability of degradation factors (or conditions) to cleave the candidate binding group. It is also desirable to test the candidate binding group for its resistance to cleavage in blood or in contact with other non-target tissues. Therefore, the relative sensitivity to cleavage between a first condition and a second condition can be determined, with the first condition selected to demonstrate cleavage in target cells and the second condition selected to demonstrate cleavage in other tissues or biological fluids, such as blood or serum. Evaluations can be performed in cell-free systems, in cells, in cell cultures, in organ or tissue cultures, or in whole animals. It may be useful to perform initial evaluations under cell-free or culture conditions and confirm them with further evaluations in whole animals. In some embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster intracellularly (or under in vitro conditions selected to mimic intracellular conditions) compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

[0116] Redox-cleavable bond groups In one embodiment, the cleavable binding group is a redox-cleavable binding group that is cleaved by reduction or oxidation. An example of a reductively cleavable binding group is a disulfide binding group (--S--S--). To determine whether a candidate cleavable binding group is a suitable “reductively cleavable binding group” or suitable for use with, for example, a particular oligonucleotide moiety and a particular targeting agent, one can rely on the methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT) or other reducing agents using reagents known in the art to mimic the cleavage rate that would be observed in cells, e.g., target cells. The candidate can also be evaluated under conditions selected to mimic blood or serum conditions. In one embodiment, the candidate compound is cleaved by up to about 10% in blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster intracellularly (or under in vitro conditions selected to mimic intracellular conditions) compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The cleavage rate of candidate compounds can be determined using standard enzyme kinetic assays under conditions selected to mimic an intracellular medium compared to conditions selected to mimic an extracellular medium.

[0117] Phosphate-based cleavable bonding groups In another embodiment, the cleavable linker includes a phosphate-based cleavable binding group. The phosphate-based cleavable binding group is cleaved by factors that degrade or hydrolyze the phosphate group. Examples of factors that cleave phosphate groups in cells include enzymes such as phosphatases in cells. Examples of phosphate-based binding groups are -OP(O)(ORk)-O-, OP(S)(ORk)O-, -OP(S)(SRk)-O-, -SP(O)(ORk)-O-, -OP(O)(ORk)-S-, -SP(O)(ORk)-S-, OP(S)(ORk)S, -SP(S)(ORk)-O-, -OP(O)(Rk)-O-, -OP(S)(Rk)-O-, -SP(O)(Rk)-O-, -SP(S)(Rk)-O-, SP(O)(Rk)-S-, and -OP(S)(Rk)-S-, R k H or C 1-6 They are alkyl groups. These candidates can be evaluated using methods similar to those described above.

[0118] Acid-cleavable bonding groups In another embodiment, the cleavable linker includes an acid-cleavable binding group. An acid-cleavable binding group is a binding group that is cleaved under acidic conditions. In a preferred embodiment, the acid-cleavable binding group is cleaved in an acidic environment with a pH of about 6.5 or less (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or less), or by a factor such as an enzyme that can act as a general acid. In cells, certain low-pH organelles such as endosomes and lysosomes can provide a cleavage environment for acid-cleavable binding groups. Examples of acid-cleavable binding groups include, but are not limited to, hydrazones, esters, and amino acid esters. Acid-cleavable groups can have the general formula -C=NN--, C(O)O, or --OC(O). A preferred embodiment is when the carbon attached to the oxygen of the ester (alkoxy group) is an aryl group, a substituted alkyl group, or a tertiary alkyl group such as dimethylpentyl or t-butyl. These candidates can be evaluated using methods similar to those described above.

[0119] Ester-based bonding groups In another embodiment, the cleavable linker comprises an ester-based cleavable binding group. The ester-based cleavable binding group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable binding groups include, but are not limited to, esters of alkylene, alkenylene, and alkylylene groups. The ester-cleavable binding group has the general formula --C(O)O-- or --OC(O)--. These candidates can be evaluated using methods similar to those described above.

[0120] Peptide-based cleavage groups In yet another embodiment, the cleavable linker comprises a peptide-based cleavable linking group. The peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. The peptide-based cleavable linking group is a peptide bond formed between amino acids to produce oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. The peptide-based cleavable group does not contain an amide group (--C(O)NH--). The amide group can be formed between any alkylene, alkenylene, or alkylene. A peptide bond is a special type of amide bond formed between amino acids to produce peptides and proteins. The peptide-based cleavable group is generally limited to peptide bonds (i.e., amide bonds) formed between amino acids to produce peptides and proteins, and does not include the entire amide functional group. The peptide-based cleavable linking group has the general formula --NHCHRAC(O)NHCHRBC(O)--, where RA and RB are the R groups of two adjacent amino acids. These candidates can be evaluated using methods similar to those described above.

[0121] In one embodiment, the oligonucleotides described herein are conjugated to a carbohydrate via a linker. The linker includes divalent and trivalent branched linker groups. Exemplary oligonucleotide-carbohydrate conjugates having a linker include, but are not limited to, those described in formulas 24-35 of PCT Publication WO2018 / 195165.

[0122] Representative U.S. patents teaching the preparation of oligonucleotide conjugates include U.S. Patents Nos. 4,828,979, 4,948,882, 5,218,105, 5,525,465, 5,541,313, 5,545,730, 5,552,538, 5,578,717, 5,580,731, 5,591,584, 5,109,124, 5,118,802, 5,138,045, 5,414,077, and 5,486,603. No. 5,512,439, No. 5,578,718, No. 5,608,046, No. 4,587,044, No. 4, No. 605,735, No. 4,667,025, No. 4,762,779, No. 4,789,737, No. 4,824,941 No. 4,835,263, No. 4,876,335, No. 4,904,582, No. 4,958,013, No. 5, No. 082,830, No. 5,112,963, No. 5,214,136, No. 5,082,830, No. 5,112,963 No. 5,214,136, No. 5,245,022, No. 5,254,469, No. 5,258,506, No. 5, No. 262,536, No. 5,272,250, No. 5,292,873, No. 5,317,098, No. 5,371,24 No. 1, No. 5,391,723, No. 5,416,203, No. 5,451,463, No. 5,510,475, No. 5 ,512,667, 5,514,785, 5,565,552, 5,567,810, 5,574,14 Nos. 2, 5,585,481, 5,587,371, 5,595,726, 5,597,696, 5,599,923, 5,599,928, and 5,688,941, 6,294,664, 6,320,017, 6,576,752, 6,783,931, 6,900,297, 7,037,646, and 8,106,022 are included, but are not limited to these, and the entire contents of each of these are incorporated herein by reference.

[0123] In certain cases, the oligonucleotides described herein can be modified with non-ligand groups. Several non-ligand molecules have been conjugated to oligonucleotides to enhance their activity, cell distribution, or cell uptake, and procedures for such conjugations are available in the scientific literature.Such non-ligand portions include cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm, 2007, 365(1):54-61, Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), thioethers, for example, hexyl-S-tritylthiol (Manoharan et al., Ann. NYAcad. Sci., 1992, 660:306, Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), and thiocholesterol (Oberhauser et al., Nucl. Acids Res.,1992,20:533), aliphatic chains, e.g., dodecanediol or undecyl residues (Saison-Behmoaras et al.,EMBO J.,1991,10:111, Kabanov et al.,FEBS Lett.,1990,259:327, Svinarchuk et al.,Biochimie,1993,75:49), phospholipids, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,Tetrahedron Lett.,1995,36:3651, Shea et al.,Nucl.Acids Res.,1990,18:3777), polyamine or polyethylene glycol chains (Manoharan et al.,Nucleosides & It contains lipid moieties such as Nucleotides (1995, 14:969), adamantane acetate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923).Representative U.S. patents teaching the preparation of such oligonucleotide conjugates are listed above. A typical conjugation protocol involves the synthesis of an oligonucleotide having an aminolinker at one or more positions in its sequence. The amino group is then reacted with the molecule to be conjugated using a suitable coupling agent or activating reagent. The conjugation reaction can be carried out either using the oligonucleotide while it is still bound to a solid support, or in the solution phase following cleavage of the oligonucleotide. Purification of oligonucleotide conjugates by HPLC typically yields a pure conjugate.

[0124] Method for preparing oligonucleotides The ligand-conjugated oligonucleotides described herein may be synthesized by using oligonucleotides having pendant-reactive functionality, such as that derived from the attachment of the binding molecule to the oligonucleotide (as described herein). These reactive oligonucleotides may react directly with commercially available ligands, ligands synthesized with any of the various protecting groups, or ligands having binding portions attached thereto.

[0125] The oligonucleotides used in the conjugates described herein can be conveniently prepared systematically via well-known solid-phase synthesis techniques. Apparatus for such synthesis is available from several vendors, including, for example, Applied Biosystems (Foster City, Calif.). The oligonucleotides described herein can also be synthesized by standard methods known in the art, as further discussed below, using, for example, an automated DNA synthesizer (e.g., commercially available from Biosearch, Applied Biosystems, Inc.). Any other means known in the art for such synthesis may be used additionally or alternatively. Similar techniques are also known to be used to prepare other oligonucleotides, such as phosphorothioates and alkylated derivatives.

[0126] In ligand-conjugated oligonucleotides described herein, such as ligand molecules having sequence-specific binding nucleosides of the oligonucleotides described herein, the oligonucleotides and oligonucleosides can be assembled in a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, nucleotide or nucleoside conjugate precursors already having binding sites, ligand-nucleotide or nucleoside conjugate precursors already having ligand molecules, or building blocks containing non-nucleoside ligands.

[0127] When using nucleotide-conjugate precursors that already have a binding site, the synthesis of sequence-specific bound nucleosides is typically completed, and then the ligand molecule is reacted with the binding site to form ligand-conjugated oligonucleotides. In some embodiments, the oligonucleotides or bound nucleosides described herein are synthesized by an automated synthesizer using commercially available and standard phosphoramidites and non-standard phosphoramidites used routinely in oligonucleotide synthesis, as well as phosphoramidites derived from ligand-nucleoside conjugates.

[0128] The oligonucleotides described herein are synthesized and / or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, Slet al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA (incorporated herein by reference). Representative U.S. patents teaching the preparation of oligonucleotides include U.S. Patents No. 5,034,506, 5,166,315, 5,185,444, 5,214,134, 5,216,141, 5,235,033, 5,264,564, 5,405,938, 5,434,257, 5,466,677, 5,470,967, 5,489,677, and 5,541. This includes, but is not limited to, Nos. 307, 5,561,225, 5,596,086, 5,602,240, 5,608,046, 5,610,289, 5,618,704, 5,623,070, 5,663,312, 5,633,360, 5,677,437, and 5,677,439, the entire contents of each of these are incorporated herein by reference.

[0129] Oligonucleotides can be prepared using solution-phase or solid-phase organic synthesis, or both. Organic synthesis offers the advantage of easily preparing oligonucleotides, including non-natural or alternative nucleotides. The single-stranded oligonucleotides described herein can be prepared using solution-phase or solid-phase organic synthesis, or both.

[0130] For any sequence identified herein, further optimization is intended to be achieved by systematically adding or removing bound nucleotides to generate longer or shorter sequences. Such optimized sequences may be further optimized by introducing alternative nucleic acid bases, alternative sugar moieties, and / or alternative internucleotide bonds described herein or known in the art, including alternative nucleic acid bases, alternative sugar moieties, and / or alternative internucleotide bonds known in the art and / or considered herein (e.g., increasing serum stability or circulating half-life, increasing thermal stability, enhancing transmembrane delivery, targeting to specific sites or cell types, and / or increasing interaction with RNA editing enzymes (e.g., ADAR)).

[0131] How to use In this specification, the use of oligonucleotides described herein as therapeutic agents is provided. In various embodiments, oligonucleotides include structural genes, genes containing regulatory and termination regions, self-replicating systems such as viruses or plasmid DNA, single-stranded or double-stranded RNAi agents, shRNA, antisense oligonucleotides, ribozymes, microRNAs, microRNA mimes, supermirs, aptamers, antimirs, antagonistmirs, adapters, triple-stranded oligonucleotides, G-quadrilateral oligonucleotides, RNA activators, immunostimulatory oligonucleotides, or decoy oligonucleotides.

[0132] In some examples, methods are provided for treating a disease or disorder in a patient who requires treatment, the method comprising administering to the patient a therapeutically effective amount of the oligonucleotide disclosed herein. The term “therapeutically effective amount” means an amount effective in treating and / or improving a disease or disorder in a patient. Furthermore, methods are provided for delivering the oligonucleotide disclosed herein to cells, the method comprising contacting cells with the oligonucleotide disclosed herein or a pharmaceutical composition thereof. In some embodiments, the cells may be contacted in vitro. In other embodiments, the cells may be contacted in vivo. In some cases, the patient is a mammalian subject. The mammalian subject may include, but is not limited to, human or mouse subjects. In yet other embodiments where cells are contacted ex vivo, the cells are obtained from human or mouse subjects. In some cases, the cells are tumor cells. In some cases, the cells are muscle cells.

[0133] In some embodiments, oligonucleotides are administered to patients to treat a disease or disorder. Non-limiting examples of diseases or disorders that may be treated with the oligonucleotides disclosed herein include cancer, infectious diseases, autoimmune disorders, and neurological disorders. In certain embodiments, the oligonucleotides disclosed herein are used as vaccines. Genetic vaccination of patients, or administration of nucleic acid molecules (e.g., RNA), and subsequent transcription and / or translation of encoded genetic information, is useful not only for hereditary genetic diseases but also for the treatment and / or prevention of autoimmune diseases, infectious diseases, cancerous or tumor-associated diseases, and inflammatory diseases. Genetic vaccination is particularly used in the treatment of cancer because cancer cells express antigens, but tumors are generally not readily recognized and eliminated by the host, as evidenced by the development of the disease.Non-limiting examples of certain diseases and disorders that are intended to be treated with oligonucleotides disclosed herein include cystic fibrosis, albinism, alpha-1-antitrypsin deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, asthma, 11-thalassemia, Kadasil syndrome, Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease, distal spinal muscular atrophy, Duchenne / Becker muscular dystrophy, dystrophic epidermolysis bullosa, epidermal blistering disease, Fabry disease, factor V Leiden-associated disorder, familial adenomatous polyposis, galactosemia, Gaucher disease, glucose-6-phosphate dehydrogenase deficiency, hemophilia, hereditary hematochromatosis, Hunter syndrome, Huntington's disease, and Har These include Lar syndrome, inflammatory bowel disease, hereditary pampagnosis syndrome, Leber congenital amaurosis, Lesch-Nyhan syndrome, Lynch syndrome, Marfan syndrome, mucopolysaccharidosis, muscular dystrophy, myotonic dystrophy types I and II, neurofibromatosis, Niemann-Pick disease types A, B and C, NY-ESO-1 related cancer, Parkinson's disease, Peutz-Jegers syndrome, phenylketonuria, Pompe disease, primary cilia, prothrombin mutation-related disorders, pulmonary hypertension, retinitis pigmentosa, Sandhoff disease, severe combined immunodeficiency syndrome, sickle cell anemia, spinal muscular atrophy, Stargardt disease, Tay-Sachs disease, Usher syndrome, X-linked immunodeficiency, Sturge-Weber syndrome, Rett syndrome, and cancer.

[0134] Vaccines. The oligonucleotides of this disclosure are useful as vaccines, and the oligonucleotides are DNA or RNA capable of encoding immunogens, antigens, or neoantigens. The host immune system rapidly and specifically initiates a protective response against pathogenic microorganisms and provides means to contribute to the rejection of malignant tumors. The immune response has generally been described as including a humoral response in which antigen-specific antibodies are produced by differentiated B lymphocytes, and a cell-mediated response in which various types of T lymphocytes eliminate antigens by various mechanisms. For example, CD4 (also called CD4+) helper T cells capable of recognizing specific antigens may respond by releasing soluble mediators such as cytokines to mobilize additional cells of the immune system and participate in the immune response. CD8 (also called CD8+) cytotoxic T cells may also be capable of recognizing specific antigens and may bind to antigen-carrying cells or particles, destroying or damaging them. In particular, cell-mediated immune responses, including cytotoxic T lymphocyte (CTL) responses, can be powerful for eliminating tumor cells and cells infected by microorganisms such as viruses, bacteria, or parasites.

[0135] Accordingly, the present disclosure includes methods for inducing an immune response in patients requiring such induction, the methods comprising administering a therapeutically effective amount of the oligonucleotide of the present disclosure (formulated, for example, as an antigen composition) to the patient. In some embodiments, the administration is by intramuscular, intratumoral, intravenous, intraperitoneal, or subcutaneous delivery.

[0136] In various embodiments, administration of the oligonucleotides of the Disclosure (e.g., formulated as a composition, pharmaceutical formulation, or antigen composition) to a subject can result in an increase in the amount of antibodies against the antigen (e.g., neutralizing antibodies) produced in the subject compared to the amount of antibodies produced in a subject that did not receive the oligonucleotide. In some embodiments, the increase may be a 2x, 5x, 10x, 50x, 100x, 200x, 500x, 700x, or 1000x increase.

[0137] The immune response elevated by the methods disclosed herein generally includes antibody responses, preferably neutralizing antibody responses, T cell and B cell maturation and memory, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated cell-mediated phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and T cell-mediated responses such as CD4+ and CD8+. The immune response generated by oligonucleotides encoding the antigens disclosed herein produces an immune response that recognizes and, preferably, mitigates and / or neutralizes the infections described herein. Methods for evaluating the antibody response after administration (immunization or vaccination) of the antigen composition are known in the art and / or described herein. In some embodiments, the immune response includes T cell-mediated responses (e.g., peptide-specific responses such as proliferative responses or cytokine responses). In some embodiments, the immune response includes both B cell responses and T cell responses. The antigen composition can be administered by several preferred methods, such as intramuscular injection, intratumoral injection, subcutaneous injection, intradermal administration, and mucosal administration, such as oral or intranasal administration. Additional modes of administration include, but are not limited to, intravenous, intraperitoneal, intranasal, vaginal, rectal, and oral administration. Combinations of different administration routes in immunized subjects, such as simultaneous intramuscular and intranasal administration, are also contemplated in this disclosure.

[0138] Cancer. Various cancers (e.g., cervical cancer) may be treated with the oligonucleotides of this disclosure. As used herein, the term “cancer” refers to any of the various malignant neoplasms characterized by the proliferation of undifferentiated cells that tend to invade surrounding tissues and metastasize to new sites of the body, and also to the pathological condition characterized by such malignant neoplasm growth. Cancer can be a tumor or hematological malignancy and includes, but is not limited to, all types of lymphomas / leukemias, carcinomas, and sarcomas, such as those found in the anus, bladder, bile ducts, bones, brain, breast, cervix, colon / rectum, endometrium, esophagus, eye, gallbladder, head and neck, liver, kidney, larynx, lung, mediastinum (chest), mouth, ovaries, pancreas, penis, prostate, skin, small intestine, stomach, spinal cord, coccyx, testes, thyroid, and uterus.

[0139] As a non-limiting example, cancers that can be treated include acute granulocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, adenocarcinoma, adenosarcoma, adrenal carcinoma, adrenocortical carcinoma, anal carcinoma, anaplastic astrocytoma, angiosarcoma, appendiceal carcinoma, astrocytoma, basal cell carcinoma, B-cell lymphoma, cholangiocarcinoma, bladder carcinoma, bone carcinoma, intestinal carcinoma, brain carcinoma, brainstem glioma, brain tumor, breast carcinoid tumor, cervical carcinoma, cholangiocarcinoma, chondrosarcoma, and chronic lymphocytosis. Myeloid leukemia, chronic myeloid leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous lymphoma, cutaneous melanoma, diffuse astrocytoma, ductal carcinoma in situ, endometrial cancer, ependymoma, epithelioid sarcoma, esophageal cancer, Ewing's sarcoma, extrahepatic cholangiocarcinoma, eye cancer, fallopian tube cancer, fibrosarcoma, gallbladder cancer, stomach cancer, gastrointestinal cancer, gastrointestinal carcinoid cancer, gastrointestinal stromal tumor, systemic germ cell tumor, glioblastoma multiforme, glioma, pilocytic cell leukemia, head and neck cancer Hemangioendothelioma, Hodgkin's lymphoma, Hodgkin's disease, Hodgkin's lymphoma, hypopharyngeal cancer, invasive ductal carcinoma, invasive lobular carcinoma, inflammatory breast cancer, colon cancer, intrahepatic cholangiocarcinoma, invasive / invasive breast cancer, islet cell carcinoma, jaw cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, leukemia, lip cancer, liposarcoma, liver cancer, non-invasive lobular carcinoma, low-grade astrocytoma, lung cancer, lymph node cancer, lymphoma, male breast cancer, medullary carcinoma, marrow Neuroblastoma, melanoma, meningioma, Merkel cell carcinoma, mesenchymal chondrosarcoma, mesenchymal cell tumor, mesothelioma, metastatic breast cancer, metastatic melanoma, metastatic squamous cell carcinoma of the neck, mixed glioma, oral cancer, mucinous carcinoma, mucosal melanoma, multiple myeloma, nasal cavity cancer, nasopharyngeal cancer, neck cancer, neuroblastoma, neuroendocrine tumor, non-Hodgkin lymphoma, non-Hodgkin lymphoma, non-small cell lung cancer, ophthalmic cancer, ocular melanoma, oligodendroglioma, oral cancer (Oral cancer), oral cavity cancer, oropharyngeal cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, ovarian epithelial carcinoma, ovarian germ cell tumor, primary peritoneal cancer of the ovary, ovarian cord-stromal tumor, Paget's disease, pancreatic cancer, papillary carcinoma, paranasal sinus cancer, parathyroid cancer, pelvic cancer, penile cancer, peripheral nerve cancer, peritoneal cancer, pharyngeal cancer, pheochromocytoma, pilocytic astrocytoma, pineal gland tumor, pineal blastoma, pituitary cancer, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis cancer, rhabdomyosarcoma, salivary gland cancer, sarcoma, bone, sarcoma, soft tissue, sarcoma,It may be uterine cancer, sinus cancer, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cancer, vertebral column cancer, spinal cord cancer, vertebral tumor, squamous cell carcinoma, gastric cancer, synovial sarcoma, T-cell lymphoma), testicular cancer, throat cancer, thymoma / thymic cancer, thyroid cancer, tongue cancer, tonsil cancer, transitional cell carcinoma, transitional cell carcinoma, transitional cell carcinoma, triple-negative breast cancer, fallopian tube cancer, solid tubal cancer, ureteral cancer, ureteral cancer, ureteral cancer, uterine adenocarcinoma, uterine cancer, uterine sarcoma, vaginal cancer, and vulvar cancer.

[0140] Infectious diseases. Also disclosed herein are methods for treating infectious diseases (e.g., bacterial, viral, fungal, or parasitic infections) in patients requiring treatment, the methods comprising administering an effective amount of the oligonucleotides of this disclosure to the patient. Non-limiting examples of infectious diseases include hepatitis (such as HBV or HCV infection), RSV, influenza, adenovirus, rhinovirus, or other viral infections. In some embodiments, administration is by intramuscular, intratumoral, intravenous, intraperitoneal, or subcutaneous delivery.

[0141] Autoimmune diseases. Various autoimmune diseases and autoimmune-related diseases can be treated with the oligonucleotides of this disclosure. As used herein, the term “autoimmune disease” refers to a disease in which the body produces antibodies that attack its own tissues. Non-limiting examples of autoimmune diseases include acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune autonomic dysfunction, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, auto Immune retinopathy, autoimmune hemocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal and neurological neuropathy, Baro's disease, Bezett's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, celiac disease, Chagas disease, chronic fatigue syndrome**, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMO), Churg-Strauss syndrome, scarring pemphigoid / benign mucosal pemphigoid, Crohn's disease, Cogan's syndrome, cold agglutinin disease, congenital heart disease Locke, Coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathy, herpetiform dermatitis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus erythematosus, Dressler syndrome, endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia**, fibrous alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture syndrome, granulomatosis with polyangiitis (GPA) (formerly) (formerly known as Wegener's granulomatosis), Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schönlein purpura, herpes zoster of pregnancy, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, immunomodulatory lipoprotein, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes (type 1 diabetes), juvenile myositis, Kawasaki disease, Lambert-Eaton syndrome, leukocytosis-destructive vasculitis, lichen planus, lichen sclerosing, woody conjunctivitis,Linear IgA disease (LAD), lupus erythema (SLE), Lyme disease, chronic Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mohren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, sleep attacks, neuromyelitis optica (Devic's), mesoglobulinemia, ocular scarring pemphigoid, optic neuritis, relapsing rheumatoid arthritis, PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococci), paraneoplastic Cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry-Romberg syndrome, Personage-Turner syndrome, ciliary body squamous cellulitis (peripheral uveitis), pemphigus, peripheral neuropathy, periencephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, type I, II, and III autoimmune polyglandular syndromes, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, post-pericardiotomy syndrome, progesterone Rhon's dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm and testicular autoimmunity These may include epidemics, generalized rigidity syndrome, subacute bacterial endocarditis (SBE), Suzak syndrome, sympathetic ophthalmopathy, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, bullous dermatosis, vitiligo, and Wegener's granulomatosis (now called granulomatosis with polyangiitis (GPA)). In some embodiments, administration is by intramuscular, intratumoral, intravenous, intraperitoneal, or subcutaneous delivery.

[0142] Neurological disorders. Various neurological disorders can be treated with the oligonucleotides of this disclosure. In non-limiting examples, neurological disorders include septal defect pellucida, acid lipase disease, acid maltase deficiency, acquired epileptic aphasia, acute disseminated encephalomyelitis, attention deficit hyperactivity disorder (ADHD), Addy pupil, Addy syndrome, adrenoleukodystrophy, corpus callosum agenesis, cognitive impairment, Eicardi syndrome, Eicardi-Goutier syndrome disorder, AIDS-neurological complications, Alexander disease, Alpers disease, alternating hemiplegia, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), anencephaly, aneurysm, Angelman syndrome, hemangioma, anoxia, and anti-oligonucleotides. Lipid syndrome, aphasia, apraxia, arachnoid cyst, arachnoiditis, Arnold-Chiari malformation, arteriovenous malformation, Asperger's syndrome, ataxia, vasodilatory ataxia, ataxia and cerebellar or spinocerebellar degeneration, atrial fibrillation and stroke, attention deficit hyperactivity disorder, autism spectrum disorder, autonomic dysfunction, back pain, Barth syndrome, Batten disease, Becker's myotonia, Behçet's disease, Bell's palsy, benign essential blepharospasm, benign focal muscular atrophy, benign intracranial hypertension, Bernhard Roth syndrome, Binswanger's disease, blepharospasm, Bloch-Sulph Tubercener syndrome, brachial plexus rupture, brachial plexus injury, Bradbury-Eggleston syndrome, brain and spinal cord tumors, cerebral aneurysm, brain injury, Brown-Séquard syndrome, spinal and bulbar muscular atrophy, autosomal dominant cerebral arteriovenous disease with subcortical infarction and leukoencephalopathy (CADASIL), Canavan disease, carpal tunnel syndrome, burning pain, cavernous cyst, cavernous hemangioma, cavernous vascular malformation, central cervical syndrome, central spinal cord syndrome, central pain syndrome, central pontine myelin disintegration, head injury, ceremidase deficiency, cerebellar degeneration, cerebellar hypoplasia, cerebral aneurysm, cerebral arteriosclerosis, brain atrophy, cerebral beriberi, cerebral cavernous Vascular malformations, cerebral gigantism, cerebral hypoxia, cerebral palsy, cerebro-ocular-facial-skeletal syndrome (COFS), Charcot-Marie-Tooth disease, Chiari malformation, cholesterol ester storage disease, chorea, acanthocyanotic chorea, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic orthostatic intolerance, chronic pain, Cockayne syndrome type II, Coffin-Lowry syndrome, corpus callosum agenesis, coma, complex regional pain syndrome, congenital bilateral facial nerve palsy, congenital myasthenia gravis, congenital myopathy, congenital vascular cavernous malformations, corticobasal degeneration, cranial arteritis, craniosynostosis, Cree encephalitis,Creutzfeldt-Jakob disease, cumulative traumatic disease, Cushing's syndrome, giant cell inclusion body disease, cytomegalovirus infection, oculoclonus-myoclonus ataxia, Dandy-Walker syndrome, Dawson's disease, Demorsia syndrome, Degerine-Klampke palsy, dementia, multiple infarct dementia, semantic dementia, subcortical dementia, Lewy body dementia, dentate nucleocerebellar ataxia, dentatorubral atrophy, dermatomyositis, developmental coordination disorder, Devic's disease, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, autonomic dysfunction, dysgraphia, dyslexia, dysphagia, dysphagia, integrated motor skills Disorders, myoclonus cerebellar synkinesis, progressive cerebellar synkinesis, dystonia, early infant epileptic encephalopathy, sella turcica syndrome, encephalitis, encephalitis lethargica, brain herniation, encephalopathy, encephalopathy (familial infant), trigeminal nerve region hemangioma, epilepsy, epileptic hemiplegia, Elb's palsy, Elf-Duchenne and Dégerine-Klampke palsy, essential tremor, central pontine myelin collapse, Fabry disease, Fahl's syndrome, syncope, familial autonomic dysfunction, familial hemangioma, familial idiopathic basal ganglia calcification, familial periodic paralysis, familial spastic paralysis, Faber's disease, febrile seizures, fibrosis Muscular dysplasia, Fisher syndrome, hypotonia syndrome, foot drop, Friedreich's ataxia, frontotemporal dementia, Gaucher disease, systemic gangliosides, Gerstmann syndrome, Gerstmann-Streussler-Scheinker disease, giant axonal neuropathy, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, glossopharyngeal neuralgia, glycogen storage disorder, Guillain-Barré syndrome, Haller-Holden-Spats syndrome, head injury, headache, persistent hemigraine, hemifacial spasm, alternating hemiplegia, hereditary neuropathy, hereditary spastic paraplegia, polyneuropathy-type genetic Ataxia, herpes zoster, herpes zoster otomorphosis, Hirayama syndrome, Holmes-Addy syndrome, holoprosencephaly, HTLV-1-associated myelopathy, Hughes syndrome, Huntington's disease, anencephaly, hydrocephalus, normal pressure hydrocephalus, hydromyelopathy, excess adrenocortical hormones, hypersomnia, hypertonia, hypotonia, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile hypotonia, infantile neuroaxonal dystrophy, infantile phytanate storage, infantile Refsum's disease, infantile spasms, inflammatory muscle disease, foramenencephaly, enteric steatosis, intracranial cyst, increased intracranial pressure, Isaacs syndrome, Joubert syndrome,Kahns-Sayre syndrome, Kennedy disease, Kinsborne syndrome, Kleine-Levin syndrome, Klippel-Feil syndrome, Klippel-Trenaunay-Weber syndrome (KTS), Klüber-Bucy syndrome, Korsakoff amnesia syndrome, Krabbe disease, Kugelberg-Welander disease, Kuru disease, Lambert-Eaton myasthenia gravis syndrome, Landau-Kleffner syndrome, lateral femoral cutaneous nerve compression, lateral myelin syndrome, learning disability, Leigh disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Levine-Kritchery syndrome, Levy - Small body dementia, lipid storage disease, lipidoid proteinosis, gyral defects, locked-in syndrome, Lou Gehrig's disease, lupus-neurological sequelae, Lyme disease-neurological complications, Machado-Joseph disease, megacephaly, megalencephaly, Melkerson-Rosenthal syndrome, meningitis, meningitis and encephalitis, Menkes disease, paresthesia of thigh pain, metachromatic leukodystrophy, microcephaly, migraine, Miller-Fischer syndrome, petit mal seizures, mitochondrial myopathy, Möbius syndrome, juvenile unilateral upper limb muscular atrophy, motor neuron disease, moyamoya disease, mucolipidosis, mucopolysaccharidosis, multiple stroke dementia, multifocal Sexual motor neuropathy, multiple sclerosis, multiple system atrophy, multiple system atrophy with orthostatic hypotension, muscular dystrophy, congenital myasthenia gravis, diffuse demyelinating sclerosis, myoclonic encephalopathy in infants, myoclonus, myopathy, congenital myopathy, myopathy-thyroid toxicity, myotonia, congenital myotonia, sleep attacks, neuroacanthocytosis, neurodegeneration with cerebral iron accumulation, neurofibromatosis, neuroleptic malignant syndrome, neurological complications of AIDS, neurological complications of Lyme disease, neurological outcomes of cytomegalovirus infection, neurological symptoms of Pompe disease, neurological outcomes of lupus Sequelae, neuromyelitis optica, neuromuscular totonia, neuronal ceroid lipofuscinosis, neuronal cell migration disorder, neuropathy - hereditary, neurosarcoidosis, neurosyphilis, neurotoxicity, spongiform nevus, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital neuralgia, Ohtahara syndrome, olivopontocerebellar atrophy, oculoclonus-myoclonus ataxia, orthostatic hypotension, overuse syndrome, chronic pain, pantothenate kinase-associated neurodegeneration, paraneoplastic syndrome, paresthesia, Parkinson's disease, paroxysmal chorea, paroxysmal hemigraine, Perry Romberg disease, Pelizaeus-Merzbacher disease,Pena-Shocker II syndrome, perineurial cyst, periodic paralysis, peripheral neuropathy, periventricular leukomalacia, persistent vegetative state, pervasive developmental disorder, phytanic acid storage, Pick's disease, nerve compression, piriformis syndrome, pituitary tumor, polymyositis, Pompe disease, porencephaly, post-polio syndrome, postherpetic neuralgia, post-infectious encephalomyelitis, post-orthostatic hypotension, post-orthostatic tachycardia syndrome, post-orthostatic tachycardia syndrome, primary dentate atrophy, primary lateral sclerosis, primary progressive aphasia, prion disease, progressive hemifacial atrophy, progressive gait ataxia, progressive multifocal leukoencephalopathy, progressive sclerosing poliodystrophy Progressive supranuclear palsy, prosopagnosia, pseudo-TORCH syndrome, pseudotoxoplasmosis syndrome, pseudo-brain tumor, psychogenic movement disorders, Ramsay Hunt syndrome I, Ramsay Hunt syndrome II, Rasmussen encephalitis, reflex sympathetic dystrophy syndrome, Refsum disease, Refsum disease in infants, recurrent movement disorder, recurrent stress injury, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rheumatic encephalitis, Riley-Day syndrome, sacral nerve root cyst, chorea, salivary gland disease, Sandhoff disease, Schilder's disease, cerebral fissure, Zytelberger disease, paroxysmal disorder, definition Dementia, septal optic dysplasia, severe myoclonic epilepsy of infants (SMEI), shaken baby syndrome, herpes zoster, Shy-Drager syndrome, Sjögren's syndrome, sleep apnea, sleeping sickness, Sotos syndrome, spasticity, vertebral rupture, spinal cord infarction, spinal cord injury, spinal cord tumor, spinal muscular atrophy, spinocerebellar atrophy, spinocerebellar degeneration, Steele-Richardson-Olsewski syndrome, generalized rigidity syndrome, striatonigral degeneration, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, short-lived persistent hemiglinal headache (SUNCT), dysphagia, s Denham chorea, fainting, syphilitic myelosclerosis, hydrosyringomyelia, syringomyelia, systemic lupus erythematosus, tabes dorsalis, tardive dyskinesia, Tahlob's cyst, Tay-Sachs disease, temporal arteritis, tethered cord syndrome, Thomsen's muscle tension, thoracic outlet syndrome, thyroid-toxic myopathy, painful tics, Todd's palsy, Tourette syndrome, transient ischemic attack, transmissible spongiform encephalopathy, transverse myelitis, traumatic brain injury, tremor, trigeminal neuralgia, tropical spastic paraplegia, Troyer syndrome, tuberous sclerosis, vascular erectile neoplasm, vasculitis syndromes of the central and peripheral nervous systems, von Ekonomo disease,This may include von Hippel-Lindau disease (VHL), von Recklinghausen disease, Wallenberg syndrome, Werdnig-Hoffmann disease, Wernicke-Korsakoff syndrome, West syndrome, whiplash, Wipple disease, Williams syndrome, Wilson's disease, Wolmann disease, and X-linked spinal muscular atrophy. In some embodiments, administration is by intramuscular, intratumoral, intravenous, intraperitoneal, or subcutaneous delivery.

[0143] In some cases, the oligonucleotides disclosed herein have sequences that are sufficiently complementary to the target RNA. The target RNA may be associated with a disease or disorder that is intended to be treated by the oligonucleotides of this disclosure. In some cases, the target RNA is selected from Serpina1, LRRK2, NRF2, TDP-43, Nav1.7, and PCKS9.

[0144] ADAR editing Adenosine deaminases (ADARs), which act on RNA, are enzymes that bind to double-stranded RNA (dsRNA) and convert adenosine to inosine via deamination. In RNA, inosine functions similarly to guanosine for translation and replication. Therefore, the conversion of adenosine to inosine in mRNA can result in codon changes that can lead to alterations in the encoded protein and its function. There are three known ADAR proteins expressed in humans: ADAR1, ADAR2, and ADAR3. ADAR1 and ADAR2 are expressed throughout the body, while ADAR3 is expressed only in the brain. ADAR1 and ADAR2 are catalytically active, while ADAR3 is thought to be inactive.

[0145] Synthetic single-stranded oligonucleotides have been shown to edit target RNA by deaminating specific adenosines in the target RNA using ADAR proteins. The oligonucleotides are complementary to the target RNA except for at least one mismatch on the opposite side of the adenosine being deaminated. However, previously disclosed methods have not been shown to possess the selectivity and / or stability required to enable their use as therapy. Therefore, there is a need for novel oligonucleotides that can selectively edit target RNA in a therapeutically effective manner using ADAR proteins.

[0146] In certain embodiments, the oligonucleotides described herein are complementary to the target RNA and can recruit ADAR enzymes used to edit target nucleic acid bases on the target RNA, for example, to deaminate target adenosine on the target RNA. In some embodiments, only one nucleic acid base (e.g., one adenosine) is edited (e.g., deaminated). In some embodiments, one, two, or three nucleic acid bases are edited. In some embodiments, the oligonucleotide contains at least one mismatch, fluctuation, insertion, or deletion. In some cases, the oligonucleotide contains a mismatch on the opposite side of the target nucleic acid base. The oligonucleotides described herein may further include modifications (e.g., alternative nucleotides) that increase stability and / or increase deamination efficiency. In some embodiments, the oligonucleotides described herein contain one, two, three, four, or five mismatches, fluctuations, insertions, or deletions (or any combination thereof).

[0147] Accordingly, this disclosure also intends to use the oligonucleotides of this disclosure for use in the methods described herein for altering target RNA sequences in mammalian, preferably human cells. Similarly, this disclosure provides the use of these oligonucleotides in the manufacture of pharmaceuticals for altering target RNA sequences in mammalian, preferably human cells, as described herein. In some embodiments, the target RNA is mRNA.

[0148] The disclosure also relates to a method for deamination of at least one specific target adenosine present in a target RNA sequence in a cell, the method comprising the steps of providing the cell with an oligonucleotide described herein; enabling the uptake of the oligonucleotide by the cell; enabling the annealing of the oligonucleotide with the target RNA sequence; enabling a mammalian ADAR enzyme to deaminate the target adenosine in the target RNA sequence to inosine; and optionally, identifying the presence of inosine in the RNA sequence.

[0149] In some embodiments, oligonucleotides, compositions, and methods are provided herein in which two adjacent adenosines are co-deaminated by an RNA editing enzyme such as ADAR. In this particular case, the UAA stop codon is converted to a UII Trp code codon. Other examples of modifications resulting from the deamination of target adenosine within a target codon are provided in Tables 2 and 3 below. [Table 2] [Table 3]

[0150] Since deamination of adenosine to inosine can result in a protein that is no longer affected by the mutated A at the target site, the identification of deamination to inosine may be a functional readout, for example, an assessment of whether a functional protein is present, or even an assessment of whether the disease caused by the presence of adenosine is (partially) reversed. Functional assessments for each of the diseases referred to herein will generally follow methods known to those skilled in the art. If the presence of target adenosine causes abnormal splicing, the readout may be an assessment of whether abnormal splicing is still occurring, not occurring, or occurring less frequently. On the other hand, if it is desired to introduce a splice site by deamination of target adenosine, then a similar approach can be used to confirm whether the desired type of splicing is actually occurring. Preferred means of identifying the presence of inosine after deamination of target adenosine are RT-PCR and sequencing, using methods well known to those skilled in the art.

[0151] In general, any mutation in any target RNA that can be reversed using the oligonucleotides disclosed herein is a G-to-A mutation, and oligonucleotide constructs can be designed accordingly. Mutations that can be targeted using oligonucleotide constructs also include C-to-A and U-to-A (T-to-A at the DNA level) when adenosine deaminase is recruited. RNA editing in the latter scenario does not necessarily revert the mutation to the wild type, but the edited nucleotide may result in an improvement over the original mutation. For example, a mutation that causes an in-frame stop codon—resulting in a cleaved protein during translation—may not be the original amino acid at that position, but can be changed to a codon encoding an amino acid that produces a (full-length) protein with at least some functionality, at least more functionality than the cleaved protein.

[0152] The oligonucleotides described herein are used to treat cystic fibrosis, albinism, alpha-1-antitrypsin (A1AT) deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, asthma, 11-thalassemia, Kadasil syndrome, Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease (COPD), distal spinal muscular atrophy (DSMA), Duchenne / Becker muscular dystrophy, dystrophic epidermolysis bullosa, epidermal bullous disease, Fabry disease, factor V Leiden-associated disorder, familial adenomatous dystrophy, polyposis, galactosemia, Gaucher disease, glucose-6-phosphate dehydrogenase deficiency, hemophilia, hereditary hematochromatosis, Hunter syndrome, Huntington's disease, Harler syndrome, inflammatory bowel disease (IBD), hereditary pampagnosis syndrome, Leber congenital amaurosis, and Lesch-Nag. It is particularly suitable for treating genetic disorders such as Ihan syndrome, Lynch syndrome, Marfan syndrome, mucopolysaccharidosis, muscular dystrophy, myotonic dystrophy types I and II, neurofibromatosis, Niemann-Pick disease types A, B and C, NY-ESO-1 related cancers, Parkinson's disease, Peutz-Jegers syndrome, phenylketonuria, Pompe disease, primary cilia, prothrombin mutation-related disorders (e.g., prothrombin G20210A mutation), pulmonary hypertension, retinitis pigmentosa, Sandhoff disease, severe combined immunodeficiency syndrome (SCID), sickle cell anemia, spinal muscular atrophy, Stargardt disease, Tay-Sachs disease, Usher syndrome, X-linked immunodeficiency, Sturge-Weber syndrome, Rett syndrome, and various forms of cancer (e.g., BRCA1 and 2-related breast and ovarian cancers).

[0153] The oligonucleotides described herein can deaminate adenosine mutations that result in increased protein activity.

[0154] In certain embodiments, treatment is administered to subjects who have been diagnosed with a gene mutation but do not yet have symptoms of the disease (e.g., infants, such as those between 1 and 12 months of age or those under 2 years of age). In other embodiments, treatment is administered to individuals who have at least one symptom.

[0155] Treatment can be administered to subjects of any age from infancy to adulthood. For example, treatment may be initiated at birth, 6 months, or at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, or 18 years of age.

[0156] In certain embodiments, oligonucleotides increase protein activity in vitro and / or in vivo (e.g., increases of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, or more, or increases of 1.2x, 1.4x, 1.5x, 1.8x, 2.0x, 3.0x, 3.5x, 4.5x, 5.0x, 10x, 15x, 20x, 30x, 40x, 50x, 100x, more than 1000x, or more).

[0157] In some embodiments, oligonucleotides increase protein activity in the brain (e.g., increases of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, or more, or increases of 1.2 times, 1.4 times, 1.5 times, 1.8 times, 2.0 times, 3.0 times, 3.5 times, 4.5 times, 5.0 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, more than 1000 times, or more).

[0158] In the power to prohibit patents for methods performed in the human body, the meaning of “administration” of a composition to a human subject or patient must be limited to prescribing a controlled substance that a human subject or patient self-administers by any technique (e.g., orally, inhaled, topically applied, injected, inserted, etc.). The broadest and most reasonable interpretation is intended to be consistent with the laws or regulations defining patentable subject matter. In the power not to prohibit patents for methods performed in the human body, “administration” of a composition includes both the method performed in the human body and the aforementioned activities.

[0159] Pharmaceutical composition and route of administration The oligonucleotides described herein are preferably formulated into pharmaceutical compositions for administration to a patient (e.g., a human patient) in a biocompatible form suitable for in vivo administration.

[0160] Oligonucleotides described herein may be administered, for example, orally, parenterally, subarachnoidally, intraventricularly, intraparenchymically, buccally, sublingually, nasally, rectally, by patch, pump, intratumorally, or transdermally, and by pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, intraventricular, intraparenchymal, rectally, and topically. Parenteral administration may be by continuous infusion over a selected period.

[0161] The oligonucleotides described herein may be administered orally, for example, with an inert diluent or an assimilated food carrier, or they may be encapsulated in hard- or soft-shell gelatin capsules, or they may be compressed into tablets, or they may be directly incorporated into food in a diet. For oral therapeutic administration, the oligonucleotides described herein may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, and wafers. The oligonucleotides described herein may also be administered parenterally. Solutions of the oligonucleotides described herein can be prepared in water suitably mixed with a surfactant such as hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, DMSO, and mixtures thereof, with or without alcohol, as well as in oil. Under normal storage and use conditions, these preparations may contain preservatives to prevent microbial growth. Conventional procedures and components for selecting and preparing suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2012, 22nd ed.) and The United States Pharmacopeia: The National Formulary (USP 41 NF 36), published in 2018. Suitable pharmaceutical forms for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid enough to be readily administered via syringe. Compositions for nasal administration can be conveniently formulated as aerosols, droplets, gels, and powders. Aerosol formulations typically contain a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent, and are usually supplied in single or multiple doses in a sterile form in a sealed container, and may take the form of cartridges or refills for use with a spray device. Alternatively, the sealed container may be an integrated dispensing device such as a single-dose nasal inhaler or an aerosol dispenser with a metering valve intended for post-use disposal.If the administration form involves an aerosol dispenser, it will contain a propellant, which may be a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon. The aerosol administration form may also take the form of a pump-type sprayer. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and troches, in which the active ingredient is formulated with a carrier such as sugar, acacia, tragacanth, gelatin, and glycerin. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter. The oligonucleotides described herein may be administered as intratumoral administration, e.g., intratumoral injection. Intratumoral injection is a direct injection into the tumor vascular system and is specifically intended for individual, solid, accessible tumors. Local, local, or systemic administration may also be appropriate.

[0162] The oligonucleotides described herein may be administered to animals, such as humans, alone or in combination with pharmaceutically acceptable carriers, as noted herein, in proportion to the solubility and chemical properties of the oligonucleotides, the selected route of administration, and standard pharmaceutical practice.

[0163] i. Method for delivering film-forming molecular assemblies The oligonucleotides described herein can be delivered using a variety of membrane-forming molecular assembly delivery methods, including polymers, biodegradable microparticles, or microcapsule delivery devices known in the art. For example, colloidal dispersions can be used for targeted delivery of the oligonucleotide agents described herein. Colloidal dispersions include macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, such as oil-in-water emulsions, micelles, mixed micelles, and liposomes. Liposomes are artificial membrane vesicles useful as delivery vehicles in vitro and in vivo. Large monolayer vesicles (LUVs) with sizes ranging from 0.2 to 4.0 μm have been shown to be able to encapsulate a significant proportion of aqueous buffers containing large macromolecules. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposome membrane is structurally similar to that of biological membranes, when liposomes are applied to tissue, the liposome bilayer fuses with the bilayer of the cell membrane. As liposomes and cells fuse, their internal aqueous contents, containing oligonucleotides, are delivered to the cells, where they can specifically bind to target RNA and mediate RNase H-mediated gene silencing. In some cases, liposomes are also specifically targeted, for example, to direct oligonucleotides towards a particular cell type. The composition of liposomes is typically a combination of phospholipids, usually combined with steroids, particularly cholesterol. Other phospholipids or other lipids may also be used. The physical properties of liposomes depend on pH, ionic strength, and the presence of divalent cations.

[0164] Liposomes containing oligonucleotides can be prepared by various methods. For example, the lipid component of the liposome is dissolved in a detergent so that micelles are formed with the lipid component. For instance, the lipid component can be an amphiphilic cationic lipid or a lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholic acid, CHAPS, octyl glucoside, deoxycholic acid, and lauroyl sarcosine. The oligonucleotide preparation is then added to the micelles containing the lipid component. The cationic groups on the lipid interact with the oligonucleotide, condensing around it to form a liposome. After condensation, the detergent is removed, for example, by dialysis, to obtain the oligonucleotide liposome preparation.

[0165] If necessary, a support compound to aid in condensation can be added during the condensation reaction, for example, by controlled addition. For example, the support compound can be a polymer other than nucleic acid (e.g., spermine or spermidine). The pH can also be adjusted to favor condensation.

[0166] Methods for producing stable oligonucleotide delivery vehicles incorporating oligonucleotide / cationic lipid complexes as structural components of the delivery vehicle are further described, for example, in WO96 / 37194, the entire contents of which are incorporated herein by reference. Liposome formation has also been described by Feigner, PLet al., (1987) Proc. Natl. Acad. Sci. USA 8:7413-7417, U.S. Patent No. 4,897,355, U.S. Patent No. 5,171,678, Bangham et al., (1965) M. Mol. al.,(1979)Biochim.Biophys.Acta 557:9, Szoka et al.,(1978)Proc.Natl.Acad.Sci.75:4194, Mayhew et al.,(1984)Biochim.Biophys.Acta 775:169, Kim et al.,(1983)Biochim.Biophys.Acta 728:339, and Fukunaga et al. This may include one or more embodiments of the exemplary methods described in al., (1984) Endocrinol. 115:757. Techniques commonly used to prepare lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw, in addition to extrusion (see, e.g., Mayer et al., (1986) Biochim. Biophys. Acta 858:161). Microfluidization can be used when consistently small (50–200 nm) and relatively uniform aggregates are desired (Mayhew et al., (1984) Biochim. Biophys. Acta 775:169). These methods are readily adaptable for packaging oligonucleotide preparations into liposomes.

[0167] Liposomes are classified into two broad classes. Cationic liposomes are positively charged liposomes that interact with negatively charged nucleic acid molecules to form stable complexes. The positively charged nucleic acid / liposome complexes bind to the negatively charged cell surface and are internalized within endosomes. Due to the acidic pH within the endosome, the liposomes rupture, releasing their contents into the cytoplasm (Wang et al. (1987) Biochem. Biophys. Res. Commun., 147:980-985).

[0168] Liposomes capture nucleic acids rather than complex them. Because both nucleic acids and lipids are similarly charged, repulsion occurs rather than complex formation. Nevertheless, some nucleic acids are captured within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver nucleic acids encoding thymidine kinase genes to cell monolayers in culture. Exogenous gene expression was detected in target cells (Zhou et al. (1992) Journal of Controlled Release, 19:269-274).

[0169] One major type of liposome composition contains phospholipids other than naturally derived phosphatidylcholine. Neutral liposome compositions can be formed from, for example, dimyristoylphosphatidylcholine (DMPC) or dipalmitoylphosphatidylcholine (DPPC). Anionic liposome compositions are generally formed from dimyristoylphosphatidylglycerol, while anionic fusion liposomes are mainly formed from dioleoylphosphatidylethanolamine (DOPE). Another type of liposome composition is formed from phosphatidylcholine (PC), such as soy PC and egg PC. Yet another type is formed from a mixture of phospholipids and / or phosphatidylcholine and / or cholesterol.

[0170] Other examples of methods for introducing liposomes into cells in vitro and in vivo include U.S. Patents 5,283,185, 5,171,678, WO94 / 00569, WO93 / 24640, WO91 / 16024, Feigner, (1994) J. Biol. Chem. 269:2550, Nabel, (1993) Proc. Natl. Acad. Sci. 90:11307, Nabel, (1992) Human Gene Ther. 3:649, Gershon, (1993) Biochem. 32:7143, and Strauss, (1992) EMBO J. 11:417.

[0171] Nonionic liposome systems have also been investigated to determine their usefulness in drug delivery to the skin, particularly in systems containing nonionic surfactants and cholesterol. Cyclosporine-A was delivered into the dermis of mouse skin using nonionic liposome formulations containing NOVASOME® I (glyceryl dilaurate / cholesterol / polyoxyethylene-10-stearyl ether) and NOVASOME® II (glyceryl distearate / cholesterol / polyoxyethylene-10-stearyl ether). The results showed that such nonionic liposome systems are effective in promoting the deposition of cyclosporine-A into different layers of the skin (Hu et al., (1994) STPPharma.Sci., 4(6):466).

[0172] Liposomes can also be sterically stabilized liposomes that contain one or more specialized lipids, resulting in an enhanced circulating lifespan compared to liposomes lacking such specialized lipids. An example of a sterically stabilized liposome is one in which a portion of the vesicle-forming lipid portion of the liposome contains (A) monosialoganglioside G M1(B) These contain one or more glycolipids, or are derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While we do not wish to be bound by any particular theory, in the art, it is thought that the enhanced circulating half-life of sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivativeized lipids is due to reduced uptake by the reticuloendothelial system (RES) into cells (Allen et al., (1987) FEBS Letters, 223:42; Wu et al., (1993) Cancer Research, 53:3765).

[0173] Various liposomes containing one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. NYAcad. Sci., (1987), 507:64) developed monosialoganglioside G to improve the blood half-life of liposomes. M1 The capabilities of galactocerebroside sulfate and phosphatidylinositol were reported. These results were explained by Gabizon et al. (Proc. Natl. Acad. Sci. USA, (1988), 85:6949). U.S. patents 4,837,028 and WO88 / 04924 by Allen et al. both refer to (1) sphingomyelin and (2) ganglioside G M1 Alternatively, liposomes containing galactocerebroside sulfate ester are disclosed. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes containing sphingomyelin. Liposomes containing 1,2-sn-dimiristoylphosphatidylcholine are disclosed in WO97 / 13499 (Lim et al).

[0174] In one embodiment, cationic liposomes are used. Cationic liposomes have the advantage of being able to fuse with the cell membrane. Non-cationic liposomes cannot efficiently fuse with the plasma membrane, but they can be taken up by macrophages in vivo and used to deliver oligonucleotides to macrophages.

[0175] Further advantages of liposomes include the biocompatibility and biodegradability of liposomes derived from natural phospholipids; their ability to encapsulate a wide range of water-soluble and lipid-soluble drugs; and their ability to protect encapsulated oligonucleotides within their internal compartments from metabolism and degradation (Rosoff, in “Pharmaceutical Dosage Forms,” Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposomal formulations include the lipid surface charge, vesicle size, and aqueous volume of the liposomes.

[0176] Using the positively charged synthetic cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), it is possible to form lipid-nucleic acid complexes that spontaneously interact with nucleic acids and fuse with the negatively charged lipids of the cell membrane of tissue culture cells, thereby resulting in the delivery of oligonucleotides (see, for example, Feigner, P. Let al., (1987) Proc. Natl. Acad. Sci. USA 8:7413-7417 and U.S. Patent No. 4,897,355 for a description of DOTMA and its use with DNA).

[0177] 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP), a DOTMA analog, can be used in combination with phospholipids to form DNA complexing vesicles. LIPOFECTIN® (Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids to living tissue culture cells, containing positively charged DOTMA liposomes that spontaneously interact with negatively charged polynucleotides to form complexes. When sufficiently positively charged liposomes are used, the net charge of the resulting complex is also positive. The positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids, for example, to tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane ("DOTAP") (Boehringer Mannheim, Indianapolis, Ind.), differs from DOTMA in that the oleoyl portion is linked by an ester rather than an ether linkage.

[0178] Other reported cationic lipid compounds include those conjugated to various moieties, such as carboxyspermine, which is conjugated to one of two types of lipids, including compounds such as 5-carboxyspermylglycine dioctaoleoylamide ("DOGS") (TRANSFECTAM®, Promega, Madison, Wis.) and dipalmitoylphosphatidylethanolamine 5-carboxyspermylamide ("DPPES") (see, for example, U.S. Patent No. 5,171,678).

[0179] Other cationic lipid conjugates include cholesterol-containing lipid derivatives ("DC-Chol") formulated in lysosomes in combination with DOPE (see Gao, X. and Huang, L., (1991) Biochim. Biophys. Res. Commun. 179:280). Lipopolydin, produced by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., (1991) Biochim. Biophys. Acta 1065:8). For certain cell lines, these liposomes containing conjugated cationic lipids are said to exhibit lower toxicity and provide more efficient transfection than DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, Calif.) and lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Md.). Other cationic lipids suitable for oligonucleotide delivery are described in WO98 / 39359 and WO96 / 37194.

[0180] Liposome formulations are particularly well-suited for topical administration, and liposomes offer several advantages over other formulations. These advantages include reduced side effects associated with high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to deliver oligonucleotides into the skin. In some embodiments, liposomes are used to deliver oligonucleotides to epidermal cells and to enhance the penetration of oligonucleotides into dermal tissue, for example, into the skin. For example, liposomes can be applied topically. The topical delivery of drugs formulated as liposomes to the skin has been documented (e.g., Weiner et al., (1992) Journal of Drug Targeting, vol.2, 405-410 and du Plessis et al., (1992) Antiviral Research, 18:259-265, Mannino, R. J. and Fould-Fogerite, S., (1998) Biotechniques 6:682-690, Itani, T. et al., (1987) Gene 56:267-276, Nicolau, C. et al. (1987) Meth. Enzymol. 149:157-176, Straubinger, R. and Papahadjopoulos, D. (1983) Meth. Enzymol. 101:512-527, Wang, C. and See Huang, L., (1987) Proc. Natl. Acad. Sci. USA 84:7851-7855.

[0181] Nonionic liposome systems, particularly those containing nonionic surfactants and cholesterol, have also been investigated to determine their usefulness in drug delivery to the skin. Nonionic liposome formulations containing Novasome I (glyceryl dilaurate / cholesterol / polyoxyethylene-10-stearyl ether) and Novasome II (glyceryl distearate / cholesterol / polyoxyethylene-10-stearyl ether) were used to deliver drugs into the dermis of mouse skin. Such formulations containing oligonucleotides are useful for treating dermatological diseases.

[0182] Liposome targeting is also possible, for example, based on organ specificity, cell specificity, and organelle specificity, and is known in the art. In liposome targeted delivery systems, lipid groups can be incorporated into the lipid bilayer of the liposome to maintain the targeted ligand in a stable association with the liposome bilayer. Various binding groups can be used to bind lipid chains to the targeted ligand. Additional methods are known in the art and are described, for example, in U.S. Patent Application Publication 2006 / 0058255, the binding groups of which are incorporated herein by reference.

[0183] Liposomes containing oligonucleotides can be made highly deformable. Such deformability allows liposomes to penetrate pores smaller than the average radius of the liposome. For example, transfersomes are yet another type of liposome, highly deformable lipid aggregates that are attractive candidates for drug delivery vehicles. Transfersomes can be described as highly deformable lipid droplets that can easily penetrate pores smaller than droplets. Transfersomes can be prepared by adding surface-edge surfactants, usually surfactants, to a standard liposome composition. Transfersomes containing oligonucleotides can be delivered subcutaneously, for example by infection, to deliver oligonucleotides to keratinocytes in the skin. To traverse intact mammalian skin, lipid vesicles must pass through a series of pores, each with a diameter of less than 50 nm, under the influence of a suitable transcutaneous gradient. In addition, due to their lipid properties, these transfersomes can self-optimize (e.g., adapt to the shape of the pores in the skin), self-repair, and frequently reach their targets without fragmentation and often without self-loading. Transfersomes are used to deliver serum albumin to the skin. Transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a serum albumin-containing solution.

[0184] Other formulations that can be prepared according to the oligonucleotides and methods of this disclosure are described in WO2009 / 086558 and WO2009 / 088891. WO2008 / 042973 also describes formulations that can be prepared according to the oligonucleotides and methods of this disclosure.

[0185] Surfactants have found broad applications in formulations such as emulsions (including microemulsions) and liposomes. The most common method for classifying and ranking the properties of many different types of surfactants, both natural and synthetic, is by using the hydrophilic / lipophilic balance (HLB). The properties of the hydrophilic group (also known as the "head") provide the most useful means for classifying different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p.285).

[0186] When a surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants have found widespread use in pharmaceuticals and cosmetics and can be used across a wide range of pH values. Generally, their HLB values ​​range from 2 to about 18, depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated / propoxylated block polymers are also included in this class. Polyoxyethylene surfactants are the most popular member of the nonionic surfactant class.

[0187] Surfactants are classified as anionic if they have a negative charge when dissolved or dispersed in water. Anionic surfactants include carboxylates such as soap, acyl lactylates, acyl amides of amino acids, sulfuric acid esters such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkylbenzene sulfonates, acyl isethionates, acyl taurates, and sulfosuccinates, and phosphoric acid. The most important members of the anionic surfactant class are alkyl sulfates and soaps.

[0188] A surfactant is classified as cationic if its molecule has a positive charge when dissolved or dispersed in water. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. Quaternary ammonium salts are the most commonly used members of this class.

[0189] A surfactant is classified as amphoteric if its molecule has the ability to carry either a positive or negative charge. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkyl betaines, and phosphatides.

[0190] The use of surfactants in pharmaceuticals, formulations, and emulsions is outlined (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p.285).

[0191] Oligonucleotides for use in the methods described herein can also be provided as micelle formulations. A “micelle” is a specific type of molecular assembly in which amphiphilic molecules are arranged in a spherical structure such that all hydrophobic portions of the molecules face inward, while the hydrophilic portions remain in contact with the surrounding aqueous phase. The reverse arrangement exists when the environment is hydrophobic.

[0192] In some embodiments, formulations are provided herein comprising oligonucleotides disclosed herein and pharmaceutically acceptable excipients. In some embodiments, the pharmaceutically acceptable excipients include lipid nanoparticles. In some embodiments, the formulations are adapted as parenteral formulations.

[0193] In some embodiments, upon parenteral administration to a patient of a certain amount of oligonucleotide or formulation containing a certain amount of oligonucleotide disclosed herein, the oligonucleotide concentration measured in the patient's tissue is at least a specific percentage of the amount of oligonucleotide initially administered to the patient. The measurement may be performed by any suitable means known to those skilled in the art, for example, via assays or mass spectrometry techniques used in the art (such as quantitative mass spectrometry). In some embodiments, upon parenteral administration to a patient of the oligonucleotide or formulation disclosed herein, the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40% of the amount of oligonucleotide administered to the patient. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 45% of the amount of oligonucleotide administered to the patient. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 50% of the amount of oligonucleotide administered to the patient. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 55% of the amount of oligonucleotide administered to the patient. In some embodiments, the concentration of oligonucleotides in the patient's tissue is at least 60% of the amount of oligonucleotides administered to the patient.

[0194] In some embodiments, measuring the amount of oligonucleotides present in the tissue occurs at a specific time after administration of the oligonucleotide or formulation containing the oligonucleotides disclosed herein. In some embodiments, measuring the amount of oligonucleotides occurs at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, measuring the amount of oligonucleotides occurs at least 24 hours after administration. In some embodiments, measuring the amount of oligonucleotides occurs at least 48 hours after administration. In some embodiments, measuring the amount of oligonucleotides occurs at least 72 hours after administration.

[0195] In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 45% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 50% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 55% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours after administration.In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 45% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 50% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 55% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 48 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 48 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 45% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 48 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 50% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 48 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 55% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 48 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 48 hours after administration.In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 40% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 45% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 50% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 55% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after administration. In some embodiments, the oligonucleotide concentration in the patient's tissue is at least 60% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after administration.

[0196] ii. Lipid nanoparticle-based delivery methods The oligonucleotides described herein can be completely encapsulated in lipid formulations, such as lipid nanoparticles (LNPs), or other nucleic acid-lipid particles. LNPs are extremely useful for systemic application because they exhibit an extended circulating lifetime after intravenous (iv) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include "pSPLPs," which contain encapsulated condensant-nucleic acid complexes as shown in PCT Publication WO00 / 03683. The particles of this disclosure typically have an average diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, and most typically about 70 nm to about 90 nm, and are substantially non-toxic. In addition, when present in nucleic acid-lipid particles, the nucleic acids are resistant to degradation by nucleases in aqueous solutions. Nucleic acid-lipid particles and methods for preparing them are disclosed, for example, in U.S. Patents 5,976,567, 5,981,501, 6,534,484, 6,586,410, and 6,815,432, U.S. Publication 2010 / 0324120, and PCT Publication WO96 / 40964.

[0197] In one embodiment, the lipid-to-drug ratio (mass / mass ratio) (e.g., lipid-to-oligonucleotide ratio) may be in the range of about 1:1 to about 50:1, about 1:1 to about 25:1, about 3:1 to about 15:1, about 4:1 to about 10:1, about 5:1 to about 9:1, or about 6:1 to about 9:1. Intermediate ranges between those listed above are also intended to be part of the scope described herein.

[0198] Non-limiting examples of cationic lipids include N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N--(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N--(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), and 1,2-dilinoleyl Railcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-dilinoleyloxy-3-trimethylaminopropane chloride (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride (DLin-TAP.Cl), 1,2-dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleylamino)-1,2-propanediol (DOAP), 1,2-dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), or the same Analogues, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienietetrahydro--3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazine-1-ethylazanediididodecane-2-ol (Tech Examples include G1), or mixtures thereof. Cationic lipids may, for example, constitute about 20 mol% to about 50 mol% or about 40 mol% of the total lipids present in the particles.

[0199] Ionizable / noncationic lipids can be anionic or neutral lipids, including distearoyl phosphatidylcholine (DSPC), dioleoyl phosphatidylcholine (DOPC), dipalmitoyl phosphatidylcholine (DPPC), dioleoyl phosphatidylglycerol (DOPG), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylethanolamine (DOPE), palmitoyl oleoyl phosphatidylcholine (POPC), palmitoyl oleoyl phosphatidylethanolamine (POPE), and dioleoyl Examples of noncationic lipids include, but are not limited to, 2-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimitoylphosphatidylethanolamine (DMPE), distearoylphosphatidylethanolamine (DSPE), 16-O-monomethylPE, 16-O-dimethylPE, 18-1-transPE, 1-stearoyl-2-oleoylphosphatidiethanolamine (SOPE), cholesterol, or mixtures thereof. Noncationic lipids can be, for example, about 5 mol% to about 90 mol%, about 10 mol%, or about 58 mol% of the total lipids present in the particles, if cholesterol is included.

[0200] The conjugated lipids that inhibit particle aggregation can be, for example, polyethylene glycol (PEG) lipids, and are not limited to, PEG-diacylglycerol (DAG), PEG-diachyloxypropyl (DAA), PEG-phospholipids, PEG-ceramide (Cer), or mixtures thereof. The PEG-DAA conjugate can be, for example, PEG-dilauryloxypropyl (Ci2), PEG-dimyristyloxypropyl (Ci4), PEG-dipalmityloxypropyl (Ci6), or PEG-distearyloxypropyl (C8). The conjugated lipids that prevent particle aggregation can be, for example, 0 mol% to about 20 mol% or about 2 mol% of the total lipids present in the particles.

[0201] In some embodiments, the nucleic acid-lipid particles further contain cholesterol, for example, in an amount of about 10 mol% to about 60 mol% or about 50 mol% of the total lipids present in the particles.

[0202] Dosage The dosage of the compositions described herein (e.g., compositions comprising oligonucleotides) can vary depending on many factors, including the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and severity of the symptoms; the frequency of treatment and the type of concurrent treatment (if any); and the clearance rate of the compound in the animal being treated. Those skilled in the art can determine an appropriate dosage based on these factors. The compositions described herein may be administered initially in a suitable dose that can be adjusted as needed depending on the clinical response. In some embodiments, the dosage of the composition (e.g., compositions comprising oligonucleotides) is a prophylactic or therapeutically effective amount.

[0203] kit This specification provides a kit comprising (a) a pharmaceutical composition comprising an oligonucleotide that results in the deamination of adenosine in mRNA in cells or subjects described herein, and (b) a package insert having instructions for performing any of the methods described herein. In some embodiments, the kit comprises (a) a pharmaceutical composition comprising an oligonucleotide that results in the deamination of adenosine in mRNA in cells or subjects described herein, (b) an additional therapeutic agent, and (c) a package insert having instructions for performing any of the methods described herein. In some embodiments, a kit is provided comprising an oligonucleotide disclosed herein, or a formulation comprising an oligonucleotide disclosed herein, and optionally one or more containers, one or more additional therapeutic agents, a package insert having instructions for performing any of the methods described herein, one or more syringes for parenteral injection, one or more filter needles, and / or one or more needles. In some embodiments, the kit comprises an oligonucleotide disclosed herein, or a formulation comprising an oligonucleotide disclosed herein, one or more containers, and a package insert having instructions for performing any of the methods described herein. In some embodiments, the kit further comprises one or more additional therapeutic agents. In some embodiments, the kit further includes one or more syringes for parenteral injection, one or more filter needles, and / or one or more needles. [Examples]

[0204] General method All guide oligonucleotides were chemically synthesized in an automated RNA / DNA synthesizer using standard β-cyanoethyl phosphoramidite chemistry and universal solid supports such as controlled pore glass (CPG). N-protected β-homo-DNA phosphoramidites were synthesized using reported procedures. See Matheus Froeyen et al., (2001) Chem. Eur. J., 7:5183-5794, Herdewijn, (2010) Chem. Biodivers., 7:1-59, and Jabgunde et al., (2019) Tetrahedron, 75:1107-1114. Other 5′-O-DMT-3′-phosphoramidite RNAs, 2'-O-methyl RNAs, and DNA monomers, i.e., A, C, G, U, and T, were purchased from commercial sources. When alkylsulfonyl phosphoramidite linkers L1-L15 were introduced, the corresponding alkylsulfonyl azides were used as oxidizing agents as shown in Table 4. After synthesis, the oligonucleotides were cleaved from the solid support, deprotected, and purified by an HPLC system using a standard protocol. The oligonucleotides were desalted, dialyzed, and lyophilized. The purity of each lyophilized oligonucleotide was ≥80% when determined by analytical reverse-phase HPLC. Sequence integrity of the oligonucleotides was determined by ESI-MS. (Sequences of various oligonucleotides are provided in Tables 5 and 6 herein).

[0205] The human ADAR2 sequence (NM_001112.4) was cloned into the pcDNA3.1 plasmid under the control of the CMV promoter using BamHI and XbaI restriction sites (Quintara Bio, Berkeley, CA), and the insertion was sequence-validated to confirm correctness. This plasmid will henceforth be referred to as ADAR2 / pcDNA3.1. For editing experiments, 2 μg of the ADAR2 / pcDNA3.1 plasmid was edited using 25 μL of lipofectamine 3000 and 24 μL of P3000 (Life Technologies) per 10 cm dish in 5 × 10⁶ dishes. 6HEK293T cells (ATCC) were transfected. After 4 hours, the culture medium was replenished with fresh, warmed medium (DMEM high glucose, Life Technologies). 12–16 hours after transfection, the transfected HEK293T cells were transfected with guide oligonucleotides to a final concentration of 100 nM in each well. All transfections were performed in a 96-well format using Lipofectamine 3000 (0.4 μL / well) according to the manufacturer's instructions. 12–16 hours after the second transfection, the cells were washed once with ice-cold PBS, and total mRNA isolation was performed using the Dyna Beads mRNA Direct Kit (Life Technologies) adapted to KingFisher Flex Purification (Life Technologies) according to the manufacturer's instructions. Samples were treated with TURBO DNase (Life Technologies) before elution. The resulting isolated mRNA was used for cDNA synthesis using SuperScript IV Vilo (Life Technologies) according to the manufacturer's instructions. Amplicons for Sanger sequencing were generated using 1 μl of cDNA as a template for PCR (Platinum II Hot-Start PCR Master Mix, Life Technologies) with gene-specific primers. Sanger sequencing was performed by Quintara Biosciences (Berkeley, CA). The edit yield from adenosine to guanosine was quantified by measuring the peak heights of adenosine and guanosine, and then dividing the guanosine peak height by the combined total peak height measurement of adenosine and guanosine.

[0206] Example 1: Synthesis of oligonucleotides The oligonucleotides of this disclosure were synthesized using standard solid-phase phosphoramidite chemistry on a 200 nM to 25 μM scale, as described below. Monomer amidites were dissolved in 0.05 M anhydrous acetonitrile. These were delivered to a solid-phase synthesis column using 0.25 M 5-(ethylthio)-1H-tetrazole (ETT) in acetonitrile. Two coupling cycles of 6 minutes each were performed.

[0207] Alkyl sulfonyl azides were prepared according to literature procedures such as Luo L, Tang J, Sun R, et al., (2022) Org Lett. (15):2821-2825, and isolated after aqueous workup including washing with 0.1 M sodium bicarbonate, followed by extraction and evaporation. The reagents thus prepared were dissolved in dry acetonitrile to a final concentration of 0.5 M. Whenever an alkyl sulfonyl phosphoramidite (PAX) linker was introduced into a growing oligonucleotide sequence in this disclosure, the corresponding alkyl sulfonyl azide solution was used as an oxidizing agent during the synthetic cycle (the optimized solid-phase synthesis procedure is shown in Table 4). [Table 4]

[0208] After the synthesis was complete, the solid support was dried under vacuum, and the oligonucleotide bonds were cleaved from the support using concentrated aqueous ammonia at 55°C for 16 hours. The ammonia was removed under reduced pressure. The product adsorbed on the support was reconstituted in water, separated from the solid support using filtration, and analyzed by LC / MS. The crude solution was purified by preparative IEx-HPLC and desalted. The HELM sequences of the synthesized oligomers are shown in Table 5, and the nucleotide sequences are shown in Table 6. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7] [Table 5-8] [Table 6-1] [Table 6-2] [Table 6-3]

[0209] Example 2 - In vitro editing efficiency of 42mer oligonucleotides by PA1-binding versus non-PA1-binding The oligonucleotide editing efficiency was tested in Piz mouse hepatocytes without interferon-alpha. These were tested using RNAiMAX at the desired concentration and without lipofectamine. Piz mouse hepatocytes were thawed in a 37°C water bath in a 50 ml tube of Cryopreserved Hepatocyte Recovery Medium (CHRM-Life Technologies). After centrifugation at 80 × g for 6 minutes, the supernatant was aspirated and the cell pellet was resuspended in Hepatocyte Plating Media (MB Bioscience). Cells were seeded at 20,000 cells / well in 96-well collagen-coated tissue culture plates. Cells were transferred to an incubator (37°C), and after 4–6 hours, the medium was changed to Hepatocyte Maintenance Media (MB Bioscience). Cells were transfected with RNAiMax (Life Technologies, CA) and without, using the desired concentration of ASO according to the manufacturer's protocol, and returned to the incubator.

[0210] Forty-eight hours after oligonucleotide addition, mRNA was isolated from PiZ hepatocytes using Oligo(dT)25 magnetic beads and associated buffer from New England BioLabs. The samples were treated with EZ DNase (Life Technologies) after elution. The isolated mRNA was used for cDNA synthesis using SuperScript IV VILO® (Life Technologies) according to the manufacturer's instructions. 10 μl of cDNA was used for amplicon sequencing by next-generation sequencing (NGS) using Quintara Biosciences.

[0211] DNA amplicons were used directly for amplicon next-generation sequencing (NGS). The editing percentage at the target site was quantified as a percentage of the number of edited nucleotides based on the NGS count. Each oligonucleotide was assayed in at least triple assays. The primers used for sequencing are listed in Table 7, and the assay data are shown in Figures 1A and 1B.

[0212] Comparison of free uptake using sequences (42merA1 and 30merA12) shows that the editing activity remains unchanged when PA-1 is replaced with an L1 or L2 skeleton (Figure 1A). Transfection results show that the novel L1 and L2 skeletons exhibit similar editing activity (Figure 1B). [Table 7]

[0213] Oligonucleotides containing L4 and L15 were tested using the same method, and the editing percentage was compared to two controls (oligo A1 and A1a) containing only PS links. Oligonucleotides containing L4 links showed significantly improved editing compared to A1 at a 100 nM dose, and both oligonucleotides contained one L4 link at the 3' end and two L4 links at the 5' end. Oligonucleotides containing L15 links were edited similarly to control oligo A1, and oligonucleotides containing either L4 or L15 links were edited similarly to control oligo A1a. The data are shown in Figures 5 and 6.

[0214] These data indicate that replacing PA1 with L4 or L15 yields equivalent editing efficiency, and in some cases, L4 even improves editing efficiency.

[0215] Additional data for the oligonucleotides in which PA1 was replaced with L1 is shown in Table 8 below. [Table 8]

[0216] Additional tests were conducted using DefiniGEN ZZ HLC hepatocytes.

[0217] Cryopreserved hepatocyte-like cells (HLCs) (DefiniGEN) derived from patients with the ZZ genotype were thawed at 37°C using a thawing medium consisting of minimal essential medium (MEM, Gibco 51200-046), MEM non-essential amino acid solution (11140-050), chemically defined lipid concentrate (Gibco 11905-031), insulin (Sigma-Aldrich 11376497001), and Def-HEP components A, B, C, D, and H (DefiniGEN). The cells were seeded using Def-HEP recovery and maintenance medium consisting of HepatoZYME SFM (Gibco 17705-021), MEM non-essential amino acid solution, chemically defined lipid concentrate, insulin, and Def-HEP components A, B, C, E, F, and G (DefiniGEN), supplemented with a Rock inhibitor (Stemcell 72304). Rock inhibitors were used only for seeding and not for resupply. Cells were seeded in 384-well collagen I-coated plates and maintained at 37°C in a hypoxic incubator. After seeding, the culture medium was changed every 48 hours until cell maturation occurred in 12–14 days. For transfection, HLCs were treated with a transfection reagent consisting of oligonucleotides and OPTI-MEM (Gibco: 31985-0662) and lipofectamine RNAiMAX (Invitrogen: 13778-150) in a 1:25 ratio.

[0218] The results are shown in Table 9 below. [Table 9]

[0219] Example 3 - In vitro editing efficiency of 30-mer oligonucleotides by PA1-binding versus non-PA1-binding The editing efficiency of the oligos was tested in primary normal mouse hepatocytes without the addition of interferon alpha. These were tested at the desired concentrations using RNAiMAX, as well as without the addition of Lipofectamine. Primary mouse hepatocytes were thawed in a 37°C water bath in a 50 ml tube of Cryopreserved Hepatocyte Recovery Medium (CHRM-Life Technologies). After centrifugation at 80×g for 6 minutes, the supernatant was aspirated, and the cell pellet was resuspended in Hepatocyte Plating Media (MB Bioscience). Cells were seeded at either 20000 cells / well in 96-well collagen-coated tissue culture plates or 5000 cells / well in 384-well collagen-coated tissue culture plates. The cells were transferred to an incubator (37°C), and after 4 to 6 hours, the medium was changed to Hepatocyte Maintenance Media (MB Bioscience). The cells were transfected with the desired concentration of ASO with and without the addition of RNAiMax (Life Technologies, CA) according to the manufacturer's protocol, and then returned to the incubator.

[0220] The results are shown in Figure 7 - transfection data is shown in (A), and free uptake data is shown in (B).

[0221] The test oligos edited more comparably to the control via transfection than via free uptake. The in vivo data from this study shows that almost all of the test oligos edit as well as the control, with some performing better than the control. Considering that L1 and L2 are implemented for the purpose of enhancing stability and increasing nuclease resistance, they are expected to have the greatest effect in vivo. The combination of the in vitro and in vivo results shown in Figure 7 and Figure 8 demonstrates that L1 and L2 enhance stability and are viable alternatives to PA-1 with improvements in certain specific scenarios.

[0222] Example 4 - In vivo editing efficiency of oligonucleotides using the phosphoramidate linker of the present disclosure In vivo delivery – all procedures for animal experiments were approved by the facility's laboratory animal committee and carried out in accordance with its guidelines. Male PiZ mice (8–10 weeks old) were weighed and randomly assigned to groups of 3 mice each. The LNP preparation in MC3 buffer was administered via the lateral tail vein at a dose of 2 mg / kg, in a volume of 0.2 mL per animal. The animals were euthanized by hemorrhage, and blood was collected via cardiac puncture using a 1 mL syringe with a 25 G needle. A minimum of 500 μL of whole blood was collected and transferred to a serum microblood collection tube. Liver tissue was also taken from the mice.

[0223] Mouse liver tissue samples were ground using 2010 Geno / Grinder® according to the vendor's manual. 5-10 mg of ground tissue was transferred to a Fisherbrand® Bead Mill 24 homogenizer tube and homogenized with Trizol. Chloroform was added to each sample. After centrifugation, the aqueous layer was transferred to a silica-membrane RNeasy 96 plate. RNA extraction was performed in a Qiacube HT according to the vendor's standard miRNeasy protocol. Isolated mRNA was measured using nanodrops, and cDNA was generated using up to 1 μg of RNA from each sample. 4 μL of Superscipt VILO IV Master Mix, 14 μL of RNase-free water, and 2 μL of diluted RNA (up to 1 μg of RNA) were added to each reaction in a 96-well plate. The plates were sealed, centrifuged at 1000 rpm for 1 minute, and incubated in a thermocycler at 25°C for 10 minutes, 50°C for 10 minutes, and 85°C for 5 minutes. dPCR was performed on a QIAcuity eight dPCR system in a QIAcuity Nanoplate 8.5k 96-well using the QIAcuity Probe PCR Kit according to the vendor protocol. Primers and probes for WT and mutant SerpinA1 are listed in Table 10. Raw data were analyzed using the Qiagen plate configurator, and editing percentages were calculated based on the concentration of each target. [Table 10]

[0224] The editing percentage in PiZ mouse liver tissue was evaluated at days 4, 7, and 14 after a single dose of oligonucleotide A3 encapsulated in MC3 LNP. PiZ mice (n=3) were intravenously administered either a vehicle (DPBS) or ASO at a dose of 2 mg / kg indicated for a single dose. Liver tissue was collected at days 4, 7, and 14 post-administration. The editing percentage at each time point was evaluated by NGS (next-generation sequencing) from mRNA collected in the pulverized liver tissue. The editing percentage data at each time point (measured by E342K) is shown in Figure 2. Administration using oligonucleotide A3 with an in vivo dose of MC3 provided high levels of M-A1AT concentration in the serum.

[0225] Similar or equivalent editing activity was observed when PA1 was replaced with L2, and the activity was also maintained at all time points when PA1 was replaced with L1. Oligo A1 and modified oligos were all similarly evaluated at day 4 (peak), day 7, and day 14 (final time point) in both serum wild-type A1AT concentration and wild-type A1AT%. Oligo A12 tended to have higher editing activity and wild-type A1AT concentration than modified oligos.

[0226] The results are shown in Figure 3A (comparing oligos A1, A10, and A11) and Figure 3B (comparing oligos A12, A13, and A14).

[0227] Example 5: In vitro mouse liver homogenate stability assay The stability of different oligonucleotides in mouse liver homogenate was evaluated.

[0228] Approximately 100 mg of PiZ mouse liver powder was added to a 2 mL homogenization vial containing approximately 6 beads. 1 g of liver powder was added to 7 mL of stable buffer. The samples were briefly homogenized, and all homogenates were combined in a 15 mL centrifuge tube. 10 μL of MgCl2 and 10 μL of Anti-Anti were added to each 1 mL homogenate. The homogenates were divided into 100 μL volumes in 1.5 mL Eppendorf tubes. Triple samples were prepared for each time point and oligonucleotide. After pre-incubating the homogenates at 37°C for 0.5 hours, the oligonucleotide test samples were added. 2 μL of 100 μM oligo stock was added to each 100 μL homogenate. The samples were incubated at 37°C until the desired time point was reached. To quench the sample at each time point, 100 μL of stop buffer was added, the mixture was vortexed, and the sample was frozen at -80°C.

[0229] Sample extraction (LLE) The samples were removed from the freezer, thawed in water for 5 minutes, and briefly vortexed. The samples were spiked with 10 μL of 25 μg / mL KB6400 and vortexed again. 400 μL of 10% ammonium hydroxide was added to each sample. Next, 400 μL of phenol / chloroform / isoamyl alcohol was added to each sample. The samples were capped and then thoroughly mixed using a multi-tube vortexer (2 minutes), and then individually vortexed. The samples were then centrifuged at room temperature at 8,000 g (5194 rpm) for 30 minutes. Next, approximately 600 μL of the upper aqueous layer was removed from each sample and transferred to a clean, labeled 1.4 mL matrix vial. The lower organic layer was discarded, and 300 μL of chloroform was added to each sample.

[0230] The samples were capped, then thoroughly mixed using a multi-tube vortexer (2 minutes), and then individually vortexed. Next, the samples were centrifuged at room temperature at 8,000 g (5194 rpm) for 30 minutes. Approximately 500 μL of the upper aqueous layer was taken from each sample and transferred to a clean, labeled 1.4 mL vial. The lower organic layer was discarded.

[0231] Evaporation and concentration of the sample The caps were removed from the samples, and they were placed in a commercially available concentration system with the following settings: upper flow rate: 40 L / min, upper temperature: 40°C, lower flow rate: 40 L / min, lower temperature: 40°C. The samples were dried to approximately 200 μL. Then, 70 μL of the sample extract was transferred to a 96-well plate for LC / HRAM-MS analysis. Any remaining sample extract was frozen at -80°C. The extracted samples were then subjected to LC-MS analysis.

[0232] 42-mer oligo A1 containing PA1 binding, and modified oligos containing L2 or L3 binding, were all similarly analyzed for both edited %, wild-type A1AT concentration (Figure 4A), and serum wild-type A1AT% at day 4 (peak), day 7, and day 14 (final time point). 30-mer oligo A12 containing PA1 binding tended to be higher than modified oligos in edited %, wild-type A1AT production, and serum wild-type A1AT%. Both L2 and L3 modified 30-mer oligo analogs A13 and A14 maintained good edited and wild-type A1AT concentrations up to day 14 (Figure 4B).

[0233] The results are shown in Table 11, the trends for oligos A1-A4 are shown in Figure 4A, and the trends for oligos A5-A7 are shown in Figure 4B.

[0234] L1 and L2 oligonucleotides showed improved metabolic stability compared to PS-containing controls. The 3' and 5' oligo skeletons at the ends of A1(PA-1) substituted with L1(A3) and L2(A4) showed improved retention (43% and 47% on day 3 compared to 30%). The 3' end of oligonucleotide A9(PA-1) substituted with L1(A5) and L2(A6) showed improved retention on days 2 and 3. Both the 3' and 5' ends of oligonucleotide A9(PA1) substituted with L1(A7) and L2(A8) showed improved retention on days 2 and 3. Initial stability data for 42-mer analogues of oligonucleotide A1 did not show improvement, including designs with additional PS binding. In summary, the above data indicate that L1 and L2 binding provides superior stability beyond the PS and PA-1 moieties. [Table 11]

[0235] Example 6 - Editing of ACTb oligo in the liver The following examples evaluate editing after 5 days following a 5 mg / kg dose in a WT C57BL / 6 mouse model.

[0236] Female or male C57BL / 6 mice (6-10 weeks old) were weighed and randomly assigned to groups of 3 mice each. GalNAc was administered subcutaneously at a volume of 0.2 mL per animal. Animals were euthanized by hemorrhage 7 days after the final dose or on day 11 of the study. In vivo editing was measured in liver tissue collected from the central or lateral left lobe of euthanized mice. The tissue was collected in a cryogenic grinding jar and rapidly frozen on dry ice. The liver was ground into a fine powder, RNA was isolated, and editing activity was evaluated.

[0237] Editing data in the liver is shown in Figure 8.

Claims

1. An oligonucleotide comprising 10 to 300 nucleotides, wherein each nucleotide comprises a sugar moiety, a nucleic acid base, and an internucleotide bond, and at least one internucleotide bond is of formula (I): 【Chemistry 1】 A PAX nucleotide internucleotide bond having the structure, in the formula, R 1 is isopropyl, isobutyl, sec-butyl, C 1-6 haloalkyl, C 2-6 hydroxyalkyl, C 2-8 alkylene-N(R N ) 2 , C 0-2 alkylene-C 3-8 cycloalkyl, 4-10 membered heterocycloalkyl having 1 to 3 ring heteroatoms selected from O, N and S, or 5-10 membered heteroaryl having 1 to 3 ring heteroatoms selected from O, N and S, with the proviso that the heterocycloalkyl or heteroaryl is bonded to sulfur via a carbon ring atom, and the cycloalkyl, heterocycloalkyl or heteroaryl is substituted with 0, 1, 2, or 3 R 2 groups Each R 2 They became independent, Halo, CN, N(R) N ) 2 C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, oxo, CO 2 R N , or C(O)C 1-3 It is alkyl, Each R N However, independently, H or C 1-3 Alkyl, or oligonucleotide.

2. R 1 The oligonucleotide according to claim 1, wherein it is isopropyl.

3. R 1 However, C 3-8 The oligonucleotide according to claim 1, which is a cycloalkyl group.

4. R 1 The oligonucleotide according to claim 3, wherein the oligonucleotide is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

5. R 1 The oligonucleotide according to claim 3 or 4, wherein the oligonucleotide is cyclopropyl.

6. R 1 The oligonucleotide according to claim 3, wherein the oligonucleotide is spiro[3.3]heptyl.

7. R 1 However, C 1-6 Haloalkyl or C 1-6 The oligonucleotide according to claim 1, wherein it is a hydroxyalkyl group.

8. R 1 However, C 1-6 The oligonucleotide according to claim 7, which is a fluoroalkyl group.

9. R 1 However, CH 2 F or CHF 2 The oligonucleotide according to claim 7 or 8.

10. R 1 The oligonucleotide according to claim 1, wherein it is a 4- to 8-membered heterocycloalkyl group.

11. R 1 The oligonucleotide according to claim 10, wherein the oligonucleotide is azetidine, pyrrolidine, piperidine, oxetane, tetrahydrofuran, or tetrahydropyran.

12. R 1 The oligonucleotide according to claim 1, wherein it is 5 to 10 heteroaryl.

13. R 1 The oligonucleotide according to claim 12, wherein the oligonucleotide is furan, thiophene, thiazole, isoxazole, imidazole, pyridine, or pyrazine.

14. R 1 The oligonucleotide according to any one of claims 5 and 10 to 13, wherein it is unsubstituted.

15. R 1 However, 1, 2, or 3 R 2 The oligonucleotide according to any one of claims 5 and 10 to 13, which is substituted with

16. R 1 However, one R 2 The oligonucleotide according to claim 15, which is substituted with

17. R 1 However, the two R 2 The oligonucleotide according to claim 15, which is substituted with

18. at least one R 2 However, oxo, CO 2 The oligonucleotide according to any one of claims 15 to 17, wherein H or halo.

19. at least one R 2 The oligonucleotide according to any one of claims 15 to 18, wherein it is fluoro.

20. The oligonucleotide according to claim 1, having at least one PAX nucleotide internucleotide bond as shown in Table 1.

21. An oligonucleotide according to any one of claims 1 to 20, having 30 to 100% phosphorothioate, phosphoramidate, and PAX nucleotide internucleotide bonds.

22. The oligonucleotide according to claim 21, having 30-70% phosphorothioate, phosphoramidate, and PAX nucleotide internucleotide bonds.

23. The oligonucleotide according to claim 21 or 22, having 40-60% phosphorothioate, phosphoramidate, and PAX nucleotide internucleotide bonds.

24. An oligonucleotide according to any one of claims 1 to 23, comprising one PAX nucleotide bond.

25. An oligonucleotide according to any one of claims 1 to 23, comprising 2 to 10 PAX nucleotide interbonds.

26. The oligonucleotide according to any one of claims 1 to 25, wherein the oligonucleotide includes a PAX internucleotide bond between the 3' terminal nucleotide and the 3'-1 nucleotide.

27. The oligonucleotide according to any one of claims 1 to 26, wherein the oligonucleotide includes a PAX internucleotide bond between the 5' terminal nucleotide and the 5'-1 nucleotide.

28. The oligonucleotide according to claim 27, further comprising a PAX internucleotide bond between the 3' terminal nucleotide and the 3'-1 nucleotide, and a PAX internucleotide bond between the 5' terminal nucleotide and the 5'-1 nucleotide of the oligonucleotide.

29. The oligonucleotide according to any one of claims 1 to 28, wherein at least one internucleotide bond is a phosphorothioate.

30. The oligonucleotide according to any one of claims 1 to 29, wherein at least one internucleotide bond is a mesylphosphoamidate.

31. An oligonucleotide according to any one of claims 1 to 30, comprising 25 to 100 nucleotides.

32. The oligonucleotide according to claim 31, comprising 25 to 60 nucleotides.

33. The oligonucleotide according to claim 30 or 31, comprising 30 to 52 nucleotides.

34. The oligonucleotide according to any one of claims 1 to 33, wherein at least one sugar portion is ribose sugar or modified ribose sugar.

35. The oligonucleotide according to any one of claims 1 to 34, wherein each sugar moiety is independently 2'-methoxy-ribose, 2'-MOE-ribose, 5'-methyl-2'deoxyribose, 2'-deoxy-2'-fluororibose, 2'-fluoroarabinose, 2-methoxy-arabinose, 2'deoxyribose, locked nucleic acid (LNA), or deoxyhexose.

36. The oligonucleotide according to any one of claims 1 to 35, further comprising one or more targeting moieties.

37. The oligonucleotide according to claim 36, wherein one or more of the targeting portions include lipids, sterols, carbohydrates, vitamins, and / or peptides.

38. The oligonucleotide according to claim 36 or 37, wherein one or more targeted moieties include thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, polyhydric lactose, polyhydric galactose, ASGPR binding moiety, N-acetyl-galactosamine (GalNAc) moiety, N-acetyl-glucosamine polyhydric mannose, polyhydric fucose, glycosylated polyamino acids, polyhydric galactose, transferrin, polyglutamate, polyaspartate, cholesterol, bile acid, folate, vitamin B12, vitamin A, biotin, RGD peptide, or RGD peptide mimetic.

39. The oligonucleotide according to claim 38, wherein the ASGPR binding portion is N-acetyl-galactosamine (GalNAc) or N-acetyl-glucosamine polyvalent mannose.

40. The oligonucleotide according to any one of claims 35 to 39, wherein one or more of the targeted portions include an N-acetyl-galactosamine (GalNAc) portion.

41. The oligonucleotide according to any one of claims 36 to 40, wherein the one or more targeted portions are located at the 5' end of the oligonucleotide, the 3' end of the oligonucleotide, or both.

42. The oligonucleotide according to claim 41, wherein one or more of the targeting portions are located at the 5' end of the oligonucleotide.

43. The oligonucleotide according to claim 41 or 42, wherein one or more of the targeted portions are located at the 3' end of the oligonucleotide.

44. The oligonucleotide according to any one of claims 36 to 43, wherein one or more targeting portions are bonded to the oligonucleotide by a linker portion.

45. The oligonucleotide according to claim 44, wherein the linker portion comprises an alkylene, a polyalkylene oxide, and / or a peptide portion.

46. The oligonucleotide according to any one of claims 1 to 45, wherein the oligonucleotide is a structural gene, a gene including regulatory and termination regions, a self-replicating system such as a virus or plasmid DNA, a single-stranded or double-stranded RNAi agent, shRNA, an antisense oligonucleotide, a ribozyme, a microRNA, a microRNA mime, a supermir, an aptamer, an antimir, an antagonist mir, an adapter, a triple-stranded oligonucleotide, a tRNA (transfer RNA), a G-quadrilateral oligonucleotide, an RNA activator, an immunostimulatory oligonucleotide, or a decoy oligonucleotide.

47. An oligonucleotide according to any one of claims 1 to 46, having a sequence that is sufficiently complementary to the target RNA.

48. The oligonucleotide according to claim 47, wherein the target RNA is selected from Serpina1, LRRK2, NRF2, TDP-43, Nav1.7, and PCKS9.

49. A formulation comprising an oligonucleotide according to any one of claims 1 to 48 and a pharmaceutically acceptable excipient.

50. The formulation according to claim 49, wherein the pharmaceutically acceptable excipient comprises lipid nanoparticles.

51. The formulation according to claim 49 or 50, which is suitable as a parenteral formulation.

52. The formulation according to claim 51, wherein, when administered parenterally to a patient, the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient.

53. The formulation according to claim 52, wherein the concentration of the oligonucleotide in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient when measured in the tissue at least 24 hours, at least 48 hours, or at least 72 hours after administration.

54. The formulation according to claim 52 or 53, wherein the oligonucleotide concentration in the patient's tissue is at least 40%, at least 45%, at least 50%, at least 55%, or at least 60% of the amount of oligonucleotide administered to the patient, when measured in the tissue at least 72 hours after parenteral administration.

55. A method for treating a disease or disorder in a patient who requires treatment, comprising administering to the patient a therapeutically effective amount of an oligonucleotide according to any one of claims 1 to 48 or a formulation according to any one of claims 49 to 54.

56. The aforementioned diseases or disorders include cystic fibrosis, albinism, alpha-1-antitrypsin deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, asthma, 11-thalassemia, Kadasil syndrome, Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease, distal spinal muscular atrophy, Duchenne / Becker muscular dystrophy, dystrophic epidermolysis bullosa, epidermal bullous disease, Fabry disease, factor V Leiden-associated disorder, familial adenomatous dystrophy, polyposis, galactosemia, Gaucher disease, glucose-6-phosphate dehydrogenase deficiency, hemophilia, hereditary hematochromatosis, Hunter syndrome, Huntington's disease, Harler syndrome, inflammatory bowel disease, hereditary pampagnosis syndrome, and The method according to claim 55, wherein the condition is Recht congenital amaurosis, Lesch-Nyhan syndrome, Lynch syndrome, Marfan syndrome, mucopolysaccharidosis, muscular dystrophy, myotonic dystrophy type I and type II, neurofibromatosis, Niemann-Pick disease type A, B and C, NY-ESO-1 related cancer, Parkinson's disease, Peutz-Jegers syndrome, phenylketonuria, Pompe disease, primary cilia, prothrombin mutation-related disorder, pulmonary hypertension, retinitis pigmentosa, Sandhoff disease, severe combined immunodeficiency syndrome, sickle cell anemia, spinal muscular atrophy, Stargardt disease, Tay-Sachs disease, Usher syndrome, X-linked immunodeficiency, Sturge-Weber syndrome, Rett syndrome, or cancer.

57. A kit comprising an oligonucleotide according to any one of claims 1 to 48, or a formulation according to any one of claims 49 to 54.

58. The kit according to claim 57, further comprising one or more containers.

59. The kit according to claim 57 or 58, further comprising one or more additional therapeutic agents.

60. The kit according to any one of claims 57 to 59, further comprising an accompanying document having instructions for performing the method described in claim 55 or 56.

61. A kit according to any one of claims 57 to 60, further comprising one or more syringes for parenteral injection, one or more filter needles, and / or one or more needles.